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Abstract of the Dissertation 
Cyclotron Production and Biomedical Applications of the PET Isotope Manganese-52 
by 
Andrew Lake Wooten 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2016 
Suzanne E. Lapi, Chair 
Mark A. Anastasio, Co-Chair 
Manganese is an important element for biomedical research because of its roles as an 
essential micronutrient and as a neurotoxin from chronic elevated exposure, as well as the role of 
manganese(II) as a paramagnetic core for contrast agents in T1-weighted magnetic resonance 
imaging (MRI). Using a radiotracer of manganese provides excellent sensitivity for studying 
these phenomena, but only 52Mn met the criteria for our experiments: (1) a half-life (t1/2=5.6 
days) that was long enough to examine timepoints over several days, (2) a half-life that was short 
enough to emit sufficient counts for a realistic scan time, and (3) emitted radiation of a variety 
and energy that were appropriate for existing pre-clinical imaging modalities. Manganese-52 is 
well-suited for imaging with positron emission tomography (PET) because it emits positrons 
with a low energy (Eβ+=242 keV), which improves spatial resolution, and with an acceptable 
total abundance for positron emission (Iβ+=29.6%) for adequate signal. Manganese-52 was 
produced on site by the 52Cr(p,n)52Mn reaction by bombarding non-enriched chromium (52Cr: 
83.8%) with ~13 MeV protons that were accelerated in the CS-15 cyclotron at Washington 
University School of Medicine in St. Louis. Bombardments of stacks of thin chromium metal 
foils were used to measure nuclear cross-sections for the natCr(p,x)52,52m,54Mn reactions, with 
results that agreed closely to simulations and published results. Manganese-52 was separated 
  
 
 
 
 
xvi 
chemically from bombarded chromium metal by cation- or anion-exchange chromatography. The 
separated product was used in experiments that included biodistribution by injection or 
inhalation, PET/CT or PET/MR in phantoms and rodents, and radiolabelling of a Mn(II)-based 
contrast agent for T1-weighted MRI. To reduce radiation dose to production personnel, we 
designed a remotely controlled, semi-automated module for the remote separation of 52Mn inside 
a lead hot cell. This module was similar to other modules that we designed, built, and tested for 
the routine, scaled-up production of larger quantities of the PET isotopes 89Zr and 86Y. We 
anticipate that the module for 52Mn will be completed, routine production of greater quantities of 
52Mn will be achieved, and this radioisotope will continue to be used to study and image the 
interesting aspects and behaviors of manganese chemistry. 
  
 
Chapter 1. Introduction 
1.1. The Paradigm of Molecular Imaging 
The work in this dissertation includes non-imaging experiments related to the production 
and validation of a radiotracer for manganese, but, ultimately, the goal is to develop a radiotracer 
for manganese for in vivo nuclear imaging as an approach to molecular imaging. Radiotracers in 
biological and medical experiments has roots extending back to the earliest days of radionuclide 
production (Wagner, 2010) from cyclotrons (Ruben, et al., 1939) and nuclear reactors (Werner, 
et al., 1949), but molecular imaging as a whole extends beyond radiotracers and nuclear imaging. 
Only in recent decades, has the term molecular imaging been used and defined in 2007 as “[..]the 
visualization, characterization, and measurement of biological processes at the molecular and 
cellular levels in humans and other living systems.” (Mankoff, 2007). This definition goes on to 
explain that molecular imaging frequently generates quantitative images in two- or three-
dimensions with time resolution and that this field is not limited to nuclear imaging, but also 
includes approaches based on nuclear magnetic resonance spectroscopy and imaging, ultrasound, 
optical luminescence imaging, and other imaging modalities (Mankoff, 2007). 
One major advantage of molecular imaging for studying biological questions is that, 
unlike in vitro and ex vivo assays, biological processes can be examined in vivo—intact in a 
living organism. This is more realistic because cells are in their original microenvironment, 
including biological feedback loops (Gambhir, 2010). The ideal molecular imaging modality 
would have the ability to detect very low concentrations of molecular targets and to track cells, 
image with excellent spatial and temporal resolution, provide completely quantitative results, be 
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useful for imaging targets anywhere within cells and tissues at any realistic depth, as well as 
practical criteria of high throughput and low cost (Gambhir, 2010). Practically, the perfect 
modality does not exist, so the advantages and disadvantages of various modalities are 
considered when selecting an approach to a molecular imaging study. 
Molecular imaging typically depends on endogenous or exogenous molecular imaging 
agents that can generate imageable signal(s) that reflect the location and other biological 
information inside an organism (Mankoff, 2007). Molecular imaging agents typically satisfy the 
tracer principle (Vanbrocklin, 2010) that was originally described by de Hevesy (Hevesy, 1923), 
which asserts that a probe in a small enough concentration will not disturb the (bio)chemistry of 
the system to which it is being applied for study. Probes that satisfy the tracer criteria can be 
trusted to provide information about a practically unperturbed system. Additionally, the chemical 
toxicity of such probes is not significant for non-chronic use, which dramatically increases the 
flexibility of selecting an imaging probe, such as radioisotopes of elements that would be toxic in 
greater concentrations. The tracer principle applies most readily to nuclear imaging because most 
biomedical radiotracers produce sufficient signal for detection and imaging from trace 
concentrations, but the tracer principle can apply to probes for other modalities of molecular 
imaging as well. 
Frequently, the goal of developing a molecular imaging agent or other imaging technique 
is to translate the agent into clinical practice, but such translation requires navigating significant 
regulations associated with clinical studies (Gambhir, 2010). Some molecular imaging agents are 
not suitable for clinical use for various reasons (Gambhir, 2010), such as chemical toxicity, 
radiation dosimetry, attenuation of signal by human tissue, cost, or availability. Nevertheless, 
some agents that are only used in animal models can make valuable contributions to basic 
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research by expanding knowledge of biological questions (Gambhir, 2010). The development of 
52Mn as a radiotracer for PET imaging of manganese likely fits into this category. 
1.2. Motivations for Studying Manganese 
There are at least three biomedical roles and applications of manganese that make this 
element interesting for study, and they motivate the pursuit of quantitative detection and imaging 
of manganese. These roles include manganese (1) as an essential micronutrient that serves as a 
cofactor for important metalloenzymes, (2) as a neurotoxin that causes motor disorders following 
chronic inhalation of manganese, and (3) as a contrast agent for manganese-enhance magnetic 
resonance imaging (MEMRI). Although imaging of accumulated Mn(II) is possible by MRI, 
quantitative measurement and quantitative imaging of manganese is difficult, and MRI and CT 
contrast agents can require local concentrations as high as millimolar (10-3 M), compared to 
concentrations as low as picomolar (10-12 M) for the nuclear emission imaging techniques 
SPECT and PET (Lobatto, et al., 2011). The concentrations of contrast agents for MRI and CT 
are high enough that toxicity needs to be considered; however, this is not the case at the 
concentrations used for radiotracers for SPECT and PET. 
The results presented from biological experiments in this dissertation (Chapter 3) could 
be useful as supporting information for environmental and occupational regulations, for 
designing PET studies utilizing 52Mn, and for predicting biodistribution of manganese-based MR 
agents.  
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1.2.1. Natural Abundance of 52Mn 
Manganese is a micronutrient that is essential for human life in only trace amounts 
(Avila, et al., 2013; Averill and Eldredge, 2011). Ingestion of manganese is part of a healthy 
human diet, and deficiency is rare (OSU/LPI, 2010). Existing primarily in the Mn(IV) oxidation 
state in the earth’s crust (Greenwood and Earnshaw, 1997), manganese is the third most 
abundant transition metal in the crust (TJNAF; Greenwood and Earnshaw, 1997), and is taken up 
by plants, where it is stored in produce and nuts (USDA/ARS) and utilized in green leaves as an 
oxidizer in photosynthesis (Greenwood and Earnshaw, 1997). Although manganese can form 
complexes in more oxidation states than any other first-row transition metal (Brown, et al., 2000; 
Greenwood and Earnshaw, 1997), Mn(II) is by far the most electrochemically stable oxidation 
state for manganese (Greenwood and Earnshaw, 1997) and the state that is predominantly used 
as an enzymatic cofactor. Nevertheless, free Mn(II) is efficiently cleared from the blood by the 
liver for excretion (Gibbons, et al., 1976), so Mn in the blood is found as Mn(III) bound to 
binding sites for Fe(III) on transferrin (Scheuhammer and Cherian, 1985; Gibbons, et al., 1976) 
or as Mn(II) bound to other serum proteins (Lau and Sarkar, 1984). 
In humans, manganese is principally utilized as a co-factor for metalloenzymes in 
important biological processes, such as conversion of reactive oxygen species, gluconeogenesis, 
and the urea cycle (OSU/LPI, 2010). The body distributes manganese to tissues throughout the 
body (Yokel, 2009), where it can be taken into cells by transferrin-mediated endocytosis, the 
divalent metal transporter (DMT-1), and/or voltage-gated calcium channels (Roth, 2009). 
Manganese can also cross the blood-brain barrier by carrier-mediated transport (Yokel, 2009, 
2006; Crossgrove, et al., 2003) and calcium-release activated channels (Yokel, 2009, 2006; 
Crossgrove and Yokel, 2005), where at least one of its roles is to moderate cellular uptake of the 
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neurotransmitter glutamate (Yin, et al., 2010; OSU/LPI, 2010). In this dissertation, we examine 
the biodistribution of manganese using 52Mn as a radiotracer (Chapter 3). 
1.2.2. Toxicology of Manganese 
The necessity of manganese as a nutrient is sometimes overshadowed by its neurotoxic 
effects, resulting in manganism (Avila, et al., 2013), a condition that was first described in 1837 
(Couper, 1837). In mangansim, early-stage patients often present with psychiatric symptoms 
(Racette, et al., 2012a; Laohaudomchok, et al., 2011; Guilarte, 2010; Burton and Guilarte, 2009; 
Roth, 2006; Mergler, et al., 1994; Sjogren, et al., 1990; Rodier, 1955) that are sometimes referred 
to as “manganese madness” (Calne, et al., 1994). Later-stage patients develop symptoms of 
parkinsonism, including intellectual impairment, tremors, and rigidity similar to parkinsonism 
(Cersosimo and Koller, 2006; Josephs, et al., 2005; Hudnell, 1999; Sjogren, et al., 1996; Calne, 
et al., 1994; Mergler, et al., 1994; Rodier, 1955; Couper, 1837), with a few key differences from 
idiopathic Parkinson’s disease. It is believed that manganism typically results from chronic 
exposure to small doses of manganese, because manganese(II) chloride has relatively low acute 
toxicity in rodent models: LD50=0.22-3.59 mmol/kg for intravenous injection (Gimi, et al., 2006; 
Elizondo, et al., 1991; Wolf, et al., 1985), LD50=1 mmol/kg for intraperitoneal injection (Pan, et 
al., 2010), and LD50=7.50 mmol/kg (tetrahydrate) for oral administration (MSDS, Sigma-
Aldrich, 2015). 
Nevertheless, neurotoxicity can result in animals or humans from chronic exposure to 
manganese in the water supply (Elsner and Spangler, 2005; Kondakis, et al., 1989), in ephedrine 
(methcathinone) produced using potassium permanganate (Sikk, et al., 2013; Sikk, et al., 2011; 
Sikk, et al., 2010; de Bie, et al., 2007; Sanotsky, et al., 2007), in the farming fungicides maneb or 
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mancozeb (J. Zhang, et al., 2003; Thiruchelvam, et al., 2000a; Thiruchelvam, et al., 2000b; 
Meco, et al., 1994; Morato, et al., 1989; Ferraz, et al., 1988; Israeli, et al., 1983; Israeli, et al.), or 
in gasoline containing the additive methylcyclopentadienyl manganese tricarbonyl (MMT) 
(Zheng, et al., 2000; Komura and Sakamoto, 1994, 1992; Clay and Morris, 1989). These sources 
have led government bodies to place limits on acceptable levels of non-occupational manganese 
at 0.05-0.5 mg/L in drinking water (Australia Department of the Environment, 2015; Williams, 
et al., 2012; U.S. E.P.A., 2009; Williams-Johnson, 1999) and 0.15-1,000 µg/m3 in air (Williams, 
et al., 2012; Williams-Johnson, 1999). 
However, certain types of metalworking can cause elevated risk of exposure to airborne 
manganese, so regulations have been placed on workplace exposure to airborne manganese 
(including from compounds, particles, and fumes) at 0.3-5 mg/m3 (Australia Department of the 
Environment, 2015; Williams, et al., 2012; U.S. E.P.A., 2009; Williams-Johnson, 1999). Despite 
a few epidemiology studies—including some sponsored by industry—that dispute the existence 
of a link between metalworking and neurological disease (Fored, et al., 2006; Marsh and Gula, 
2006; Fryzek, et al., 2005), there are still many reports of manganism in exposed workers 
(Searles Nielsen, et al., 2015; Gonzalez-Cuyar, et al., 2014; Racette, et al., 2012b; Racette, et al., 
2012a; Harris, et al., 2011; Laohaudomchok, et al., 2011; Sriram, et al., 2010; Flynn and Susi, 
2009; Marsh and Gula, 2006; Kenangil, et al., 2006; Fored, et al., 2006; Josephs, et al., 2005). 
Studies in these workers have demonstrated hallmark symptoms of manganism, and the 
accumulation of manganese in the brain can be so great that the current method for diagnosis of 
manganism is quantification of signal in the globus pallidus from T1-weighted MR imaging of 
the manganese that has accumulated in that region of the brain (Criswell, et al., 2012; Kenangil, 
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et al., 2006; Josephs, et al., 2005). In our biodistribution results (Chapter 3), we observe uptake 
of radiomanganese in the brain following intravenous administration of 52Mn. 
1.2.3. Manganese-Based Contrast Agents for Magnetic Resonance Imaging 
An additional motivation for understanding the biodistribution of free manganese is that 
manganese(II) has been utilized in contrast agents for MR imaging. Manganese(II) is “high-spin” 
from its five unpaired valence electrons (Wolf, et al., 1985; Weinmann, et al., 1984), which 
shorten the spin-lattice time constant (T1) for nearby 1H nuclei, resulting in brighter signal when 
using a T1-weighted MR pulse sequence (Pan, et al., 2010; Rodriguez-Vargas, 2010; Silva and 
Bock, 2008), especially in anatomical regions with high water density. Gadolinium(III), by far 
the most commonly used cation in clinically approved T1 contrast agents (Kahakachchi and 
Moore, 2010; Rodriguez-Vargas, 2010; Caravan, et al., 1999; Lauffer, 1987) requires higher 
coordination than Mn(II), giving Mn(II) better exchange kinetics with water molecules. 
However, Gd(III) has seven unpaired valence electrons, imparting Gd(III) with greater T1 
relaxivity (R1=1/T1) than Mn(II) in several different metal chelators. 
The intravenous acute toxicity of Mn(II) chloride is similar to that of Gd(III) chloride 
(LD50=0.3-0.5 mmol/kg in rodent models (Sigma-Aldrich, 2014; Bousquet, et al., 1988; 
Weinmann, et al., 1984)), but manganese ions are nevertheless interesting for certain MR 
applications, including utilizing the redox chemistry of chelated Mn(II/III) as an activatable 
probe of the redox environment in tissue (Boros, et al., 2015; Gale, et al., 2014; Loving, et al., 
2013). Additionally, Mn complexes could serve as a safe alternative to Gd(III) (Brismar, et al., 
2012; Thomsen, 2009; Mendonca-Dias, et al., 1983), which might pose a health risk to patients 
with renal insufficiency if Gd(III) dissociates from its chelator in the body (Pierre, et al., 2014; 
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Brismar, et al., 2012; Janus, et al., 2010; Ledneva, et al., 2009; Thomsen, 2009), since free 
Gd(III) is excreted through the kidneys, but free Mn(II) is excreted through the liver (Mendonca-
Dias, et al., 1983). 
For these reasons, various complexes of Mn(II) (Zhu, et al., 2014) and Mn(III) (Cheng, et 
al., 2014; Pierre, et al., 2014; Qazi, et al., 2014) are being developed, numerous kinds of Mn-
doped inorganic and organic nanoparticles are in the in vitro and pre-clinical stages (Pan, et al., 
2010, 2009, 2008), and oral administration of liquids containing Mn(II) has been tested in 
humans (Brismar, et al., 2012; Hiraishi, et al., 1995). So far, the only manganese-based MR 
contrast agent to reach the market in the United States was Teslascan® (mangafodipir; 
manganese(II)-dipyridoxyl diphosphate (Mn-DPDP); Amersham plc, Amersham, United 
Kingdom), which was used for detecting colorectal metastases in the liver (Elizondo, et al., 1991; 
Rocklage, et al., 1989), and was withdrawn in the United States in 2003 because of low demand 
(not safety concerns). Since MRI is not inherently as quantitative as PET, and since MEMRI is 
not as widely studied as Gd-based imaging, it would be useful to “authentically” radiolabel 
manganese-based MR contrast agents with radiomanganese (Coenen, et al., 2014; Klein, et al., 
2005) for quantitative confirmation of their biodistribution—by dissection, autoradiography, 
and/or in vivo imaging. 
1.3. Radioactive Decay, Detection, and In Vivo Imaging 
Quantifying radiotracers is very sensitive and precise, and offers opportunities for in vivo 
imaging. At least twenty-seven isotopes of manganese have been discovered, one of which is 
stable. The twenty-six remaining isotopes decay by numerous different modes of radioactive 
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decay, resulting in many different types of particle and energy emissions. Based on techniques 
for detection and imaging and on half-lives that are useful for biomedical experiments, there are 
only a few radioisotopes that are potentially valuable for biomedical applications, and, for the 
majority of this dissertation, we will focus on cyclotron production and biomedical applications 
52Mn in particular. 
1.3.1. Nuclear Decay and Radiation 
There are many different modes of nuclear decay, all of which basically involve a 
radioactive isotope seeking a more stable, less energetic state. Nuclear decay typically results in 
the radioactive parent isotope releasing energy as particles (including positrons), gamma-rays, or 
in other forms, as the nucleus transforms into a daughter isotope or isomer (which itself may be 
stable or radioactive). Numerous types of radiation can be emitted—directly or indirectly—by 
nuclear decay, and some of the most common kinds are summarized in Table 1.1. 
Table 1.1. Summary of radiation emitted directly or indirectly by radioactive decay. 
Type of Radiation Charge Mass Primary Interaction(s) with 
Matter Following Scattering 
off Orbital Electrons 
α +2 4.00 
u 
Ionization (sometimes 
producing Cherenkov light) 
β- or e- -1 5.5e-4 
u 
Ionization (sometimes 
producing Cherenkov light) 
Bremsstrahlung radiation 
Photon: from γ decay None 0 Pair production (>1.02 MeV) 
Compton effect 
Photoelectric (<500 keV) 
Photon: from β+ annihilation   Photoelectric effect 
Photon: X-ray from e- capture   Photoelectric effect 
(Sources: ICSU/CODATA; Royal Society of Chemistry/Radiochemical Methods Group.)  
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1.3.2. Non-Imaging and Ex Vivo Options for Detecting Radiation in 
Biomedical Research 
Although this dissertation focuses the application of a radioisotope of manganese for in 
vivo imaging, it is important to consider alternative techniques that could also study the behavior 
of manganese by detecting radiomanganese. This section discusses a few common non-imaging 
techniques that are used for detecting radiation in medical radiochemistry. 
Ionization is a mechanism of interaction between radiation and matter that is commonly 
used for detecting and measuring radiation. Ionization of an atom occurs when the energy of the 
radiation—particles, X-rays, or gamma-rays—is greater than the energy required to remove an 
electron from an atom (different for 1st, 2nd, 3rd, etc. electrons of an atom). Following ionization, 
in a detector, the resulting free electrons are attracted to an anode, and the cations to a cathode, 
and the resulting current is measured by an electrometer circuit and is correlated to the ionizing 
radiation that was originally detected. Gases are commonly used as the ionization medium 
because of faster movement to the electrodes. The incident radiation that is best measured by 
ionization is usually gamma-rays, beta particles, and annihilation photons. 
Detectors that operate on this principle are classified as gaseous ionization detectors 
Typically gaseous ionization detectors (dose calibrators) cannot measure the energy of radiation, 
so accurately converting radiation into units of radioactivity requires the sample to only emit 
radiation from one radioisotope that is known, as well as calibrating the device itself (Appendix 
A) or by calculations. 
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Figure 1.1. Illustration of the mechanism behind ionization chambers. 
(Image courtesy of EQUIPCO. Used with permission.) 
Gamma-ray energy can be measured by scintillation detectors and semiconductor 
detectors. The most common type of scintillation detector uses a NaI crystal that has been doped 
with Tl, and this crystal produces a small amount of visible light when it encounters a photon 
with sufficient energy. The crystal is attached to the window of a photomultiplier tube (PMT), 
which detects the light in the crystal, converts it to an electrical pulse, and amplifies this pulse 
until it is large enough to be counted by the electronics connected to this system (Figure 1.2). 
The brightness of the light in the crystal and the pulse height in the PMT are correlated to the 
energy of the incident photon, so this energy can be estimated. A NaI(Tl) detector is used in 
many gamma counters, including the ones that we used for quantifying radioactivity in our ex 
vivo biodistribution experiments (Chapter 3), and this kind of detector was also used in the 
radiation detector used in the radiation detector attached to our high-pressure liquid 
chromatography (radio-HPLC) system.  
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Figure 1.2. Illustration of the mechanism underlying scintillation radiation detectors. 
(Image courtesy of EQUIPCO. Used with permission.) 
The most common type of semiconductor detector in recent years is the high-purity 
germanium (HPGe) detector use for gamma-ray spectroscopy in Section 2.2.4, which detects 
photons while the HPGe crystal is maintained at a high voltage. When a photon enters the 
crystal, it creates numerous electron-hole pairs that are quickly pulled toward the anode and 
cathode, respectively, by the large bias on the crystal, creating an electric pulse (Figure 1.3). The 
number of electron-hole pairs and the magnitude of the electric pulse are proportional to the 
energy of the incident photon, so this detector can also detect photon energy with much better 
energy resolution than the NaI(Tl) detector. 
 
Figure 1.3. Illustration of the mechanism underlying semiconductor radiation detectors. 
(Image from Q. Zhang, et al., 2013. Creative Commons.)  
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1. Introduction 
Semiconductor nuclear radiation detectors have experienced a rather rapid development in the last 
few decades. A major characteristic of this type of detector is the capability of converting γ-rays 
directly into electronic signals. In comparison to scintillators, semiconductor detectors avoid the 
random effects associated with scintillation light production, propagation and conversion to electrical 
signal in such a way that they represent the main alternative to scintillator-based single photon imaging 
systems. Compared to established use of Si and Ge, cadmium zinc telluride (CdZnTe) is the most 
promising material for radiation detectors with high atomic number (good stopping power), large 
band-gap (room-temperature operation), and the absence of significant polarization effects [1,2]. The 
incident gamma-ray interacts with the semiconductor and excites electron-hole pairs, that are 
proportional to the deposited energy and drifts apart under the applied electric field. Electrons drift 
towards the anode and holes drift towards the cathode (Figure 1). Charge signal is induced on the 
electrodes of the detector by the moving charge carriers. It is due to the direct conversion from the 
energy deposition by gamma-ray interaction to electric signal that semiconductor detector can easily 
achieve high energy resolution and spatial resolution [3]. In practice, CdZnTe materials exhibit varying 
degrees of charge carrier trapping, which in fact is the dominant problem that has limited their energy 
resolution. Our group at the Molecular Imaging Lab of Peking University is developing micro  
single-photon emission computed tomography (SPECT) for small animal imaging. This paper reviews 
the techniques of overcoming hole trapping problems for CdZnTe detector, including particular 
irradiation configuration of the same, electronic methods to distinguish events from a large 
contribution of the holes and the various electrode designs. We also review the state of art 
development of 3-D position sensing and Compton imaging techniques using CZT detectors. 
Figure 1. Planar configuration of a semiconductor detector. The cathode is applied with a 
negative voltage and anode grounded. Electron-hole pairs excited by gamma rays are swept 
by the bias voltage. 
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Finally, autoradiography presents a method for two-dimensional mapping of the 
distribution of radioactivity. This technique is best applied to mapping radioactivity in a planar 
region, such as in a thin layer chromatography (TLC) plate, thinly sectioned ex vivo tissues, or 
other applications. One common method for autoradiography utilizes a storage phosphor screen, 
which consists of a layer of microparticles of BaFBr doped with Eu2+. Incident radiation of 
sufficient energy will excite electrons in Eu2+ to a highly mobile state, causing Eu2+ to oxidize to 
Eu3+, and BaFBr to be reduced to BaFBr-. These new states are maintained for up to a few weeks 
until the screen is read in a scanner that excites the screen with 635 nm light and, using a band-
pass filter, measured the blue light emitted by the screen at wavelengths surrounding ~390 nm. 
The intensity of this light at each spot on the screen is proportional to the radioactivity originally 
detected by the screen at that location, and this signal can be mapped in the control software to 
form images. For anatomical imaging corresponding to the autoradiography, the tissue sections 
are imaged in bright field by photography. Autoradiography presents a useful option for mapping 
distribution of radioactivity that emits various types and energies of radiation, including gamma-
rays and charged particles. Table 1.2 summarizes the different mechanisms and instruments that 
were discussed that could be used to detect and quantify radiomanganese in experiments that do 
not require in vivo nuclear emission imaging.  
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Table 1.2. Summary of non-imaging technologies for detecting radioactivity. 
 Typical Particles Detecteda Examples of Applications 
Gaseous Ionization Detectors   
Ionization chamber γ Dose calibrator, survey meters 
Scintillation counter γ NaI(Tl) gamma spectroscopy, gamma counter, detector for radio-HPLC 
Semiconductor detector γ HPGe detector 
Storage phosphor screen α,β,γ,n Autoradiography for radioTLC plates, sectioned tissues, whole body autoradiography of sliced small animals 
aDetection of positrons is not listed specifically in this table, but the 511 keV annihilation photons 
can be detected by any detector that is capable of detecting gamma-rays with energy of 511 keV. 
1.3.3. Techniques for In Vivo Imaging of Emitted Radiation 
Despite the useful characteristics of these detectors, our goal was to perform in vivo 
nuclear emission imaging. In general, for in vivo imaging applications, the best emissions are 
photons that have either a low energy of or a specific known energy, specifically 511 keV 
photons that result when a positron is emitted then annihilates with a nearby electron (Section 
1.3.3.2). Photons with energy 30-250 keV (Peterson and Furenlid, 2011) have an energy that is 
great enough that, on average, they are not completely attenuated within a body, but low enough 
to be useful for imaging modalities based on gamma cameras (i.e., planar scintigraphy and 
SPECT). The 511 keV photons are useful for PET imaging, which uses a filter that will only 
count photons with an energy surrounding 511 keV (~350-650 keV (Phelps, et al., 2006)). This 
ability to resolve the energy of photons and then select signal from photons in a specific energy 
range enables rejection of counts from photons that originated from another location and have 
lost energy from significant scattering, thereby increasing the signal-to-noise ratio (SNR) in the 
  
 
 
 
 
15 
imaging. These factors are important to consider when selecting radioisotopes for experiments 
because of the different kinds of radiation required for different nuclear imaging modalities. 
1.3.3.1. Non-PET Nuclear Emission In Vivo Imaging Modalities 
For isotopes that emit photons in the 30-250 keV window, gamma cameras present a very 
useful technology for detecting radiation to produce signals that can be reconstructed into 
images. Gamma cameras, also known as an Anger camera after its inventor, operate on similar 
principles as scintillation counters (Section 1.3.2) and in some ways are simply an array of these 
counters that are used to produce two-dimensional maps of radiation emitted from the imaging 
subject. Gamma cameras are the detectors behind the modalities of conventional nuclear 
medicine: planar scintigraphy and single photon emission computed tomography (SPECT). 
1.3.3.2. Positron Emission Tomography 
The positron emission mode of nuclear decay is of particular importance in medical 
imaging. In a typical medium, positrons will scatter inelastically off orbital electrons, causing 
ionization of atoms, over a range of only a few millimeters before annihilating with an electron. 
This annihilation converts the mass of the positron and the electron into two photons that are 
released at 511 keV each in directions that are almost exactly 180° from each other due to 
conservation of momentum. The physics of positron annihilation, particularly the specific 
direction and energy of the annihilation photons, form the basis of positron emission tomography 
(PET), which is an imaging modality in clinical nuclear medicine. 
PET has important advantages over the more traditional nuclear medicine modalities 
based on its underlying physics. PET is optimized to only image the distribution of annihilation 
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events from positrons, which gives PET high specificity in terms of signal. This signal specificity 
relies on a few special aspects of positron emission and annihilation: 
 
(1) Positrons in tissue have a short range before annihilation. 
(2) The photons emitted from annihilation are always ~180° in opposite 
directions. 
(3) The annihilation photons always have energy of 511 keV. 
(4) Both photons, travelling through different amounts of tissue and air, have high 
enough velocities that they will reach a ring of detectors quickly and with very 
little difference in time of arrival (i.e., in coincidence). 
 
These characteristics mean that determining the concentration of annihilation events is related to 
the concentration of parent nuclei. Furthermore, the location of annihilation events in each slice 
can be detected by a ring of detectors that only count photons with energy in a range surrounding 
511 keV and only when another photon is detected in a detector located ~180° away within a 
very short time window (on the order of nanoseconds). The mechanism of PET is illustrated in 
Figure 1.4.  
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Figure 1.4. Illustration of the physics of positron emission tomography. 
(Image: van der Veldt, et al., 2013. Creative Commons.) 
After detecting coincident photons that meet these criteria, the PET system can define a 
line of response (LOR) for those two photons. As the number of counts of coincident photons 
increase during a scan the many LORs that are created begin to intersect in regions with the 
highest density of annihilation events during the scan time, which closely describes areas that 
had high concentration of positron emitting nuclei during the scan. This information can be 
acquired as two-dimensional regions if only a single ring of detectors is used for each image 
slice, or as three-dimensional regions if multiple rings are used. At this point, various signal 
processing algorithms can be applied to improve the image that will result from image 
reconstruction. The image slices are reconstructed into a three-dimensional tomograph that 
reflects the distribution of a PET radiotracer in vivo.  
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Figure 1.5. Photograph of a General Electric (GE) Optima PET/CT 560 human scanner. 
(Image courtesy of GE Healthcare. Used and adapted with permission.) 
Detailed anatomical imaging is provided by computed tomography (CT) or magnetic 
resonance imaging (MRI) and is frequently co-registered with a PET image in multimodality 
techniques known as PET/CT or PET/MR, respectively. When two-dimensional presentation is 
desired, the co-registered tomographs are often converted to a maximum intensity projection 
(MIP) in the direction of a selected point of view. Figure 1.6 shows examples for PET, CT, and 
MR images (with fusion) from a 62 year-old woman with multiple myeloma (Fowler, et al., 
2013). Signal from PET clearly shows a lesion in the region of the left shoulder that was avid for 
[18F]-fluorodeoxyglucose (18F-FDG), which is a simple analog for glucose that has been 
radiolabelled with the positron-emitting radionuclide 18F. 18F-FDG is currently the most 
commonly used radiotracer for PET worldwide, and it can detect regions of high glucose 
consumption, such as tumors that demonstrate sufficient contrast in PET imaging by not being 
near areas of naturally high signal, especially the brain and bladder. 
The physics of PET translates into advantages for this modality, including extremely high 
sensitivity because all radiation is rejected except for that which has a specific energy, 
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directionality, and coincidence timing. The sensitivity of PET is on the order of picomolar 
concentration of radiotracer, and better sensitivity means that much less total mass of a contrast 
agent needs to be administered, which can decrease concerns for chemical toxicity and radiation 
dosimetry in patients. Although nuclear imaging in general has poor resolution compared to 
other medical imaging modalities such as CT or MRI, PET generally boasts better spatial 
resolution than SPECT. 
 
Figure 1.6. Lesion from multiple myeloma viewed with FDG-PET, CT, and MR. 
Arrow: lesion; AC: attenuation correction; HASTE, STIR: pulse sequences for MRI. (Image: 
Fowler, et al., 2013. Reprinted with permission of Anderson Publishing Ltd. From Fowler, K.; 
McConathy, J.; Khanna, G.; Dehdashti, F.; Benzinger, T.L.S., et al., 2013. Simultaneous 
PET/MRI acquisition: Clinical potential in anatomically focused and whole-body examinations, 
Applied Radiology, pp. 9-14. ©Anderson Publishing Ltd.)  
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SIMULTANEOUS PET/MRI ACQUISITION
Clinical cases
The following are some examples of 
the clinically relevant cases acquired for 
anatomically focused and whole-body 
examinations with the Biograph mMR.
Neuro-oncologic brain imaging
While separately acquired brain MR 
and FDG-PET images can be fused 
through various software tools, a com-
bined examination permits streamlined 
patient care and improves diagnostic 
specificity. The convenience and re-
duced burden to the patient of a single 
imaging session is particularly relevant 
to patients with brain tumors, who often 
have a reduced functional status.
Figure 1 displays a panel of selected 
simultaneous FDG-PET/MR images of 
a 41-year-old man with a left temporal 
lobe primitive neuroectodermal tumor 
(PNET) treated with near-total resec-
tion, craniospinal and resection-bed 
radiation therapy, and adjuvant che-
motherapy. Follow-up MRI showed a 
growing, enhancing mass, and FDG-
PET/MRI was performed to differen-
tiate recurrent tumor from radiation 
necrosis. The white arrow denotes an 
enhancing nodule with markedly in-
creased FDG uptake, highly suspicious 
for recurrent PNET. Subsequent surgi-
cal resection demonstrated a mixture of 
recurrent PNET and radiation necrosis.
Amyloid PET brain imaging
The development of F-18-labeled 
PET tracers for imaging beta-amyloid 
plaques that occur in Alzheimer’s dis-
ease (AD) has the potential to increase 
the certainty of diagnosis in patients 
with cognitive impairment. One of 
these tracers, F-18 florbetapir, recently 
received FDA approval for clinical use, 
and several other amyloid PET tracers 
in late-phase clinical trials may soon 
become clinically available. If drugs 
that slow or reverse the development of 
AD dementia become clinically avail-
able, amyloid PET imaging may be a 
key component of patient selection for 
treatment and for monitoring response 
to therapy. The anatomic, volumetric, 
and functional data available through 
FIGURE 3. Buccal cancer. Images depict a metabolically active tumor in the right buccal 
space (arrows), which also is well shown on the DWI and ADC map to restrict diffusion. The 
patient had biopsy-proven metastatic involvement of Ib lymph nodes within the right subman-
dibular space (open arrows). 
FIGURE 4. Multiple myeloma. Images depict a focus of metabolically active disease in the 
left humeral neck that is more conspicuous on MRI than on CT alone (arrows). 
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1.4. Selection of 52Mn as a Radiotracer 
A need exists for a tracer of manganese that is radioactive, detectable, and imageable, 
specifically by PET, at timepoints of hours and days. The radioisotope that best satisfied our 
criteria was 52Mn, which can be produced on-site at our medical center using cyclotrons from a 
low-energy, biomedical cyclotron. 
1.4.1. Selection Criteria for a Radioisotope of Manganese 
Many different factors, including scientific, engineering, facilities, and cost reasons 
contribute to the selection of a radioisotope for experiments. These considerations result from the 
following factors related to the production of medical isotopes: capabilities and limitations of 
radiation detection and imaging, decay properties and radiation emissions of radioisotopes, 
requirements for nuclear reaction channels, and production costs associated primarily associated 
with target materials and beam time for a cyclotron. This section discusses these selection 
factors, which are also summarized in Table 1.3. 
Based on the technologies discussed earlier (Sections 1.3.2-1.3.3), many different types 
of emitted radiation can be useful for imaging and non-imaging applications. For both imaging 
and non-imaging technologies, these different kinds of radiation can be detected directly or 
indirectly. However, when selecting the radionuclide, it also must emit the desired radiation at a 
sufficient total intensity (Itot), which is the total fraction of radionuclei that will emit a particular 
radiation type, at a certain energy as a part of their decay to a daughter nuclide.  
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Table 1.3. Selection considerations for radionuclides in biomedical experiments. 
Criteria Application Typical Choice 
   
Radiation emitted can be detected Ionization/Proportional counter γ 
Semiconductor γ 
Phosphor screen γ 
Scintillation: counter γ 
Scintillation: scintigraphy/SPECT γ (Eγ~30-250 keV) 
Scintillation: PET 511 keV coincident photons 
(from positron annihilation) 
   
Nuclear half-life matched to 
biological half-life 
Small molecules Minutes-Hours 
Peptides, antibody fragments Hours 
Intact antibodies, nanoparticles Days 
Long-term biodistribution Months 
   
Production routes Generator (from nuclear reactor)  
Low-energy cyclotron  
High-energy ion accelerator  
Nuclear reactor  
 
 
 
 
It is also important to consider the timescale of the experiment that will be utilizing the 
radiotracer. Most benchtop chemistry and in vivo experiments require isotopes with half-life for 
nuclear decay (t1/2) of at least 1 minute for very quick experiments and less than 1 year for the 
longer tracer experiments. In particular, radiolabelled compounds for in vivo experiments should 
use radiolabels that correspond to the biological half-life of the targeting agent, meaning the time 
from administration for one-half of the dose to either reach its target or to be excreted. These 
targeting times can vary over a broad range, typically increasing with the size of the 
radiolabelled compound: roughly minutes for small molecules, hours for peptides and antibody 
fragments, and days for nanoparticles and intact antibodies. It is essential to select a radiolabel 
with a half-life that is long enough for sufficient radioactivity to remain at the desired timepoints 
post-administration for detection or imaging. In vivo imaging studies require more emission 
signal than simple counting and spectroscopy experiments, so the half-life of an imaging 
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radioisotope should also be short enough to provide a sufficient rate of nuclear decay to produce 
enough counts in a reasonable scan time. 
A final major consideration for radioisotope selection is the cost and ease of acquisition 
or in-house production. Many radioisotopes with sufficient market demand are available 
commercially, including numerous long-lived radiotracers and several isotopes for SPECT and 
PET, even the non-traditional PET isotopes 64Cu, 89Zr, and 124I. Certain government laboratories 
and universities are capable of producing a variety of radioisotopes from large instruments, such 
as nuclear reactors, linear accelerators, ion beams, and spallation targets. These instruments are 
necessary for isotope production via certain nuclear reaction channels that require different 
incident particles and/or higher incident energies, and these facilities supply commercial vendors 
with large batches of parent isotopes for generators, alpha- and beta-emitting radioisotopes for 
therapy, and certain SPECT isotopes. 
However, the vast majority of production of PET isotopes is performed by proton 
bombardment from a low-energy cyclotron located on-site at academic or commercial medical 
centers. The cost of target material can be reduced by selecting isotope products and reaction 
channels that require target nuclei with high natural abundance. Due to the costs charged for 
isotopically enriched materials, even slight enrichment of the most abundant metals can cost 
more than naturally monoisotopic metals. Recovery and recycling of target material for future 
productions, which can be a time consuming process can also help keep costs down. A good 
example of a cost-efficient cyclotron target is production of the PET isotope 89Zr by the 89Y(p,n) 
reaction. Natural yttrium is monoisotopic (as 89Y), affordable, and, therefore, the dissolved target 
material does not necessitate recovery from its chemical processing and can simple be disposed 
as waste.  
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1.4.2. Potentially Useful Radioisotopes of Manganese 
There are several radioisotopes of manganese that satisfy broad criteria for being useful 
for radiochemistry experiments, and a smaller number satisfy practicality criteria for half-life and 
production. Nuclear decay properties for several of these potentially useful radioisotopes of 
manganese are summarized in Table 1.4. The radioisotope 54Mn emits positrons and beta 
particles that might be useful for various applications, but the intensities are Iβ+=5.8×10-7% and 
Iβ-=2.9×10-4%, which are much too low to be practically useful. However, 54Mn also emits a 
gamma-ray at an energy (Eγ=835 keV) that is not suitable for in vivo imaging but very feasible 
for several non-imaging detection methods, and the intensity of this gamma-ray is more than 
sufficient (Iβ+=99.98%). Many other radioisotopes of manganese emit radiation that meets the 
criteria described above, yet only a few of these radioisotopes satisfy the half-life requirements 
for most radiolabelling and in vivo experiments. The radioisotopes 46-52,46m,50m,52m,54Mn all emit 
positrons, and the intensities exceed, to varying degrees, the intensities of several other PET 
radiometals: Iβ+>99% for 46-50Mn, Iβ+>95% for 51,52mMn, and Iβ+=29.6% for 52Mn. However, only 
positron emitters 50m,51,52,52mMn have nuclear half-lives that are in the realistic range to be of 
practical use in terms of half-life of nuclear decay.  
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Table 1.4. Comparison of decay properties of radioisotopes of manganese. 
Applications Candidate Isotopes Half-Lifea Pertinent Emissiona 
Long-lived gamma-emitter 54Mn 312 days 834.8 keV (99.98%) 
    
PET 46-50Mn <0.5 sec Various (≥99%) 
 50mMn 1.8 min 1.54 MeV (106%) 
 51Mn 46.2 min 963 keV (97.1%) 
 52mMn 21.1 min 1.17 MeV (95.0%) 
 52Mn 5.6 days 242 keV (29.6%) 
  
SPECT None 
    
Radiotherapy 56Mn 2.6 hours 833 keV (99.9%) 
Percentages reflect total intensities for each type of emission. (Data accessed via: 
aBNL/NNDC/ENSDF.) 
Only 52Mn satisfied our preferences for a positron-emitting radioisotope of manganese 
with a relatively long half-life, so we selected 52Mn as the radiotracer for manganese behavior in 
our experiments. This isotope had the additional benefit that it can be produced in-house by 
proton bombardment from a low-energy cyclotron, instead of requiring a large-scale ion 
accelerator or a nuclear reactor. 
1.4.3. Characteristics of 52Mn 
Manganese-52 is unique in its half-life of several days which, was ideal for our 
applications. The total intensity and average energy of positron emission makes 52Mn a strong 
candidate for PET imaging; the abundance of gamma-rays make it a good candidate for non-
imaging radiotracer experiments where a detector for gamma-rays is used. Figure 1.7 and Table 
1.5 show simplified decay data for 52,52mMn.  
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Figure 1.7. Simplified level decay scheme for 52,52mMn. 
Only showing emissions with Itot>1%. (Data accessed via BNL/NNDC/ENSDF.) 
 
Table 1.5. Data for radioactive decay of 52Mn. 
 
(Data accessed via BNL/NNDC/ENSDF.)  
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1.4.4. Comparison of 52Mn to Other PET Isotopes 
Our primary motivation for using 52Mn for PET imaging is to study the interesting in vivo 
behavior of manganese and manganese-labeled compounds. The radioactive decay 
characteristics of 52Mn as compared to other PET isotopes is provided in Table 1.6. 
Table 1.6. Comparison of decay characteristics of 52Mn to other PET radionuclides. 
  Positron Emission Gamma Radiation 
 Half-Lifea Weighted Average Energya Total Intensitya Gamma Factorb 
  (keV)  (R·cm2·mCi-1·h-1) 
52Mn 5.6 d 242 29.6% 18.4 
124I 4.2 d 820 22.7% 6.6 
89Zr 3.3 d 396 22.7% 6.6 
86Y 14.7 h 660 31.9% 18.9 
64Cu 12.7 h 278 17.6% 1.1 
18F 110 m 250 96.7% 5.7 
68Ga 68 m 830 88.9% 5.4 
11C 20 m 386 99.8% 5.9 
(aData accessed via BNL/NNDC/ENSDF. bData from: Smith and Stabin, 2012.) 
In terms of acquiring the radionuclide needed for a PET study, Table 1.7 compares the 
routes for producing the PET isotopes that were listed in Table 1.6. 
Table 1.7. Comparison of 52Mn to other PET radionuclides. 
 Production 
 Most Common Target Target Natural Abundancea 
52Mn 52Cr(p,n)  (Solid) 83.8% 
124I 124Te(p,n)  (Solid) 4.7% 
89Zr natY(p,n)  (Solid) 100.0% 
86Y 86Sr(p,n)  (Solid) 9.9% 
64Cu 64Ni(p,n)  (Solid) 0.9% 
18F 18O(p,n)  (Liquid) 0.2% 
68Ga 68Ge (Generator) - 
11C 14N(p,α)  (Gas) 99.6% 
(aData accessed via: BNL/NNDC/ENSDF.)  
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In summary, the 52Cr(p,n) reaction provides a route for producing 52Mn, an imageable 
radiotracer with a half-life of several days, for experiments that depend on the chemistry of 
manganese. 
1.5. Thesis and Scope of this Dissertation 
The thesis for this dissertation is: Manganese-52 (52Mn) is feasible to produce using a 
biomedical cyclotron and simple chemical isolation that can be automated, and 52Mn can be a 
useful PET radioisotope for detecting and imaging the chemical and biological behavior of 
Mn(II) cations, salts, and radiolabelled compounds. The scope for this dissertation can best be 
grouped into four categories that are reflected in the chapters herein: 
 
• Nuclear cross-sections and chemical separation (Chapter 2) 
• Biodistribution and PET imaging of 52Mn (Chapter 3) 
• Applications of 52Mn in PET/MR imaging (Chapter 4) 
• Remotely-controlled modules for the isolation of PET radiometals (Chapter 5) 
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Chapter 2. Nuclear Cross-Sections and 
Chemical Separation of 52Mn1,2,3,4 
2.1. Background 
Essential to any routine isotope production protocol is the ability to select target 
thickness, beam energy, beam current, and bombardment time based on predicted yield, which in 
turn is based on nuclear cross-section data. Nuclear cross-sections are a means of expressing the 
probability of a nuclear reaction channel occurring when matter is bombarded with ions, 
neutrons, etc. It is expressed as the effective cross-sectional area of the target nuclei, hence its 
name and dimensions of length squared. Cross-section is often expressed as cm2 or barns, 
                                                
1 Much of this chapter was published previously: 
Wooten, A.L.†; Lewis, B.C.†; Lapi, S.E., 2015. Cross-sections for (p,x) reactions on natural 
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although millibarns are more appropriate for many reaction channels that are induced by low-
energy protons, such as those from the cyclotrons at our institution. 
Target thickness and beam energy are typically selected so that the entry and exit 
energies of the beam will span a region of the excitation function with high cross-sections for the 
product and little or no cross-sections for other, competing reaction channels that may produce 
contaminant isotopes. Designing production runs to optimize this energy “window” can improve 
yield and radionuclidic purity of the final product. Thus, it is important to have accurate cross-
section data for not only the reactions that produce the desired product, but also for the reactions 
that would produce contaminant isotopes. In this investigation, we bombarded chromium targets 
of natural isotopic abundance (natCr = 50Cr (4.3%), 52Cr (83.8%), 53Cr (9.5%), 54Cr (2.4%)), 
which could potentially produce several product isotopes. This work focused primarily on 
measurements for the production of 52Mn, but also for 52mMn and 54Mn as radiocontaminants. 
Only a few data sets are currently available with points at proton beam energy (Ep) ≤14 MeV for 
the natCr(p,x) reactions that produce 52,52mMn (Buchholz, et al., 2013; West Jr, et al., 1987; 
Barrandon, et al., 1975), and there are only data sets from enriched targets available for 54Mn at 
these low energies (Levkovskij, 1991; Gusev, et al., 1990; Skakun, et al., 1986; Zyskind, et al., 
1978; Kailas, et al., 1975; Johnson, et al., 1960). In this work, we contribute new experimental 
cross-section data for each of these (p,x) reactions that produce 52,52m,54Mn from bombardment of 
natural chromium with protons at low-energies. 
The excitation peak for the 52Cr(p,n)52Mn reaction is in the 24à6 MeV range of proton 
energies, meaning that production is optimized with ~24 MeV incident protons bombarding a 
target containing 52Cr that is thick enough to degrade the proton energy all the way to ~6 MeV 
(threshold for the 52Cr(p,n)52Mn reaction: Ep = 5.6 MeV). This is also the optimal energy range 
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for producing the metastable isomer 52mMn, which has an excitation function ~2-3x greater than 
the ground state. However, this short-lived radiocontaminant (t1/2=21.1 min.) is practically 
eliminated by decay within hours, without contributing significantly to production of the ground 
state because 52mMn has a branching ratio of <2% for isomeric transition to 52Mn. 
2.2. Experimental 
2.2.1. Materials 
Copper sheet (0.762 mm thick, 99.9% purity) was purchased from ESPI Metals (Ashland, 
Oregon, United States), and copper foil (0.025 mm, 99.999% purity) was purchased from Alfa 
Aesar (Ward Hill, Massachusetts, United States). Natural abundance chromium was 
electroplated by Four Star Finishing (Saint Louis). The aluminum for the target holders were 
6061-T6 aluminum alloy, pure aluminum (A.D. MACKAY, Denver North Carolina, United 
States), or pure niobium metal (A.D. MACKAY). All other solid and liquid chemicals were 
purchased from Sigma-Aldrich (Saint Louis, Missouri, United States), unless otherwise 
indicated. Nitrogen (N2) gas was purchased from Cee Kay Supply (Saint Louis). 
2.2.2. Target Preparation 
Copper monitor foils were produced by punching ~9.5 mm discs from 0.762 mm 
(nominal) copper foil. However, Cr metal is very brittle, so cutting or punching discs from thin 
Cr foil was not feasible. Furthermore, thin Cr foil was not commercially available without a 
permanently attached Mylar (polyethylene terephthalate) backing. 
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Therefore, we developed a method for fabricating batches of thin Cr foils that would fit 
into target holders. Thin, circular foil discs were produced through a process of electrodeposition 
of non-enriched Cr onto small plugs of Cu backing material, followed by removal of the Cu 
backing, similar to a method used in the past (Tanaka and Furukawa, 1959). Holes (~10 mm 
diameter) were cut or punched from Cu sheet, and these holes were then filled using ~9.8 mm Cu 
discs that were punched from elsewhere on the Cu sheet. On the “back” side of the plate, these 
discs were fixed in place by soldering the back of each disc to one of several long strips of thick 
(~1-2 mm diameter) bus bar wire that was also soldered to the large copper plate. Figure 2.1 
shows a sample that contained a 13x13 grid of copper plugs soldered in place on the back. 
The back of the sample was masked with a lacquer, and the entire sample was submerged 
(while connected to the cathode) into an industrial-scale chrome plating bath, and the unmasked 
side of the sample was electroplated with Cr. This bath electroplated with “hard chrome,” 
meaning thick (tens to hundreds of µm), ultra hard deposits of pure Cr metal. (The more popular 
type of chrome plating, “decorative chrome”, is roughly 1,000x thinner and usually plated over 
nickel or copper.) The bath was an aqueous solution of 100:1 chromic acid (H2CrO4) and sulfuric 
acid (H2SO4). (Safety note: The chromic acid was made from chromium(VI) oxide (CrO3 
powder), which is acutely toxic (Sigma-Aldrich, 2014).) The sulfuric acid was a commonly used 
additive that contributed sulfate groups to the solution, which catalyzed the electroplating 
reaction (Mandich and Snyder, 2010). To produce individual Cr discs, the bus bar wire was 
clipped on either side of each copper plug in the assembly, producing individual copper plugs 
plated on one side with chromium. These plugs were placed in ~3-8 M nitric acid in a large glass 
container. The nitric acid digested the copper while leaving the chromium intact, and the acid 
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solution was changed several times during this process. The final result was circular discs of thin 
(and very brittle) Cr metal foils with a diameter of 9.8 mm. 
 
Figure 2.1. Photographs illustrating the process for the fabrication of thin Cr foil discs. 
These images are representative images and not from the same production. (A similar figure was 
published in Wooten, et al., 2015 (supplementary information). Image courtesy of Elsevier. Used 
with permission.) 
Before each stack of foils was assembled, the thickness of each Cr and Cu foil was 
calculated based on its diameter and mass, assuming cylindrical geometry. Based on instrumental 
uncertainty from the measurements of diameter and mass, the uncertainty in the calculated 
thickness of each Cu or Cr foil was <1.1%. Across all the Cr foil discs in all configurations and 
bombardments the diameter was 9.8 mm for all discs, with an average thickness of 82 µm 
(±10.5%), and the Cu foil discs had a diameter of 9.5 mm and an average thickness of 18.6 µm 
(±2.6%).  
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Cr foils were tested for elemental purity by a sixty-element screening performed by 
Galbraith Laboratories (Knoxville, Tennessee, United States). The foil was dissolved in acid and 
analyzed by inductively coupled plasma mass spectrometry (ICP-MS). The only contaminants 
>100 ppm (within uncertainty) were Sn (1195 ppm) and Se (134 ppm). This was a semi-
quantitative screening with relative error of up to 50% for all measurements. 
A custom target holder was designed and machined out of 6061-T6 aluminum alloy 
(95.8-98.6% aluminum) to hold the stacks of foils during cyclotron bombardment. Our design 
consisted of a base containing a dish with smooth vertical walls to hold the stack of foils yet 
allow for quick, easy removal of the foils from the dish after bombardment. The base had a blind 
hole on the non-vacuum side for improved contact with the circulating cooling water. The target 
holder also included a screw-on cap to hold the stack of foils in the holder when the foils were 
held vertically in the target station—perpendicular to the incident beam. This cap was threaded 
to match corresponding threads on the base, and the cap had a circular “window” to expose the 
foils directly to the beam. 
 
Figure 2.2. Photograph of one style of target holder used in this dissertation. 
(The photographs on the left and right sides of the arrow are representative images, since they are 
not pictures of the exact same components or even the exact same designs.) 
Four different stacked foil configurations consisting of Cu and Cr foils were used in this 
work to measure cross-sections in the Cr foils. The Cu foils were included for determination of 
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flux (Section 2.2.4.5) and entry energy (Section 2.2.4.4) of the proton beam based on monitor 
reactions in the Cu. Each configuration was bombarded in three separate targets, for a total of 12 
bombarded targets in this work. The energy of the proton beam at the middle of every chromium 
foil was predicted using The Stopping Range of Ions in Matter (SRIM) software (Ziegler, et al., 
2010), which implements the perturbative Bethe formula (with Bloch correction) for the stopping 
power (i.e., energy loss) of charged particles due to interactions with orbital electrons in a 
material. 
2.2.3. Cyclotron Bombardment 
Each target assembly was bombarded with low-energy (Ep<15 MeV) protons from the 
CS-15 cyclotron (The Cyclotron Corporation, Berkeley, California, United States) at the 
Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine 
(WUSM). During bombardment, the back of the target holder was cooled by circulating chilled 
water (T≈2-5 °C), and the front of the target was cooled by a He gas jet. Bombardments used in 
this work were typically 1-3 µA for a duration of bombardment (tb) that varied between 105 and 
135 sec, (120±15 sec). This uncertainty was accounted for (Section 2.2.4.8) in our determination 
of beam energy, beam current, cross-sections, and saturation yields. 
2.2.4. Cross-Section Measurement 
2.2.4.1. Gamma-Ray Spectroscopy 
Proton bombardment of the stacked foil targets produced radioisotopes in each Cu and Cr 
foil, and these product isotopes were identified and quantified by gamma-ray spectroscopy from 
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a high-purity germanium (HPGe) detector (model: GC2018; relative efficiency: 24.5%) that was 
connected to a digital spectrum analyzer (DSA; model: DSA-1000) and operated by the Gamma 
Acquisition & Analysis module of the Genie 2000 spectroscopy software package (v. 3.3). All 
three components were from Canberra (Meriden, Connecticut, United States). The principal 
isotopes measured were 63,65Zn in the Cu foils and 52,52m,54Mn in the Cr foils, and their production 
and decay characteristics are summarized in Table 2.1. 
A few hours after each bombardment, the stacked foil target was carefully disassembled. 
For each gamma-ray counting experiment, one foil was placed in a small weigh boat that was 
then placed on a 3 mm thick plastic shelf positioned at one of several distances directly above the 
open end of the HPGe crystal. Various positions were utilized so that samples could be counted 
at different distances from the detector to ensure a detector dead time (td) that was ≤5% of 
detector real time (tr). Each Cu and Cr foil was counted for at least 10 min. of detector live time 
(tl). Additionally, all of the Cu foils were counted again several months later for 10 h each to 
measure a greater number of counts from the long-lived product 65Zn (t1/2=244 days) for better 
statistics.  
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Table 2.1. Summary of the radioisotope products in irradiated Cu and Cr foils. 
Primary Target† Product Gamma-Rays‡ Daughter 
 (Natural Abundance)  (Half-Life)  (Branching Ratio) (Half-Life) 
 
Cu foil:    
63Cu (69.2%) 63Zn (38.5 min.) 670 keV (8.2%) 63Cu (stable) 
  962 keV (6.5%)  
65Cu (30.9%) 65Zn (244 d) 1116 keV (50.0%) 65Cu (stable) 
 
Cr foil:    
52Cr (83.8%) 52Mn (5.6 d) 1434 keV (100%) 52Cr (stable) 
  936 keV (94.5%)  
  744 keV (90.0%)  
  1334 keV (5.1%)  
  1246 keV (4.2%)  
  848 keV (3.3%)  
52Cr (83.8%) 52mMn (21.1 m) 1434 keV (98.3%) 52Cr (stable) 
  378 keV (1.7%) 52Mn (5.6 d) 
54Cr (2.4%) 54Mn (312 d) 835 keV (99.98%) 54Cr (stable) 
 
†All of the product isotopes in this table are produced primarily by (p,n) reactions from proton 
bombardment of Ep<15 MeV. ‡In our analysis, we only considered gamma-rays that were emitted 
by only one isotope/isomer, so the 1434 keV gamma-rays emitted by both 52Mn and 52mMn was 
excluded from analysis. (Nuclear data accessed via: BNL/NNDC/ENSDF.) 
The HPGe detector was calibrated for photopeak energy and detector efficiency. The 
energy calibration was performed using a mixed-gamma source in a sealed microcentrifuge tube 
(Eckert & Ziegler Analytics, Atlanta, Georgia, United States). We also performed our own 
detector efficiency calibrations using a mixed-gamma “point source” (Eckert & Ziegler 
Analytics). The detector efficiency (εc) was calculated for each gamma-ray energy (Eγ), and ln εc 
was plotted versus ln Eγ. This plot was linear between 166-1836 keV, so the data in this range 
were fit to the equation: 
 ln !! = m ∙ ln!! + ! , (2.1)  
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where m and b are the slope and intercept of the linear fit. All gamma-rays measured in this 
investigation were within this range and are listed in Table 2.1. Equation 2.1 was solved for εc 
and fitted by floating for m and b using the gnuplot software (v. 4.6.6) (Williams, 1986), which 
implemented a non-linear least squares algorithm (Levenberg-Marquardt algorithm) (Crawford, 
2014). The resulting fits served as calibration curves for calculating detector efficiencies for 
gamma-rays emitted by radionuclide products in the irradiated Cu or Cr foils. This calibration 
was performed for each geometry counting of irradiated Cu or Cr foils. 
The fitting method weighted the fit parameters based on y-direction uncertainty in the 
data points. This uncertainty represented the uncertainty of the gamma emission rates for each 
gamma-ray from the calibration source (taken from the reference sheet), as well as the 
uncertainty in the counting of these emissions (Section 2.2.4.8). To improve the goodness-of-fit 
value, we would sometimes increase the level of statistical error to 1.5 or 2 standard deviations. 
This improved the fitting, and the additional uncertainty was accounted for in the uncertainty of 
the fitted parameters and propagated accordingly. 
Additionally, to test for self-shielding in our Cr foils, we performed a calibration with the 
point source positioned directly above the same type of Cr foil used in our stacked foil 
experiments. The resulting efficiency calibration curve had a slope and y-intercept that were both 
within 0.5% of the values in the efficiency curve that we used for foils that were counted from 
the same geometry, thus illustrating that there was no significant attenuation of gamma rays by 
the foils themselves.  
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2.2.4.2. Data Analysis 
We concur with Gagnon, et al. (2011a) that transparent, detailed explanation of analysis 
in cross-section experiments can reduce confusion in comparing and categorizing these studies. 
Here, we explain in detail the analysis that was used to transform counts from gamma 
spectroscopy into activity, then beam energy, then beam current, and finally into cross-section 
results for 52,52m,54Mn. We also describe our uncertainty analysis. Unless otherwise stated, all 
analysis work was performed in Excel for Mac 2011 (v. 14.4.4) (Microsoft, Redmond, 
Washington, United States) or Excel 2002 (v. 10) (Microsoft) for Windows (Microsoft). 
2.2.4.3. Calculating Radioactivities of Radionuclide Products 
The principle raw data for this investigation came from gamma spectroscopy, specifically 
the net peak area or number of counts (Nc) in each full-absorption photopeak of interest. For each 
such peak, the activity of the corresponding radioisotope at the beginning of counting (Ac) was 
proportional to the number of counts according to the following equation (Canberra, 2009): 
 !! = !!!!!!!!!! , (2.2) 
where Iγ is the branching ratio for the gamma-ray, and Cd is the following correction factor for 
decay during counting of the first member of a decay chain (Canberra, 2009; IEEE, 1999; 
Moore, 1973): 
 !! = !!!!!!!!!!  , (2.3)  
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where λ is the decay constant for the isotope (λ=ln(2)/t1/2). For isotopes with multiple 
characteristic gamma-rays, the activities (and uncertainties) calculated for the gamma-ray peaks 
were combined to a single value by an inverse-variance weighted average. Then, each activity 
was decay-corrected to the activity at EOB (AEOB). 
2.2.4.4. Calculating Energy of Proton Beam 
The entry beam energy was calculated based on monitor reactions (Gagnon, et al., 2011a; 
Avila-Rodriguez, et al., 2008; Kim, et al., 2006; Takacs, et al., 1997; Blessing, et al., 1995; 
Scholten, et al., 1994; Kopecky, et al., 1993; Piel, et al., 1992; Tarkanyi, et al., 1991; Kopecký, 
1985). In this work, we used the natCu(p,x)63,65Zn monitor reactions with recommended cross-
section data provided by the Nuclear Data Section of the International Atomic Energy Agency 
(IAEA/NDS). The activities were measured (Section 2.2.4.3) for 63Zn and 65Zn produced in a Cu 
monitor foil on top of the stack in n=5 different targets, and the ratio of the activities, AZn-63 / AZn-
65, was used to find the corresponding proton beam entry energy. This was determined by linear 
interpolation between two adjacent points of the activity ratio calculated using the IAEA-
recommended cross-section data (increment=0.1 MeV) in the following equation (Gagnon, et al., 
2011a; 2011b; Avila-Rodriguez, et al., 2009): 
 
!!"!!"!"#!!"!!"!"# = !!"!!" !!!!!!"!!"!!!!"!!" !!!!!!"!!"!!  , (2.4) 
where σ is the cross-section and tb=120±15 sec. Uncertainty was propagated through Equation 
2.4 and through the linear interpolation.  
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After determining the proton beam energy in those foils, the inverse-variance mean of 
those energies was determined to be the beam energy at the midpoint of the Cu foil on top of the 
stack (Ep=13.10±0.04 MeV) (Figure 2.3). The Transport of Ion in Matter (TRIM) module within 
the SRIM software package was used to perform Monte Carlo simulations of transmitted ions to 
determine that the entry energy was 13.285±0.065 MeV, thus this was used as the entry energy 
for simulating the energy of the proton beam at the midpoint of all foils in all targets. Because of 
the spread in the thickness of our Cr foils, the beam energies for all foils in all configurations 
(excluding top Cu foils) were simulated using individual thicknesses that had been determined 
by mass (Section 2.2.2). We excluded from the data set any Cr foils where the beam energy was 
degraded >1.5 MeV from the midpoint of the previous foil to the midpoint of that Cr foil because 
of the thickness of the foils and the energy of the beam. The longitudinal straggling of the 
protons was estimated as the population standard deviation of the energies of N≈1,000 
transmitted protons. We estimated that the uncertainty in the entry energy (±0.04 MeV) was not 
correlated to the uncertainty in the beam energy in each foil in the stack, so we added this value 
(in quadrature) to the uncertainty due to longitudinal straggling in each TRIM simulation. We 
increased this uncertainty for the simulated beam energy at the midpoint of each foil by 1.1% to 
estimate the effect of the uncertainty in the measured thickness of each Cu and Cr foil (Section 
2.2.2).  
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Figure 2.3. Plot showing the activity ratios calculated using tb=120 sec and recommended 
cross-section data from the IAEA for the natCu(p,x)63,65Zn monitor reactions. 
A 6th-order polynomial fit to those results between 10-16 MeV proton energies; and beam energies 
for the copper foil on top of stacked targets in Configurations E and F that were calculated using 
this equation. Based on these results, the average beam energy at the midpoint of the top Cu foil 
was 13.10±0.04 MeV. This translated to an entry beam energy of 13.285±0.065 MeV, which was 
used for all calculations and simulations for all bombardments. Horizontal and vertical error bars 
for the experimental points are plotted but small. (IAEA data from: IAEA/NDS.) (Image: Wooten, 
et al., 2015. Image courtesy of Elsevier. Used with permission.) 
2.2.4.5. Calculating Flux of Proton Beam 
Similar to published methods (Lapi, et al., 2007; Kopecký, 1985; Greene and Lebowitz, 
1972), the beam current was determined by production of 63Zn in the Cu monitor foils. The 
standard activation equation was used to calculate current: 
 !!"# = !"# 1− !!!!!  , (2.5) 
where AEOB is the activity of a product at EOB; n is the number of target nuclei per area; and ϕ is 
the flux of beam particles passing through the target. The activity of 63Zn produced from the 
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natCu(p,x)63Zn reaction was calculated as described in Section 2.2.4.3. The number of target 
nuclei per area was calculated by the following equation: 
  n=!! !!! ℎ  , (2.6) 
where NA was Avogadro’s constant; ρ was the density of Cu metal; Ar was the relative atomic 
mass of the non-enriched Cu metal; and h was the individual thickness of the Cu foil (determined 
by mass). To determine the cross-section for calculating beam current, we interpolated between 
adjacent cross-section points (interval: 0.1 MeV) from the IAEA-recommended excitation curve 
for the natCu(p,x)63Zn reaction (IAEA/NDS). Uncertainty in the beam energy was propagated 
(Section 2.2.4.8) through the interpolation. Equation 2.5 was solved for ϕ, calculated based on 
the production of 63Zn in the topmost Cu foil in each stacked foil target. The uncertainties in the 
values entered in these calculations were propagated to give the uncertainty in the beam current 
for that bombardment and eventually were propagated to the uncertainty of the proton energies in 
the final results. 
2.2.4.6. Calculating Nuclear Cross-Section Results 
Cross-sections were measured solving Equation 5 for σ. The following values were used: 
AEOB calculated for 52,52m,54Mn in each Cr foil (Section 2.2.4.3); n calculated using the mean 
thickness of our Cr foils; ϕ calculated for each bombardment; and tb=120±15 sec. We bombarded 
three targets for each configuration, and the same beam energy was assumed for every foil in the 
same position within a configuration, as calculated using the TRIM module. Cross-section results 
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from foils across different configurations were grouped into “bins” based on beam energy. For 
each bin, the energy and cross-section result (and uncertainties) were determined by inverse-
variance weighted averages in the x- and y-directions and reported as our final results (Figure 
2.4-Figure 2.6, Table 2.2-Table 2.4). As not all irradiated chromium foils were counted soon 
enough to detect 52mMn, our calculation neglects its contribution to production of 52Mn. 
2.2.4.7. Calculation of Predicted Yields at Saturation 
Cross-section results were used to calculate the saturation activity yield. The activation 
equation (Equation 2.5) was used to calculate yields at saturation from our cross-section data, 
with a proton flux of 1 µA. Table 2.5 shows the predicted saturation yields that we calculated for 
each isotope product using our measured cross-section data. 
2.2.4.8. Uncertainty Analysis 
Error was propagated from the origin to final results as absolute uncertainty, not as 
percentages. Uncertainties <0.05% were neglected. Instrumental uncertainty was considered for 
every measurement, and random uncertainty was calculated for every repeated measurement and 
for counting of a random process (i.e., gamma spectroscopy). Our statistics are presented in a 
descriptive (not inferential) manner and thus we present the mean, standard deviation, and 
sample size for all of our final cross-section results (Table 2.2-Table 2.4). 
Instrumental uncertainty was typically either provided by the instrument, or otherwise 
estimated to be ±0.5 times the most precise digit of the measurement from that instrument. All 
random uncertainties were calculated as ± one standard deviation for a sample, population, or 
Poisson distribution, and this standard deviation was propagated onward. For the foil counting, 
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we estimated that the uncertainty in the net peak area to be one standard deviation of the Poisson 
distribution (i.e., the square root of the number of counts in each peak). Whenever an average 
was calculated, the error was expressed as either a sample standard deviation (for sample size, N, 
<20) or a population standard deviation was calculated (e.g., for Monte Carlo results for ~1,000 
transmitted ions from simulations in TRIM). Whenever a weighted average was appropriate, the 
inverse-variance weighted mean, !!, was calculated by the equation: 
 !! = !! !!!!! !!!!  , (2.7) 
where xi is a measurement and si is the uncertainty in that value. This type of weighting 
minimizes the uncertainty in the mean, which was: 
 !! !! = !! !!!!   . (2.8) 
Uncertainties were propagated by applying the following equation (Arras, 1998; 
Croarkin, 2003) for the propagation of relatively small uncertainties through any calculation that 
used input values that had uncertainty: 
 !! ! = !"!!! ! !!! + !"!!! !"!!! !!"!!!!  , (2.9) 
where s(f) is the error in the calculated value f; Xi is each variable used to calculate f; si is the 
standard deviation in Xi; and sij is the covariance for variables i and j (for i ≠ j). Our only 
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correlated sources of error were the fitted parameters for our efficiency calibrations, so the 
second term of Equation 2.9. This equation was zero for all other propagations of error. The 
partial derivative(s) in Equation 2.9 account for the relative influences of the uncertainty of each 
quantity on the uncertainty of the calculated quantity. All uncorrelated uncertainties for the same 
value, such as rounding error, instrumental error, and statistical error, were added in quadrature 
to give the total uncertainty for that quantity. 
2.2.5. Chemical Separation 
2.2.5.1. Chemical Isolation by Cation-Exchange Chromatography 
Following a method published by Buchholz, et al. (2013), we used cation-exchange 
chromatography to separate 52Mn from the chromium metal target after proton bombardment. 
The irradiated chromium metal was dissolved in approximately 0.5-1 mL hydrochloric acid that 
was diluted to a final concentrations of approximately 0.6-6.1 M. The solution was then 
repeatedly evaporated and resuspended in sulfuric acid to replace the chloride anions with 
sulfate, then diluted to form ~0.1 M sulfuric acid. Under these conditions, the solution was 
transferred to a pre-conditioned column of AG 50W-X8 cation-exchange resin (Bio-Rad, 
Hercules, California, United States). Much of the chromium(III) passed through the column and 
was further eluted in 0.1 M sulfuric acid, while 52Mn(II) was immobilized on the column. 
Frequently, a visible band of Cr(III) was also immobilized on the column. Manganese-52(II), 
along with this band of Cr(III), was eluted in ammonium citrate (which was used by Buchholz, et 
al.), as well as aqueous solutions of ammonium oxalate, hydrochloric acid, or sodium(I) chloride.  
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Chloride (Cl-) anions were removed from the solutions of HCl and NaCl by evaporating 
the product solution to dryness using heat and, sometimes, simultaneous evaporation with 
nitrogen (N2) gas. To remove the oxalate and citrate anions from their respective solutions, the 
solution was dried and elevated heat was used decompose those molecules, leaving behind a dry 
residue containing metal solutes. This method had been validated previously by heating a visible 
mass of ammonium oxalate until all visible solid had disappeared. The remaining dried 52Mn 
could be resuspended in another solvent, for example saline. Before animal injections, the pH of 
the solution containing 52Mn was tested and, if necessary, raised to the range of pH~4-7 using 
dilute sodium hydroxide (NaOH). 
2.2.5.2. Chemical Isolation by Anion-Exchange Chromatography 
An alternative method for isolating 52Mn from chromium metal was published recently 
by Graves, et al. (2015), which utilized anion-exchange chromatography. The key to this method 
was adding a large volume of ethanol to the digested target solution, presumably to complex with 
the Cr(III) cations (Severin, 2015), which would leave more chloride ions to complex with the 
Mn(II) cations. A method similar to the one described in the article was shared with us by the 
authors before publication, and we rapidly adapted it as our preferred separation method. 
First, the bombarded target was digested in ≤0.5 mL of concentrated (12.1 M) 
hydrochloric acid with gentle heat. Next, 200 proof ethanol was added to make the resulting 
solution 96% ethanol and 4% concentrated HCl (both percentages by volume). The resulting 
solution was transferred to a pre-conditioned column of ~100-300 mg of AG 1-X8 strong anion-
exchange resin. Under these conditions, most Cr(III) ions were eluted, while Mn(II) was 
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immobilized on the small resin column. After rinsing the column with additional 96%/4% 
ethanol/HCl, most of the 52Mn(II) and Cr(III) that were on the column were eluted in dilute HCl. 
Although the Cr(III) had decreased significantly from the original target solution, its 
presence in the eluted product meant that the above separation procedure neeeded to be repeated. 
Graves, et al. recommended performing the separation a total of three times. The eluted product 
was dried down with heat and sometimes N2 gas and then redissolved in a small volume (~0.1-
0.5 mL) of concentrated HCl. Next, 200 proof ethanol was added to make the resulting solution 
into 96%/4% ethanol/HCl. In later experiments we were able to “recondition” the same column 
by rinsing it with >10x column volume of each of the following solvents: 2 M HCl, 6 M HCl, 
96%/4% ethanol/HCl, and water, always ending with the 96%/4% ethanol/HCl solution. The 
52Mn in ethanol/HCl was transferred to either a fresh, pre-conditioned column or the 
“reconditioned” original column, and the separation process was repeated at least two more times 
to further reduce Cr(III) content. 
Chromium(III) content was determined at various check-points in the procedure using 
microwave plasma atomic emission spectroscopy (MP-AES). These samples were tested for 
Cr(III) by ICP-AES that had been calibrated using an atomic absorption spectroscopy (AAS) 
standard solution for Cr(III) in dilute HCl. Additional metal contaminants were assayed by ICP-
AES following a similar procedure and using standard solutions for the corresponding metal 
cation, always in dilute HCl. 
2.2.6. Characterization of Products 
The recovery of the separation was assayed by measuring the radioactivity of the product 
using an ionization dose calibrator. The radionuclidic purity was tested using gamma-ray 
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spectroscopy by calculating the amount of any radionuclide other than 52Mn and then expressing 
this amount as a percentage of the total radioactivity or total number of radioactive atoms 
detected by gamma-ray spectroscopy. Manganese-52m was removed by overnight decay, and 
54Mn was produced at a very low reaction rate because the natCr(p,x)54Mn reaction had a cross-
section that was ~10x lower than the natCr(p,x)52Mn reaction, presumably due to the low natural 
abundance of 54Cr (n.a.=2.4%) needed for the 54Cr(p,n)54Mn reaction. 
Since many transition metals form bold colors in solution, visual observation with the 
unaided eye can be a good quick test for significant concentrations of the dissolved metal target 
in the separated product. Since Cr(III) is green in solution, we could quickly oberve by eye the 
presence of Cr(III) above a certain threshold. Future work would include developing a protocol 
for determining effective specific activity (Section 5.2.5) by titration with a chelator, followed by 
radio-TLC. DOTA has been show to be a suitable chelator for manganese (Graves, et al., 2015). 
For all of the methods mentioned above for characterizing chemical purity, it is worth noting that 
although 52,52m,54Mn all decay to stable daughter isotopes of chromium, and any other radiometal 
contaminants would decay to stable daughter isotopes of other transition metals, none of these 
stable daughters would be present in great enough concentrations to contribute significantly to 
chemical impurities.  
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2.3. Results 
2.3.1. Nuclear Cross-Section Results 
The stacked-foil experiments performed in this work produced cross-section data for the 
natCr(p,x)52,52m,54Mn reactions for proton energies <14 MeV. We did not observe any other 
isotopes in the Cr foils from any other reactions or from the two other stable isotopes of Cr: 50Cr 
(4.3% natural abundance) or 53Cr (9.5% natural abundance). Our final cross-section results are 
plotted in Figure 2.4-Figure 2.6. 
2.3.1.1. natCr(p,x)52Mn 
At low proton energies, 52Mn was likely only produced by the 52Cr(p,n)52Mn reaction 
(threshold: 5.600 MeV; 52Cr: 83.8% natural abundance) as the 53Cr(p,2n)52Mn reaction 
(threshold: 13.688 MeV; 53Cr: 9.5% natural abundance) (BNL/NNDC/QCalc, 2014) has an 
energy threshold above the upper limit for our calculated entry beam energy. Therefore, results 
can be compared to published cross-sections for not only the natCr(p,x)52Mn reaction, but also the 
52Cr(p,n)52Mn reaction, after scaling down the published results from enriched targets based on 
natural abundance of 52Cr. Results for the natCr(p,x)52Mn reaction are shown in Figure 2.4. Our 
results are in agreement with published results for natural chromium targets (Buchholz, et al., 
2013; West Jr, et al., 1987; Barrandon, et al., 1975), as well as re-scaled results from enriched 
targets (Levkovskij, 1991; Skakun, et al., 1986; Wing and Huizenga, 1962; Linder and James, 
1959; Boehm, et al., 1952).  
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Figure 2.4: Cumulative cross-section results for the natCr(p,x)52Mn reaction. 
Other published data sets are also plotted, including rescaled results from enriched 52Cr targets. 
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.) 
Table 2.2 Cross-section results for the natCr(p,x)52Mn reaction. 
Energy Cross-Section 
Ep  
(MeV) (b) 
12.68±0.04 0.102±0.009 
12.37±0.04 0.099±0.007 
12.0±0.1 0.104±0.011 
11.2±0.1 0.086±0.011 
10.3±0.1 0.085±0.011 
9.3±0.1 0.060±0.011 
8.9±0.1 0.059±0.007 
8.3±0.1 0.047±0.005 
8.0±0.1 0.050±0.005 
6.6±0.2 0.032±0.004 
(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.)  
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2.3.1.2. natCr(p,x)52mMn 
52mMn has cross-sections roughly three times larger than 52Mn in our energy range, and 
52mMn can be produced by the 52Cr(p,n)52mMn reaction (same threshold as the ground-state 
reaction) (BNL/NNDC/QCalc, 2014). Just as with the natCr(p,x)52Mn results, there are no 
competing reactions that produce 52mMn from natural Cr in our proton energy regime. Therefore, 
our cross-section results can be compared to published results for both the natCr(p,n)52mMn 
reaction, as well as for the 52Cr(p,n)52mMn reaction, after scaling down the published results from 
enriched targets based on natural abundance of 52Cr. Our results for the natCr(p,x)52mMn reaction 
are shown in Figure 2. For this reaction product, only five values were reported because many Cr 
foils were not counted quickly enough to detect 52mMn before it decayed. The results from 
Barrandon, et al. (1975) are noticeably less than all other published results at Ep>10 MeV. 
However, our results agree well with 52mMn cross-section data from other natural chromium 
target publications that were also cited for 52Mn in Section 2.3.1 (Buchholz, et al., 2013; West Jr, 
et al., 1987; Barrandon, et al., 1975), as well as re-scaled results from enriched targets 
(Levkovskij, 1991; Skakun, et al., 1986; Wing and Huizenga, 1962; Linder and James, 1959; 
Boehm, et al., 1952). It appears that the excitation peak from Barrandon, et al. (1975) is not as 
high as all of these other published cross-sections, and our results are closer to the other studies.  
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Figure 2.5. Cross-section results for the natCr(p,x)52mMn reaction. 
Other published data sets are also plotted, including rescaled results from enriched 52Cr targets. 
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.) 
Table 2.3. Cross-section results for the natCr(p,x)52mMn reaction. 
Energy Cross-Section 
Ep  
MeV b 
12.45±0.04 0.274±0.022 
11.3±0.1 0.233±0.042 
9.3±0.1 0.246±0.043 
8.4±0.1 0.209±0.028 
6.6±0.2 0.116±0.023 
(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.)  
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2.3.1.3. natCr(p,x)54Mn 
54Mn was detected in lower yields than 52,52mMn. The only logical reaction channel that 
would have produced this isotope in natural Cr was the 54Cr(p,n)54Mn reaction (threshold: 2.200 
MeV; 54Cr: 2.4% natural abundance) (BNL/NNDC/QCalc, 2014). Results were also compared to 
cross-section results from enriched targets that were scaled down based on the natural abundance 
of 54Cr. Our results for the natCr(p,x)54Mn reaction are shown in Figure 2.6. Only one published 
data set was reported for the production of 54Mn from natural chromium with Ep≤30 MeV, and 
this data set only included cross-sections for Ep ~17-38 MeV. Therefore, we compared our 
results with published cross-sections from enriched 54Mn targets (Levkovskij, 1991; Gusev, et 
al., 1990; Skakun, et al., 1986; Zyskind, et al., 1978; Kailas, et al., 1975; Johnson, et al., 1960) 
by rescaling the published cross-sections according to the natural abundance of 54Cr. 
 
Figure 2.6. Cross-section results for the natCr(p,x)54Mn reaction. 
Other published data sets are also plotted, including rescaled results from enriched 54Cr targets. 
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.)  
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Table 2.4. Cross-section results for the natCr(p,x)54Mn reaction. 
Energy Cross-Section 
Ep  
MeV b 
12.5±0.1 0.0105±0.0014 
12.24±0.05 0.0138±0.0015 
10.0±0.1 0.0146±0.0015 
8.5±0.1 0.014±0.002 
7.8±0.1 0.0147±0.0011 
(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.) 
2.3.1.4. Predicted Saturation Yields 
Table 2.5 shows the predicted saturation yields for 52,52m,54Mn from natCr(p,x) reactions in 
the range of proton energies that was encompassed in our cross-section results for each isotope 
(Sections 2.3.1.1-2.3.1.3). 
Table 2.5. Predicted yields for natCr(p,x) reactions at saturation. 
Product Energy Range Predicted Yield at Saturationa 
 Ep Ypredicted 
 MeV mCi·A-1 GBq·A-1 
52Mn 12.7à6.6 27.1±1.0 1.00±0.04 
52mMn 12.4à6.6 82.2±5.1 3.0±0.2 
54Mn 12.5à7.8 4.5±0.2 0.165±0.008 
aSaturation defined as bombardment time, tb=10t1/2. (Data: Wooten, et al., 2015. Data courtesy of 
Elsevier. Used with permission.) 
2.3.2. Chemical Separation of 52Mn 
For the cation-exchange method, Figure 2.7 shows elution profiles for Cr(III), eluted in 
0.1 M H2SO4 and measured by UV-Vis spectroscopy, plotted along with 52Mn, eluted in various 
solutions and measured by radioactivity using a gas ionization dose calibrator. Not shown in 
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Figure 2.7 is the quantity of Cr(III) that was present in the eluted product, which was also visible 
often, especially when the volume of the product was concentrated. Preliminary separations 
using the anion-exchange isolation method demonstrated approximately equivalent durations for 
the procedure and resulted in lower recovery rates that were in the range of 40-70% (without 
decay correction). 
 
Figure 2.7. Elution profiles showing the elution of Cr(III) in 0.1 M H2SO4 and 52Mn(II) in 
various eluents. 
Cr(III) was measured by ultraviolet-visible spectroscopy, and 52Mn(II) was measured by 
radioactivity using a gas ionization dose calibrator. Solid and hollow symbols with the same shape 
correspond to the same experiment. The gap between plots includes intermediate rinses with 
various solutions between eluting Cr(III) and 52Mn(II). Not plotted: Cr(III) eluted after the initial 
elution of Cr(III), such as with the 52Mn product or in any of the intermediate rinses. 
2.4. Discussion 
We have bombarded 2-3 stacked Cr foils with thickness of ~60-90 µm with ~13-14 MeV 
protons at 10-15 µA beam current. Typically, the top Cr foil contains enough activity for each 
subsequent experiment, but this incident beam energy only exploits approximately half of the 
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excitation peak for the 52Cr(p,n)52Mn reaction. At proton energies of 13-14 MeV greater 
activities are required for scaled-up production, an incident proton energy of ~24 MeV and a 
thicker Cr metal target could significantly increase bombardment yields for 52Mn, while 
radiocontaminants could still be removed: 51Cr (t1/2=27.7 days) by chemical separation with the 
Cr target material, and 51Mn (t1/2=46.2 min.) by radioactive decay. 
Reliable cross-section data that includes results from multiple groups is beneficial for 
confirming cross-section results, which in turn affect several parameters for accelerator-based 
isotope production that are essential to product yield and radionuclidic purity. However, few 
published studies currently exist for the reaction channels that produce 52gMn and other isotopes 
from bombardment of natural Cr with protons at energies <14 MeV, which is an important 
energy range for many biomedical cyclotrons worldwide. In this work, we have measured cross-
sections for the natCr(p,x)52,52m,54Mn reactions. Our results were in general agreement with 
published results from natural Cr targets and re-scaled results from isotopically enriched Cr 
targets. Cross-section results reported here will contribute to more accurate yield predictions and 
enhanced radionuclidic purity in the production of the isotopes studied here, particularly 52Mn. 
2.5. Conclusions and Recommendations 
• Nuclear cross-sections have been measured for the natCr(p,x)52,52m,54Mn 
reactions for incident protons with energy ≤13 MeV, which is easily achieved 
by most cyclotrons at medical centers. The cross-section results agreed closely 
with theoretical simulations, and they can be used to predict yields of 
52,52m,54Mn when bombarding natural chromium with low-energy protons.  
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• Chemical isolation was performed using a published method that involved 
digesting the chromium target in HCl, replacing the HCl with dilute H2SO4 
and then immobilizing 52Mn(II) on a cation-exchange column. This method 
resulted with visible amounts of Cr(III) in the product. 
• Chemical isolation using a recently published method was more effective. 
This method involved digesting the chromium target in HCl, diluting this 
solution in ethanol, immobilizing 52Mn(II) on an anion-exchange column, and 
performing this process repeatedly. 
• Recommended future directions: Trace metal analysis after each round of the 
anion-exchange separation method to determine how many rounds are 
necessary; characterization of routine production including cyclotron yields, 
chemical recovery percentage, radionuclidic purity, and trace metals analysis. 
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Chapter 3. Biodistribution and PET Imaging 
of 52Mn1,2,3,4 
3.1. Background 
Although imaging of accumulated Mn(II) is possible by T1-weighted MRI, truly 
quantitative measurement of the biodistribution of manganese in vivo is difficult. Direct, 
quantitative testing of manganese concentrations in humans is difficult because the exact 
ingested or inhaled dose is typically unknown. However, preclinical imaging and biodistribution 
studies using tracer amounts of radiomanganese provide a route to quantify the amount of 
manganese as a percentage of administered dose in animal models. Past studies have examined 
the biodistribution of manganese in various forms administered by different routes in rodents and 
fish, and have generally found that manganese is distributed to many tissues throughout the 
body. Several studies have shown the distribution of manganese using the radiotracers 52Mn or 
54Mn, or utilizing stable manganese (55Mn: 100% natural abundance) (Baum, et al., 2010) and a 
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non-radioactive technique for quantifying metals. In this work, we utilized the isotope 52Mn to 
study the biodistribution of injected and inhaled solutions of free manganese in mice and rats. 
As discussed in Section 1.4, 52Mn is a radiotracer with a half-life that is useful for 
biomedical studies and emits positrons with a high enough branching ratio to make it a realistic 
radionuclide for in vivo imaging by PET. Therefore, we also performed a PET imaging study in 
mice following I.V. administration of 52Mn in aqueous solution. CT imaging of the same mice 
provided anatomical imaging, and ex vivo biodistribution after completion of all imaging 
confirmed quantification of the distribution of 52Mn that was visualized in the PET images. 
In the literature, free manganese has been shown to accumulate in the human pancreas 
following administration of a weakly bound manganese(II) chelate for manganese-enhanced 
MRI (MEMRI) (Botsikas, et al., 2012). Published ex vivo biodistribution results (Graves, et al., 
2015) and our own results determined that the pancreas tends to accumulate and retain free 
manganese. Studying uptake of 52Mn(II) by the pancreas is of interest for possible imaging 
applications related to diabetes, which showed significantly lower uptake of the MEMRI contrast 
agent in humans (Botsikas, et al., 2012). Since many diabetes studies use rats as animal models, 
and since rats have larger organs that can be better for imaging than in mice, we also studied the 
biodistribution of manganese in rats. Relatively long timepoints up to seven days post-injection 
were examined to allow time for manganese to decrease in tissues near the pancreas to increase 
contrast on PET imaging. After performing a biodistribution study in rats at these timepoints, 
PET/CT imaging studies were also performed. 
This chapter presents experiments using animal models investigating the biodistribution 
for free 52Mn that was administered in either saline or water. The biodistribution results and 
PET/CT images presented here are potentially useful as supporting information for 
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environmental and occupational regulations, for designing PET studies utilizing free 52Mn, such 
as pancreas imaging in diabetes applications, and for predicting biodistribution of free 
manganese that might dissociate in vivo from a MEMRI contrast agent. 
3.2. Experimental 
3.2.1. Radionuclide Production 
The radioactivity that was used in this chapter was produced and isolated using methods 
that are described in Section 2.2.5. In almost every production, the 52Mn was eluted in HCl, the 
product was dried down, then resuspended in saline. If necessary, the pH of the resuspended 
saline product was adjusted with HCl and/or NaOH. 
However, for the PET/CT imaging (and post-imaging ex vivo biodistribution) in mice, the 
52Mn was eluted in 0.067 M ammonium oxalate solution, and the ligand was removed in the 
following manner. The ammonium oxalate product was heated to dryness, and then the heat was 
increased to burn away the ammonium oxalate, leaving behind a residue containing 52Mn in the 
vessel. The remaining 52Mn was resuspended by adding water followed by a drop of 6 M 
hydrochloric acid, then heated to dryness. This evaporation and resuspension was repeated 
without any hydrochloric acid, then the 52Mn was finally resuspended in water, resulting in a 
solution with pH of ~6.5, so pH adjustment was not performed because this pH was considered 
safe for intravenous injection in the mice.  
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3.2.2. Animal Models 
All animal models used in this dissertation were purchased from Charles River 
Laboratories (Wilmington, Massachusetts, United States). Mice were allowed to eat and drink ad 
libitum, except for during handling, injection, and imaging until sacrifice. No mice in any group 
died during injection, inhalation or otherwise prior to their designated timepoint. All animal 
keeping and husbandry conformed to regulations of the Division of Comparative Medicine 
(DCM) at WUSM, and all experiments involving animal subjects were performed under a 
protocol that was approved by the Animal Studies Committee of WUSTL. 
The biodistribution-only studies in mice that compared intravenous injection and aerosol 
inhalation were performed using male CD-1 mice. The PET/CT and post-imaging biodistribution 
study was performed using two male C57-Black-6 mice. All rat studies used male Sprague-
Dawley rats. 
3.2.3. Intravenous Injection of 52Mn 
Mice and rats were injected via tail vein with ~100 µL volume that contained: ~5-10 µCi 
for biodistribution-only studies and ~80-120 µCi for PET imaging studies of rats. For the mouse 
PET/CT, each animal was injected with 41 µCi of 52Mn in 50 µL volume. The sample sizes for 
the studies included in this chapter were as follows: n=4 for biodistribution-only in mice, n=3 for 
biodistribution only in rats, and n=2 for PET/CT imaging in mice or rats. 
The standard dose for administration was based on a single extra syringe of the dose that 
was weighed before and after expelling its contents to determine the mass of this liquid. The 
expelled contents were diluted to 100 mL volume, and then the radioactivity was measured in an 
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aliquot from this dilution. This result was used to calculate the concentration of activity of the 
original dose solution. 
3.2.4. Inhalation of Aerosols Containing 52Mn 
The inhaled doses of 52Mn salt solutions were administered to mice as previously 
reported by our group (Aweda, et al., 2013; Aweda, et al., 2015) using other radiolabeled 
compounds. Solutions were loaded into a Small Volumetric Mean Diameter (VMD) Nebulizer 
Unit (Aeroneb Lab, Aerogen, Dangan, Galway, Ireland) with the following specifications 
(Aerogen, 2004): >0.1 mL·min-1 flow rate, 4.0-6.0 µm VMD, <0.2 mL residual volume. The exit 
port of the nebulizer was inserted into a chamber made from a clear plastic (Figure 3.1). 
Four mice were inserted individually into four tubes with a plastic plunger to gently push 
their body to the front of the tube and their snout through a small opening at the opposite end of 
the tube. The 52Mn solution was pipetted into the liquid reservoir of the nebulizer and then the 
nebulizer was powered on, producing an aerosol that filled the chamber. The mice were allowed 
to inhale the aerosol for ~4-7 min., then the tubes were detached, and the mice were removed 
from their tubes. One of the mice from each inhalation group of four mice was euthanized 
immediately to serve as the standard dose received for its cohort—before activity could be 
excreted from its body. The remaining three mice would be used for ex vivo biodistribution 
studies, so the biodistribution results for each timepoint after inhalation of 52Mn represent n=3 
mice.  
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Figure 3.1. Plastic chamber for inhalation studies in mice. 
Nebulizer shown inserted in the ceiling of the chamber, but not connected to its power supply. 
(Image: Aweda, et al., 2013 (supplementary information). Image courtesy of The Royal Society of 
Chemistry. Used with permission.) 
3.2.5. Ex Vivo Biodistribution 
At each timepoint post-administration, the mice or rats for that timepoint were 
euthanized, dissected, and each tissue was weighed and analyzed for radioactivity (Beckman 
Instruments, Irvine, California, United States) (De Silva, et al., 2012). The radioactivity in the 
diluted standard dose solution for the intravenous cohort (Section 3.2.3) and the carcass of the 
standard dose mouse from the inhalation cohort (Section 3.2.4) were each measured in the same 
manner. The percentage of injected or inhaled dose per gram of tissue (%ID/gram) was 
calculated. When comparing the results from these studies, we examined the magnitude of the 
uptake of 52Mn in tissues as %ID/gram and as a function of time and mode of administration. 
3.2.6. PET/CT Imaging 
To reduce scanner time and because these mice were small enough, all imaging in the 
mouse study was performed simultaneously for both mice lying together side-by-side on a 
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specially made bed of each scanner. Rat imaging was performed individually. Shortly before 
each timepoint for PET imaging, anatomic images were obtained by non-contrast CT using an 
Inveon small animal PET/CT scanner (Siemens Preclinical Solutions, Knoxville, Tennessee, 
United States). CT imaging was repeated before each timepoint for PET imaging. 
PET imaging was performed using either the Inveon PET/CT scanner or a microPET 
Focus 220 scanner (Siemens Preclinical Solutions). Static PET data were acquired for 30 minutes 
at the 1-hour timepoint and for 1 hour at the 3-day timepoint. Attenuation maps for each subject 
were obtained from either the CT scan in the Inveon scanner or by a transmission scan on the 
Focus 220 scanner. Images were analyzed using Inveon Research Workplace software (Siemens 
Preclinical Solutions). 
3.3. Results 
Figure 3.2 shows the results from ex vivo biodistribution of 52Mn in saline administered 
via intravenous injection or by inhalation. Manganese-52 was cleared rapidly from the blood, as 
demonstrated by its rapid decrease from 1 to 24 hours p.i., and the activity in the gastrointestinal 
tract—stomach and intestines—also decreased rapidly between those same timepoints. At 1 hour 
p.i., the highest activity was found, in decreasing order, in the liver, kidney, lung, heart, 
pancreas, spleen, and salivary glands; however, by 24 hours p.i., the concentration of 52Mn in all 
of these organs of high initial uptake had decreased greatly, except for the salivary glands, 
pancreas, and kidney. Among the tissues that had lower initial uptake at 1 hour p.i., 52Mn was 
retained, to various degrees, in the brain, bone, and thyroid.  
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Figure 3.2. Plot showing results from ex vivo biodistribution of saline solutions containing 
52Mn administered via intravenous injection or inhalation. 
The timepoints shown represent time after administration of the dose. Sample sizes for each 
timepoint were n=4 mice for injection and n=3 for inhalation. Error bars: negative error bars not 
shown for visual clarity; error bars represent statistical uncertainty across animals in each cohort 
and no propagated uncertainty from other sources of uncertainty. 
The results from inhalation show high concentration of 52Mn at 1 hour p.i., in decreasing 
order, stomach, intestines, lung, and thyroid. From the data at 24 hour p.i., 52Mn was detected in 
the lungs and thyroid, but it was cleared from the stomach and intestines. Additionally, low 
activity of 52Mn was observed in the blood, suggesting that manganese was cleared rapidly from 
the blood, just as in the results from IV injection. Figure 3.2 also shows that, from 1 to 24 hours 
p.i., 52Mn accumulated in the kidney, pancreas, brain, liver, and spleen. 
Figure 3.3 shows co-registered PET/CT images of the exact same two mice at 1 hour and 
3 days following intravenous injection of 52Mn in aqueous solution. The PET signal in this figure 
had been windowed for ease of visualizing signal from the abdomen. At 1 hour post-injection, 
52Mn is observed in the digestive tract, kidneys, and likely the pancreas, although the pancreas is 
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difficult to identify definitively. At 3 days post-injection, the 52Mn left the digestive tract, while 
it is retained in the kidneys, as well as liver, pancreas, and thyroid gland. Figure 3.4 shows the 
results from the ex vivo biodistribution measurements that were performed after all PET and CT 
imaging were completed at 3 days post-injection. 
 
Figure 3.3. PET/CT images of mice at 1 h and 3 days following intravenous administration of 
52Mn in aqueous solution, windowed for visualizing activity in the abdomen. 
 
Figure 3.4. Results from ex vivo biodistribution performed shortly after imaging at 3 day 
timepoint.  
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The biodistribution results from CD-1 rats at 1 hour, 1 day, 3 days, and 7 days post 
injection of 52Mn are shown in Figure 3.5. 
 
Figure 3.5. Biodistribution results of 52Mn isolated by anion-exchange chromatography and 
administered in a saline solution by intravenous injection into male CD-1 rats. 
The timepoints shown represent time from administration until sacrifice of rats. For each 
timepoint of intravenous injection, n=3. 
 
Figure 3.6. Excretion profile for male rats from the 7-day cohort that received intravenous 
administration of [52Mn]MnCl2. 
Excretions were collected at 1 hour, 1, 3, and 7 days, so the timepoints plotted above are at the 
midpoint of each collection period. Error bars represent statistical uncertainty across animals in 
each cohort and no propagated uncertainty from other sources of uncertainty.  
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Figure 3.7 shows a typical co-registered PET/CT MIP image of a CD-1 rat at 7 days post-
injection of 52Mn, windowed for visualizing radioactivity in the abdomen, and Figure 3.8 shows 
the excretion profile and post-imaging biodistribution for the CD-1 rats (n=2) that were imaged 
by PET/CT. 
 
Figure 3.7. Approximately ventral view of a maximum intensity projection (MIP) image of 
PET signal co-registered with CT image of a male CD-1 rat at 7 days following intravenous 
administration of 52Mn in saline. 
CT was windowed for visualization of skeleton; PET signal was windowed for improved 
visualization of PET signal from the abdomen.  
  
 
 
 
79 
 
Figure 3.8. Post-imaging biodistribution results of 52Mn in male CD-1 rats. 
Animals euthanized 7 days post-injection of 52Mn (n=2). 
 
 
3.4. Discussion 
For the comparison of IV injection to inhalation of 52Mn in mice, the concentration of 
52Mn in most tissues at both 1- and 24-hour timepoints is higher than in the inhalation results. 
The activity in the gastrointestinal tract was much greater in the inhalation results, suggesting 
that some of the dose may have been either swallowed directly from the aerosol or inhaled, 
cleared by mucociliary clearance, and then swallowed. Also in our studies, we observed uptake 
in the pancreas and brain, while 52Mn that entered the stomach or intestines did not appear to be 
retained, although the one hour amounts were much higher in the inhalation groups likely due to 
putative swallowing of some of the dose. Retention of 52Mn in the brain, thyroid, and thymus 
was observed in results from both injection and inhalation. We also found significant uptake of 
52Mn at 24 h in the bone (2.6%) resulting from injection, but not from inhalation.  
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For both injection and inhalation, 52Mn was cleared rapidly from the blood, and the 
injection data showed 52Mn in the liver and kidney in <1 hour. The inhalation data also suggest 
accumulation in the liver and kidneys, but this accumulation took much longer than one hour. 
Although manganese appears to accumulate in both liver and kidneys, results from the literature 
(Cikrt, 1972; Bertinchamps, et al., 1966; Papavasiliou, et al., 1966; Kato, 1963) suggest that very 
little manganese is excreted in urine. Instead, the vast majority of manganese is excreted in feces, 
primarily due to release of manganese from the liver into the enterohepatic circulation. In other 
studies, animals that were administered manganese or radiomanganese intravenously (Ni, et al., 
1997; Chauncey, et al., 1977; Hughes, et al., 1966; Kato, 1963; Koshida, et al., 1963; Fore and 
Morton, 1952b), high uptake was generally observed in the kidney, pancreas, liver, adrenal 
glands, and intestine, as well as comparatively small amounts in the brain. Brain, et al. (2006) 
and Helig, et al. (2006) reported that, for intratracheal instillation, 54MnCl2 was retained in the 
lungs to a large extent but was also found in significant concentrations in the intestines, liver, 
kidneys, and in a small concentration in the brain. These intratracheal instillation studies also 
showed that Mn can enter the bloodstream from the lungs, possibly by ion channels, but not by 
the divalent metal transporter-1 (DMT-1) in that particular tissue (Brain, et al., 2006; Heilig, et 
al., 2006). These general trends in manganese distribution agree with studies that focused more 
narrowly on the in vitro or in vivo uptake of manganese by cells or tissues that included liver 
(Kodama, et al., 1991; Cikrt, 1972), kidney (Kodama, et al., 1991), pancreas (Kodama, et al., 
1991), intestines (Brain, et al., 2006; Leblondel and Allain, 1999), salivary glands (Seshadri and 
Hoy, 2010; Ni, et al., 1997), myocardium (Chauncey, et al., 1977), and bone (Fore and Morton, 
1952a).  
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Owing to its neurotoxic effects, particular interest has been paid to uptake of manganese 
in the brain by various routes. Kanayama, et al. (2005) administered to mice by eight different 
routes a solution containing sixteen different radiotracers, mostly transition metals, and, for most 
administration routes, 54Mn(II) had higher brain uptake than most of the other tracers. In several 
other studies, rodents received radiomanganese by carotid injection or continuous in situ brain 
perfusion brain. These studies suggest that manganese enters the brain by more than one 
mechanism, including carrier-mediated uptake of Mn-citrate (Crossgrove, et al., 2003), by store-
operated calcium channels as Mn(II) (Crossgrove and Yokel, 2005), by transferrin-receptor 
mediated endocytosis as Mn-transferrin (Aschner and Gannon, 1994; Aschner and Aschner, 
1990), or by other unspecified mechanism(s) that are faster than simple diffusion (Aschner and 
Gannon, 1994; Rabin, et al., 1993). In a comparison of 54Mn species administered by in situ 
brain perfusion, Mn-citrate was transported across the blood-brain barrier faster than either free 
Mn(II) or Mn-transferrin, suggesting that Mn-citrate might be an important route for manganese 
uptake in the brain (Crossgrove, et al., 2003). Furthermore, it appears likely that manganese 
could accumulate in the brain because it appears to efflux at a rate that is consistent with simple 
diffusion (Yokel, et al., 2003; Yokel, 2002). 
Since it is known that certain inhaled substances can enter the brain directly from the 
olfactory bulb—without entering the bloodstream—there have been a considerable number of 
studies examining the possibility of manganese entering the brain by such mechanisms. 
Characterization of this mechanism(s) would be particularly relevant to the problem of inhaled 
manganese in metal workers. Animal studies using radiomanganese (Tjalve, et al., 1996; Tjalve, 
et al., 1995) or MEMRI (Pautler, et al., 1998; Serrano, et al., 2008), suggested that Mn(II) can be 
transported from the olfactory bulb and into olfactory neurons, transported through those 
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neurons, across synaptic junctions, into secondary olfactory neurons, and then into the 
diencephalon and cerebrum, and (in rats) into the spinal cord. Thompson et al. (2007) tested 
uptake in rats with defective divalent metal transporter-1 (DMT-1) proteins and confirmed that 
this transporter is involved in manganese uptake in the rat olfactory bulb based on higher uptake 
in healthy control rats. In rats, ninety minute nose-only inhalation of aerosolized [54Mn]MnCl2 
(Brenneman, et al., 2000) or [54Mn]MnHPO4 (Dorman, et al., 2002) solution leads to uptake in 
the olfactory bulb and olfactory tubercle. In both studies, they observed uptake in lungs, liver, 
kidney, and pancreas, and—at much lower amounts—in the striatum of the brain. In a similar 
study, Lewis, et al. (2005) exposed mice and rats to nebulized, non-radioactive MnCl2 for 10 
nose-only doses of 6 hours each. Sample analysis by proton induced X-ray emission (PIXE) 
revealed elevated manganese in trigeminal ganglia, suggesting this nerve as a possible pathway 
for brain entry of manganese. 
In our studies, relatively high uptake was observed in the lung and thyroid following 
either route of administration. Although several papers confirmed thyroid uptake of manganese 
from different administration routes in animal models (Nishida and Kawada, 1992; Kawada, et 
al., 1985; Deysach and Ray, 1949; Ray and Deysach, 1942), the biology of uptake of manganese 
in the thyroid does not seem clear (Nishida and Kawada, 1992). Interestingly, electron spin 
resonance (ESR) has shown that only a small fraction of the manganese naturally found in the rat 
thyroid is in the 2+ oxidation state (Sakurai, et al., 1985), perhaps suggesting that it is bound to 
serum protein(s) as Mn(III) and not present as a free Mn(II). Additionally, following 
subcutaneous injection of Mn(II)Cl2, in guinea pigs (Deysach and Ray, 1949), manganese rapidly 
accumulated in thyroid by 24 hours p.i., but then 70% of the manganese in the thyroid at 24 
hours had cleared by 48 hours p.i.; and then 85%, by 96 hours p.i. Inhaled manganese uptake in 
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salivary glands was in agreement with observations in welders exposed to manganese (Wang, et 
al., 2008). Interestingly, our results showed that injection of 52MnCl2 exhibited higher and faster 
uptake in salivary gland than in the inhalation study. Our results demonstrate uptake of 52Mn in 
the brain, thyroid, and pancreas in all trials. Interestingly, uptake from IV administration was 
higher in brain and pancreas, but lower in thyroid, compared to inhalation results. Also, IV 
administration resulted in very high activity in salivary glands. Manganese-52 might someday be 
used as a PET agent for niche clinical research applications, but our biodistribution results in 
mice can be used, in conjunction with other published results, to inform regulations for safe 
levels of environmental and occupational exposure to manganese. 
Additionally, we have presented PET/CT images that visualize biodistribution of free 
52Mn(II) in mice, along with results from ex vivo biodistribution that was performed after 
imaging. The distribution of PET signal in the images from the final timepoint generally agrees 
with the biodistribution results. Building off the results presented, ongoing and future work could 
include: using a more effective method for separating 52Mn from a chromium metal matrix; more 
complete characterization of the separated 52Mn product, including radionuclidic purity, trace 
metals analysis, and/or effective specific activity titration; examining biodistribution at longer 
timepoints than 24 hours; contrast-enhanced CT that will reveal the pancreas on CT, making it 
possible to draw ROIs on the CT images for PET quantification; and possible applications in 
PET imaging of diseases that can alter the absolute magnitude or relative distribution of 
manganese in vivo. 
One factor that motivated our interest in PET imaging of pancreas function with free 
cations of radiomanganese was a MEMRI study by Botsikas, et al. (2012). In that study, humans 
were imaged by T1-weighted MRI, and the signal in the pancreas of a normoglycemic (non-
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diabetic) person increased dramatically (became brighter, as shown in Figure 3.9) after 
intravenous infusion of the manganese chelate mangafodipir trisodium (manganese dipyridoxal 
diphosphate (Mn-DPDP), Teslascan, GE Healthcare, Amersham, Buckinghamshire, United 
Kingdom; See Section 1.2.3). For patients with diabetes, signal also increased after infusion of 
mangafodipir, but by a significantly (p=0.01) smaller increase. Patients with advanced diabetes 
that required insulin treatment demonstrated even smaller average increase that was also 
significantly (p=0.007) less than the control group. Mangafodipir is a weakly bound chelate, and 
a significant portion of it dissociates in vivo (Gallez, et al., 1996; Harisinghani, et al., 2001), so it 
was likely that at least some of the enhanced signal observed by Botsikas, et al. was from free 
Mn(II) cations and not only from chelated Mn(II)-DPDP. This is not surprising because 
pancreas, like several other organs, naturally takes up manganese (Yokel, 2009). Uptake of 
manganese by healthy pancreas was further confirmed in our own ex vivo biodistribution studies 
in mice and rats, as well as in another similar study using radiomanganese (Graves, et al., 2015).  
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Figure 3.9. T1-weighted MRI images of a normoglycemic (non-diabetic) human and a human 
with type 2 diabetes. 
Left column: normoglycemic patient; right column: patient with type-2 diabetes mellitus; top row: 
before contrast; bottom row: 20 min. following administration of Mn-DPDP, a manganese-based 
T1-shortening contrast agent. The graph at far right shows statistically significant lower 
enhancement of MR signal in patients with diabetes compared to normoglycemic controls. (Image: 
Botsikas, et al., 2012. Image courtesy of Taylor & Francis. Creative Commons.) 
Based on this knowledge, we endeavored to use 52Mn for PET imaging of pancreas 
function. For sufficient contrast to observe the pancreas, the signal from the pancreas needed to 
be significantly greater than from nearby tissues. Therefore, the high 52Mn radioactivity that we 
observed in the liver and kidneys at 24-hour post-injection might pose a problem for imaging 
with 52Mn at those timepoints. Therefore, we examined the biodistribution of free 52Mn injected 
intravenously into healthy normal rats at timepoints extending up to 7 days. The results (Figure 
3.5) showed that indeed the 52Mn was retained at a higher level than the liver or kidneys at the 
longer timepoints of 3 and 7 days. For the same injections, we also examined the excretion 
profile of 52Mn, and the results (Figure 3.6) agree with what we found in the literature that 
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manganese is excreted almost exclusively by the liver-bile-feces system, rather than through the 
kidneys and into the urine. The PET/CT imaging study in general-use rats (CD-1) revealed that 
by waiting 7-days post-injection can indeed provide adequate signal and contrast to visualize a 
healthy pancreas. A MIP of the co-registered PET/CT images (Figure 3.7) clearly shows signal 
from liver and kidneys, but much stronger signal from the region of the pancreas. This signal 
from the pancreas was confirmed by post-imaging ex vivo biodistribution (Figure 3.8). 
3.5. Conclusions and Recommendations 
• Biodistribution studies of intravenously injected 52Mn(II) in mice showed 
uptake in many organs, most interestingly: salivary glands, brain, thyroid, 
thymus, pancreas, liver, kidney, and bone. 
• Similar studies in rats that extended to longer timepoints showed that activity 
in all of those organs decreases significantly over the course of seven days, 
except for brain, adrenals, and pancreas and confirmed that manganese is 
excreted almost exclusively through the feces and not the urine. 
• Biodistribution studies of inhaled manganese in mice showed uptake in lung, 
brain, thyroid, pancreas, liver, and kidney. 
• PET imaging of [52Mn]MnCl2 in mice and rats confirmed the observations 
from biodistribution, including high signal from 52Mn in the pancreas at seven 
days post-injection, after the activity had significantly decreased in nearby 
tissues, such as the liver and kidneys. 
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• Recommended future directions: PET/CT imaging using a CT contrast agent 
that will reveal the pancreas on CT, which will enable quantitative imaging of 
free manganese in the pancreas with possible applications in diagnostic 
imaging of diabetes. 
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Chapter 4. Applications for 52Mn in PET/MR 
Imaging1,2,3 
4.1. Background 
An additional motivation for understanding the biodistribution of free manganese is that 
manganese(II) has been utilized in contrast agents for MR imaging. Manganese(II) is considered 
to be “high-spin” from its five unpaired valence electrons (Weinmann, et al., 1984; Wolf, et al., 
1985), which shorten the spin-lattice time constant (T1) for nearby 1H nuclei, resulting in brighter 
signal when using a T1-weighted MR pulse sequence (Pan, et al., 2010; Rodriguez-Vargas, 2010; 
Silva and Bock, 2008), especially in anatomical regions with high water density. Since MRI is 
not inherently as quantitative as PET, and since MEMRI are not as widely studied as Gd-based 
agents, it could be useful to “authentically” radiolabel manganese-based MR contrast agents with 
radiomanganese (Klein, et al., 2005; Coenen, et al., 2014) for quantitative confirmation of their 
biodistribution—by dissection, autoradiography, and/or in vivo imaging.  
                                                
1 A.L.W. contributed to: experimental design, preparation of phantoms, and image analysis, preparation of figures 
and tables, and writing. 
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cyclotron at WUSM/MIR. 
 
3 Project-specific funding: This work was funded in part by an internal award from WUSM/MIR. 
  
 
 
 
92 
4.2. Experimental 
4.2.1. MRI Phantom Imaging and Measurement of Relaxivity 
In magnetic resonance techniques, including MRI, the magnetic spins of a sample are 
aligned to a strong external magnetic field and then a radiofrequency electromagnetic pulse 
temporarily realigns the magnetic spins of a selected frequency—typically the frequency of 1H in 
the case of MRI. The exponential relaxation of nuclear spin to the original magnetic field is 
described by the spin-lattice relaxation constant (T1), which is typically expressed in seconds. 
The T1 relaxivity (r1) of a T1 contrast agent is often expressed in mM-1·sec-1 (or similar units) and 
is the primary quantity used to compare the capability of a contrast agent to shorten T1 for nearby 
nuclei. This change in T1 causes brighter MR signal in that vicinity when imaging is performed 
using a T1-weighted pulse sequence. 
We measured T1 for several concentrations of Mn(II) in aqueous solution using an 
inversion-recovery experiment. Aqueous solutions of several different concentrations of 
Mn(II)Cl2·4H2O, ranging from 10 µM to 2 mM were prepared, and placed in several different 
conical centrifuge tubes upright in a rack. This rack was imaged using a birdcage head coil in the 
human-sized Biograph mMR PET/MR scanner (Siemens Medical Solutions USA, Malvern, 
Pennsylvania, United States) at the Center for Clinical Imaging Research (CCIR) at WUSM. The 
imaging was performed by an inversion-recovery MR pulse sequence at a range of values for the 
inversion time (TI). In this experiment, the real component of MR signal—positive or negative—
in each concentration of MnCl2 was imaged. Using the ImageJ software (Ferreira and Rasband, 
NIH/NIMH), the signal in the cross-section of each tube and the background was measured, and 
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the signal intensity (SI) from the background was subtracted from all signals. This was repeated 
for all values of TI, and the values for SI were plotted versus TI for each concentration of Mn(II). 
Using the Curve Fitting Toolbox in the MATLAB software (MathWorks, Natick, 
Massachusetts, United States), the signal intensity (SI) versus TI data were fit to the equation 
(Hashemi, et al., 2010): 
 !" ∝ !! 1− 2!!!" !! + !!!" !!  , (4.1) 
where M0 is the original longitudinal magnetization in arbitrary units, and TR is repetition time of 
the pulse sequence in sec. The result of the fit was a value for (T1), expressed in seconds, for 
each concentration of Mn(II). The relaxation rate (R1), which is expressed in sec-1, for each 
concentration, was simply the inverse of T1, and r1 was the slope of the linear fit of R1 versus 
concentration of Mn(II). 
4.2.2. PET/MR Phantom Imaging 
This experiment was repeated as a PET/MR imaging study. Aqueous solutions of 
Mn(II)Cl2·4H2O were prepared in concentrations ranging from 10 µM to 2 mM and added 
different amounts of radioactivity of 52Mn(II) ranging from 2-12 µCi. PET data was collected for 
30 min. and MR images using an inversion recovery sequence for a variety of values for TI, with 
TE=12 msec using the Biograph mMR.  
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4.3. Results 
A typical MR image from a phantom that included several different concentrations of 
non-radioactive Mn(II) at a few selected inversion times is shown in Figure 4.1. The signals 
resulting from an inversion-recovery sequence with numerous inversion times is shown in Figure 
4.2, and the corresponding results for R1 are plotted versus concentration of Mn(II) are plotted in 
Figure 4.3. The slope of the linear fit through those data yields the relaxivity of Mn(II)—
specifically MnCl2·4(H2O)—in water as r1=8.6 mM-1sec-1. 
 
Figure 4.1. Phantom design and images from inversion-recovery MRI experiment with 
different concentrations of Mn(II) in water imaged at many different inversion times (TI). 
Images from only four of the TI values are shown here.  
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Figure 4.2. Results from inversion recovery experiment for several concentrations of Mn(II) 
solutions in water. 
Signal acquired by real-component acquisition, signal from a region of the background was 
subtracted from all samples, and fitted to the equation shown. (Equation: Hashemi, et al., 2010). 
 
Figure 4.3. Plot of longitudinal relaxation rate (R1) versus concentration of Mn(II) based on 
inversion recovery experiment.  
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Figure 4.4 shows the imaging results from PET/MR imaging of a phantom of aqueous 
solutions of different concentrations of non-radioactive Mn(II) as MnCl2·4(H2O) and radioactive 
52Mn(II). In both panels of Figure 4.4, the TE for MR and the PET imaging parameters were 
constant; however, the left panel shows MR signal from a pulse sequence with short TI and short 
TR, while the right panel shows MR signal from a pulse sequence with long TI and long TR. 
  
Figure 4.4. PET/MR images of phantom consisting of conical tubes containing aqueous 
solutions of different amounts of non-radioactive MnCl2·4(H2O) and radioactive 52Mn(II). 
Images acquired in a Siemens mMR human scanner. PET: 30 min. acquisition; attenuation 
correction based on a Dixon sequence. MR: magnitude acquisition in an inversion-recovery 
sequence (left panel: TR=3 sec, TE=12 msec, TI=50 msec; right panel: TR=10 sec, TE=12 msec, 
TI=9.93 sec).  
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4.4. Discussion 
The curve fits for both SI versus TI and R1 versus [Mn(II)] were both very close, and the 
latter fit produced a result for r1 that was close to published values. These r1 values are less than 
for Gd(III) because it has seven unpaired valence electrons versus five for Mn(II), and the 
number of unpaired valence electrons is the most important characteristic of a T1-shortening 
contrast agent for MRI. The results from MRI-only images and quantification informed our 
selection of concentrations of non-radioactive Mn(II) for our phantom for PET/MR imaging. The 
PET/MR images demonstrated the feasibility of PET/MR imaging of dual-modality contrast 
agents that incorporate non-radioactive Mn(II) at sufficient concentrations to generate T1-
weighted MR contrast and radiotracer concentrations of 52Mn for generating PET signal. The 
phantom images from both short and long TI also provide examples of positive and negative MR 
signal resulting from different values of TI. 
Compounds that can bind paramagnetic cations, such as Mn(II) (Section 1.2.3), hold 
potential for dual-modality PET/MR imaging if they can be radiolabelled with a radiotracer of 
the same cation. In unpublished results from collaborators at another institution, a compound has 
demonstrated the ability to bind manganese for potential MEMRI applications. In future work, 
we will endeavor to radiolabel this compound with 52Mn for potential PET/MR imaging studies. 
This radiolabelling will be carried out by altering pH, confirmed by radio-HPLC, and applied to 
PET/MR imaging, first in phantom studies. Just as we demonstrated with our PET/MR imaging 
of free Mn(II)/52Mn in solution in a phantom, any platform for a PET/MR contrast agent would 
require many times more atoms of non-radioactive metal compared to its PET radioisotope(s) 
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because PET inherently has much better sensitivity to PET radiotracers than MRI does to 
contrast agents for that modality. 
4.5. Conclusions and Recommendations 
• A phantom containing various concentrations of non-radioactive 
Mn(II)Cl2·(H2O)4 dissolved in water ,was imaged by MRI using an inversion 
recovery pulse sequence. The signal from the images were analyzed, and these 
results were used to calculate the relaxivity of this compound in aqueous 
solution. 
• Another phantom was constructed that contained a matrix of different 
concentrations of non-radioactive Mn(II)Cl2·(H2O)4 dissolved in water to 
which different amounts of 52Mn had been added. This phantom was imaged 
by PET/MR and revealed changes in both MR and PET signals. 
• Recommended future directions: Investigate the utility of 52Mn by 
radiolabeling a compound that has been used to chelate Mn(II) for MRI 
imaging; perform PET/MR imaging of phantoms containing the compound 
complexed with non-radioactive Mn(II) and radioactive 52Mn(II) in various 
concentrations and radioactivities. 
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Chapter 5. Remotely-Controlled Modules for 
the Isolation of PET Radiometals1,2,3,4 
This chapter describes purification modules that were designed, constructed, and wired 
for being controlled remotely by software running on a laptop. These modules are useful for 
isolating the product radionuclide from a bombarded solid target because the module can be 
placed inside of a lead hot cell, where the separation processes can be carried out. The user 
                                                
1 Much of this section was published previously or is being prepared for publication elsewhere: 
Wooten, A.L.; Madrid, E.; Schweitzer, G.D.; Lawrence, L.A.; Mebrahtu, E., et al., 2013. Routine 
Production of 89Zr Using an Automated Module. Appl. Sci. 3, 593-613. 
Wooten, A.L.; Schweitzer, G.D.; Lawrence, L.A.; Madrid, E.; Lapi, S.E., 2012. An automated 
system for production of 89Zr. AIP Conf. Proc. 1509, 201-205. 14th International 
Workshop on Targetry and Target Chemistry, Playa del Carmen, Mexico, 26-29 Aug. 
2012. 
Wooten, A.L.; Lawrence, L.A.; Lewis, B.C.; Mebrahtu, E.; Sultan, D.H.; Madrid, E.; Lapi, S.E. A 
remotely controlled, semi-automated module for the isolation of 86Y from a proton-
bombarded 86SrO powder target. In preparation. 
2 A.L.W. contributed to the following aspects of projects in this chapter. For the 89Zr module: module assembly, 
module installation inside hot cell, test productions of 89Zr. For the 86Y module: ordering and assembling 
components, electrical wiring, installation of module into hot cell, cold testing of module. For the 52Mn 
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3 Project acknowledgments: The authors for the manuscripts mentioned above have contributed to design of the 
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Madrid, E. Mebrahtu, and D.H.S. of the isotope production team (WUSM/MIR) have contributed to data 
from repeated productions during scaling up the levels of radioactivity and during routine production of 
isotopes. E. Mebrahtu performed much of the DFO titrations. 
The authors acknowledge G.G. Gaehle (WUSM/MIR) for advice in designing automated modules; W.H. Margenau 
(WUSM/MIR) and J.W. Linders (Dept. of Chemistry, WUSTL) for constructing certain components of the 
systems; J.W. Linders and the WUSM Instrument Machine Shop for machining the Niobium target holders; 
G.G. Gaehle, W.H. Margenau, and P.M. Margenau (WUSM/MIR) for operation and maintenance of the 
cyclotron; and O.F. Ikotun (Lapi group) and B.V. Marquez (Lapi group) for general advice on 89Zr 
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4 Project-specific funding: This work was funded by the United States Department of Energy, Office of Science, 
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controls the module from outside the hot cell and thus receives significantly diminished radiation 
dose. Additionally, utilizing automated modules for separations can reduce opportunities for 
human error in a separation procedure and even improve the purity of the final product by 
reducing exposure to contaminants that may be present in a more open laboratory environment. 
5.1. Background 
Although the radionuclides and procedures can vary widely, certain design principles for 
production modules can be broadly applied. Section 5.1 provides background for the work 
presented later in this chapter by first examining other modules that have been published for 
production of radionuclides and radiopharmaceuticals. Despite increasing interest in recent years 
in using positron-emitting radiometals for pre-clinical and clinical PET imaging research, most 
of these isotopes are produced and shipped from only a few centers and companies worldwide. 
Consequently, there is not widespread demand for modules capable of producing PET 
radiometals. The vast majority of modules developed for production of PET radiometals are 
found in research literature, and special attention will be paid here to these examples. 
Regardless of the radionuclide or the chemical process implemented, automated modules 
are typically designed to operate behind heavy radiation shielding, such as inside a hot cell, for 
scaled-up, high radioactivity processes. In addition to the primary objective of radiation 
shielding, a hot cell can provide a clean environment that is shielded from airborne contaminants 
in the lab, and the hot cell can also include air scrubbing, radiation monitoring, and live video 
feed of the module. Figure 5.1 shows examples of hot cells with and without a lead glass 
window.  
  
 
 
 
102 
 
Figure 5.1. Examples of commercially available hot cell capable of housing and integrating 
with automated modules. 
A unit by Comecer (Castel Bolognese, Italy) containing two cells, one with a lead glass window, 
each containing a module connected by wire to an exterior laptop for monitoring and control. The 
top of the unit shows pressure monitors and radiation dose readouts for both cells and a video 
monitor for the bottom cell. The interior of these hot cells includes a tray on which to place a 
module for remotely-controlled chemistry, a video camera, vapor exhaust, power outlets, a rubber 
block of ports for feeding relatively large wires and tubes into the interior of the hot cell, and two 
septa for relatively small wires and tubes. 
Several modules have been designed for the chemical isolation of PET radiometals. 
Production of PET radiometals tends to be centralized at a limited number of production centers 
that ship the radionuclides to end users. Thus, the modules that have been developed for 
production at these centers have not been imitated widely by other research institutions. In recent 
years, interest has increased in using antibodies and nanoparticles as platforms for imaging 
contrast agents, and certain positron-emitting radiometals, especially 64Cu and 89Zr, have 
emerged as valuable radiolabels for these potential agents (Section 1.4.4). Thus, there has been 
an increase automation for scaled-up production of 64Cu and 89Zr, and even a few commercially 
available modules have become available for these radionuclides. Table 5.1 summarizes a few 
published automated modules for the separation of 60,64Cu, 86Y, and 89Zr.  
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Table 5.1. Published automated modules for production of 60,64Cu, 86Y, and 89Zr. 
Product 
Isotope 
Chemical 
Form Target
a Separation Process Reference 
     
60/64Cu 
64Cu(II) 
in 0.5 M HCl 
enriched 64Ni 
electroplated onto 
Au disc 
Anion-exchange chromatography (Kume, et al., 2012) 
 
 
 
64Cu(II) in 0.1 
M HCl " " (Burke, et al., 2010) 
 
 
 
60/64Cu(II) 
in 0.5 M HCl 
enriched 60/64Ni 
electroplated on 
Pt surface 
" (Matarrese, et al., 2010) 
 
 
 
60/61/64Cu(II) 
in 0.5 M HCl 
enriched 60/61/64Ni 
electroplated on 
Au surface 
" (Welch, et al., 2006) 
86Y 
86Y(III) 
in 3 M HCl 
86SrCO3 powder 
Sr-specific resin, Y-specific resin, 
cation-exchange resin 
 
(Park, et al., 2004) 
89Zr Oxalic acid natY metal foil 
Cation-exchange chromatography via 
hydroxamate-functionalized resin 
 
(Siikanen, et al., 2012) 
     
aDescription of the portion of the cyclotron target that enters the automated system. (Table from 
Wooten, et al., 2013. Table courtesy of MDPI. Creative Commons.) 
5.1.1. Production and Applications of 89Zr 
The isotope 89Zr is one of several positron-emitting radiometals that are increasing in 
popularity as radiolabels for PET (Anderson and Welch, 1999; Ikotun and Lapi, 2011; Nayak 
and Brechbiel, 2009; Wadas, et al., 2010). In particular, 89Zr holds significant potential as a 
radiolabel for antibodies, antibody fragments, and peptides for the in vivo molecular imaging of 
antigens using PET (McCabe and Wu, 2010; van Dongen, et al., 2007; van Dongen and Vosjan, 
2010; Verel, et al., 2005; Vugts, et al., 2013). Zirconium-89 is well-suited for this technique 
because it is a positron-emitter with a half-life that is long enough to accommodate the longer 
targeting time and biological half-life for these relatively large imaging agents. So far, the most 
prevalent application for 89Zr has been cancer imaging. The information obtained using PET 
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imaging of 89Zr compounds can be useful for cancer staging, therapy planning, and treatment 
monitoring, making 89Zr a potentially valuable tool for personalized cancer care. 
There are several properties of 89Zr that make it an attractive radiolabel for peptides, 
antibodies, and nanoparticles. Most importantly, the half-life of 89Zr (t1/2=3.3 days) is close 
enough to the targeting time and biological half-life of antibodies and other macromolecules that 
could be used as targeting agents. Additionally, 89Zr emits positrons with a sufficient branching 
ratio (Iβ+,total=22.7%) and provides good spatial resolution in PET because it emits positrons at a 
low average energy (Eβ+,avg.=396 keV), and therefore a lower positron range (1.2 mm) 
(Disselhorst, et al., 2010) compared to several other PET isotopes. Unfortunately, 89Zr also emits 
a high-energy (909 keV) gamma ray with a high branching ratio (99.0%), meaning that the dose 
rate for this isotope is significant (Γ=6.6 R⋅cm2/mCi⋅h). The decay product of 89Zr (and 89mZr) is 
always the stable nuclide 89Y, so there is no additional dose from daughter nuclei. Figure 5.2 
shows a simplified decay scheme for 89Zr. 
 
Figure 5.2. Simplified decay scheme for 89Zr. 
(Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons.)  
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The vast majority of medical centers capable of producing medical isotopes do so using a 
low-energy “biomedical” cyclotron capable of bombarding a target with protons with energy (Ep) 
<20 MeV (and alternatively deuterons with energy (Ed) <10 MeV). For these particles and 
energies, the highest cross-section is the (p,n) reaction with a peak cross-section of ~0.8 b at 
Ep~14 MeV. The (p,n) reaction uses natY target material, which is monoisotopic as 89Y and thus 
relatively inexpensive. For the above reasons, the natY(p,n)89Zr reaction is the most common 
reaction route for 89Zr production (Kasbollah, et al., 2013). However, contaminants can also be 
produced in a natY foil via the following common proton reactions: (p,n)89mZr, (p,2n)88Zr, 
(p,pn)88Y. Fortunately, high radionuclidic purity can still be achieved using ~15 MeV protons 
because 89mZr has a short half-life (t1/2 = 4.2 m) and a high degree of isomeric transition (IT = 
93.8%) and because the (p,2n) and (p,pn) reactions require greater proton beam energies, so they 
have low cross-sections at Ep~15 MeV—less than 0.2 and 0.02 b, respectively 
(BNL/NNDC/CSISRS). Figure 5.3 shows plotted cross-section data for reactions that are 
relevant to bombardment of natY with low-energy protons: (p,n)89gZr, (p,n)89mZr, (p,2n)88Zr, and 
(p,pn)88Y, and the important characteristics of 89Zr production in general are summarized in 
Table 5.2. 
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Figure 5.3. Screen shot of published cross-section data for reactions relevant to 
bombardment of natY with low-energy protons. 
Screenshot of nuclear reaction cross-section data that were accessed via 
NRDC/BNL/NNDC/CSISRS and plotted using the X4-Servlet from BNL/NNDC. (Data accessed 
via: NRDC/BNL/NNDC/CSISRS; Otuka, et al., 2014; Zerkin, 2015.) 
Table 5.2. Summary of characteristics for production of 89Zr using a low-energy cyclotron. 
Target (natural abundance) natY (100% 89Y) 
Production reaction (p,n)89Zr (t1/2 = 3.27 days) 
Reaction threshold 3.7 MeV 
Stopping range of 14.7 MeV protons 1.02 mm 
Other possible reactions (p,n)89mZr (t1/2 = 4.2 m) 
 (p,2n)88Zr (t1/2 = 83.4 days) 
 (p,pn)88Y (t1/2 = 107 days) 
Optimum beam energy, Ep 13 MeV 
Target preparation hot-rolled natY metal foil 
Optimum beam energy was selected to avoid production of 88Zr contaminant, while still producing 
89Zr. (Table from: Wooten, et al., 2013. Table courtesy of MDPI. Creative Commons.)  
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Out of several papers that we examined for using the (p,n) reaction for 89Zr production 
and isolation, five used Y foil targets (Dejesus and Nickles, 1990; Dutta, et al., 2009; Holland, et 
al., 2009; Link, et al., 1986; Walther, et al., 2011), two used sputtered Y onto Cu (Meijs, et al., 
1994; Verel, et al., 2003), and one used Y2O3 pellets (Kandil, et al., 2008). Although the 
sputtered targets provided superior heat transfer and therefore allowed for higher beam currents, 
we chose to use Y foil for ease of use. For a hypothetical irradiated Y foil that contains 100 mCi 
of 89Zr, <0.3 µg of 89Zr atoms are present in the foil, and these product atoms must be extracted 
chemically to give the desired product—a solution containing 89Zr(IV) ions. So far, the most 
prevalent chelator of the 89Zr(IV) cation is desferrioxamine (DFO) (Deri, et al., 2013; Meijs, et 
al., 1992). This separation has been performed with mixed results using several different 
techniques (Holland, et al., 2009), including solvent extraction (Dejesus and Nickles, 1990; 
Dutta, et al., 2009; Kandil, et al., 2008; Lahiri, et al., 1997; Link, et al., 1986), cation-exchange 
(Dutta, et al., 2009; Kandil, et al., 2008), anion-exchange (Dejesus and Nickles, 1990; Kandil, et 
al., 2008; Link, et al., 1986; Zweit, et al., 1991), and solid hydroxamate resin (Fadeeva, et al., 
1989; Herscheid, et al., 1983; Holland, et al., 2009; Meijs, et al., 1994; Verel, et al., 2003). 
Hydroxamate resin separation has emerged as the preferred method following the publication of a 
standardized method for producing and separating 89Zr by Holland, et al. (Holland, et al., 2009). This 
separation can produce high recovery, radionuclidic purity, and effective specific activity (ESA). 
Our objective for this work was to automate the process that was reported by Holland, et al. 
(2009) based on chemistry that was developed by Verel, et al. (2003), Meijs, et al. (1994), and 
Herscheid, et al. (1983).  
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5.1.2. Production and Applications of 86Y 
Yttrium-86 is a medically important radioisotope for imaging by positron emission 
tomography (PET) because of favorable decay characteristics, amenability to radiolabelling, and 
because it has identical chemistry to 90Y, a therapeutic radioisotope. The nuclear decay 
properties of 86Y are summarized in Table 5.3. Yttrium-86 emits positrons at a low enough 
average energy (Eβ+,avg=660 keV) for acceptable spatial resolution in PET and with a total 
positron branching ratio (Iβ+,total=31.9%) that is greater than the PET radiometals 64Cu and 89Zr 
(ENSDF/NNDC/BNL, 2015), providing more signal per radioactivity. The half-life (t1/2=14.7 
hours) for 86Y is similar to the biological half-lives of peptides and antibodies, and it can be 
attached to these molecules with numerous bifunctional chelators, including derivatives of 
DTPA, DOTA, EDTA, NOTA, and TETA (Ikotun and Lapi, 2011; Wadas, et al., 2010; Nayak 
and Brechbiel, 2009). This capability makes 86Y a suitable radiolabel for nuclear imaging of the 
biodistribution of these targeting molecules, along with 64Cu, 89Zr, and other radionuclides 
(Ikotun and Lapi, 2011; Nayak and Brechbiel, 2009). Additionally, 86Y-PET can be applied to 
new molecules because chelating molecules, including derivatives of DOTA and DTPA, have 
proven useful for radiolabelling with 86Y and 90Y. This includes the FDA-approved 
radioimmunotherapy drug, Zevalin® (ibritumomab tiuxetan; Spectrum Pharmaceuticals, 
Henderson, Nevada, United States), which consists of a monoclonal antibody labeled with 90Y 
chelated in a derivative of DTPA.  
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Table 5.3. Summary of chemical and nuclear decay properties of 86Y with a simplified decay 
scheme. 
Half-life, t1/2 14.74 hours 
Daughter isotope 100% 86Sr (stable) 
Decay modes 32% β+ 
 68% EC 
β+ energy, !!!,!"#  660 keV 
γ-ray energy, Eγ (intensity) 1077 keV (82.5%) 
Gamma factora, Γ 18.9 R·cm2·mCi-1·h-1 
Theoretical specific activity 212.53 Ci·µmol-1 
Metastable isomer(s) 86mY 
(Data: BNL/NNDC/ENSDF; aSmith and Stabin, 2012.) 
In Zevalin and other applications of 90Y, the radioisotope 111In is often used as an 
imageable surrogate for 90Y by single photon emission computed tomography (SPECT) for 
determining distribution and dosimetry. However, this approach suffers the limitations of SPECT 
with respect to spatial resolution and calculating dosimetry, and indium does not have exactly the 
same chemistry as yttrium, which would affect labeling efficiency and stability, as well as the in 
vivo distribution of any ions that might become de-complexed. Furthermore, different metal 
radiolabels, even while still chelated and bound to a peptide or antibody, can affect in vivo 
distribution. Yttrium-86 is attractive as a surrogate for 90Y because it has identical chemistry to 
90Y and is imageable by PET, which has better spatial resolution than SPECT and is inherently 
quantitative for more accurate dosimetry calculations for 90Y. Table 5.3 summarizes the nuclear 
decay and chemical properties of 86Y.  
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Figure 5.4. Cross-sections for the production of 86,86mY via bombardment of 86Sr with low-
energy protons. 
Screenshot of nuclear reaction cross-section data that were accessed via 
NRDC/BNL/NNDC/CSISRS and plotted using the X4-Servlet from BNL/NNDC. (Data accessed 
via: NRDC/BNL/NNDC/CSISRS; Otuka, et al., 2014; Zerkin, 2015.) 
Many PET centers that produce medical isotopes from cyclotron bombardment do so 
using low-energy medical cyclotrons with proton energies (Ep) <20 MeV. At these energies, the 
most practical way to produce 86Y by proton bombardment would be via the 86Sr(p,n) reaction, 
which produces 86Y with a maximum cross-section (σmax) of ~0.7-0.8 b at Ep~11-15 MeV and 
86mY with σmax~0.3 b at Ep~14-15 MeV (Figure 5.4). Furthermore, 86mY has a relatively short 
half-life (t1/2=48 min.) and undergoes isomeric transition to 86Y with a branching ratio >99.3%, 
so it contributes significantly to production of ground-state 86Y and is therefore not considered a 
contaminant for 86Y production. Since strontium has four stable isotopes and 86Sr is only 9.9% 
naturally abundant, it is preferable to bombard an enriched 86Sr target, to reduce production of 
radiocontaminants from other isotopes of Sr in the target, such as 85,85m,87,88Y, 84Rb, and 85Sr, all 
of which have t1/2>1 h, as well as σ<0.1 b at Ep<20 MeV. Based on cross-section data, we 
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expected contamination from some of these products even with a perfectly enriched target, yet 
we only observed contamination from 87,88Y, which we believed resulted from enrichment 
<100% (see Results and Discussion). Since strontium is not stable in ambient conditions, several 
published studies used commercially available 86SrCO3 powder as a target material, while Yoo et 
al. converted 86SrCO3 to 86SrO by thermal decomposition. In addition to having a greater 
percentage of 86Sr by total mass than 86SrCO3, they observed that 86SrO tolerated higher proton 
beam currents because of better thermal conductivity. In this work, we have designed, built, and 
commissioned a module that has performed the separation of 86Y safely and routinely. 
5.2. Experimental 
5.2.1. Materials 
Natural yttrium foil was purchased from Alfa Aesar (Ward Hill, Massachusetts, United 
States), and niobium and platinum metals were purchased in rod form from A.D. Mackay 
(currently in Denver, North Carolina, United States). A silica-based weak cation-exchange resin 
was purchased from Waters (Milford, Massachusetts). The chelator DFO-NCS was purchased 
from Macrocyclics (Dallas, Texas, United States). Ultrapure (~18 MΩ) water was purified in a 
Millipore system (Billerica, Massachusetts) and was used for all other purposes, including 
cleaning the automated modules before each use and making solutions for DFO titrations. 
[86Sr]SrCO3 was purchased from Isoflex (San Francisco, California, United States). All other 
chemicals were purchased from Sigma-Aldrich (Saint Louis).  
  
 
 
 
112 
5.2.2. Cyclotron Production 
5.2.2.1. Cyclotron Production of 89Zr 
Discs with diameter 9.5 mm were punched from 0.64 mm thick natY foil (disc mass ~0.2 
g). Niobium metal target holders were machined, consisting of a base and a screw-on lid with a 
centered, circular hole to expose the target foil to the cyclotron beam. Niobium was selected 
because of its high melting temperature (Tm = 2,468 °C) and high chemical inertness 
(Greenwood and Earnshaw, 1997). A single natY disc was placed inside the target holder, as 
shown in Figure 5.5. Due to activation, many target holders were machined to allow residual 
activity to decay before reuse. Before each target holder was reused, it was scrubbed by hand 
using a cotton swab dipped into a slurry made from Al2O3 powder and water. The target holder 
was placed in 6 M HCl for 1–4 h for cleaning and dried in an oven. The target assembly was 
mounted in the CS-15 cyclotron (The Cyclotron Corporation, Berkeley, California, United 
States) at the Mallinckrodt Institute of Radiology (MIR) at Washington University in Saint Louis 
School of Medicine (WUSM) and bombarded with protons (Ep ≈ 14.7 MeV) to produce 89Zr via 
the natY(p,n)89Zr reaction. The beam exit energy was Ep ≈ 7.9 MeV, based on calculations 
performed using The Stopping Range of Ions in Matter (SRIM) software (Ziegler, et al., 2010), 
which implements the Bethe formula for stopping power. After Ep was degraded by the Y foil, 
the beam stopped in the base of the Niobium target holder, as calculated with Transport of Ions 
in Matter (TRIM) module within the SRIM package. During bombardment, the target holder 
assembly was cooled on the beam side by a He gas jet and on the reverse side by flowing chilled 
water (T ≈ 2.2 °C). Following irradiation, the target remained in the solid target station for a few 
hours to allow for the decay of short-lived contaminants, especially 89mZr in the Y foil. Then, the 
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target assembly was removed by hand, and other short-lived contaminants were allowed to decay 
overnight while the target was in a shielded location. On the following morning, chemical 
separation was performed in the hot cell that contained the automated module. 
 
Figure 5.5. Photograph of the disassembled (left) and assembled (right) Y foil target and 
Niobium target holder. 
(The samples on the left and right sides of the arrow above are photographs of representative 
samples, and they may not necessarily be the exact same samples.) (Image: Wooten, et al., 2013. 
Image courtesy of MDPI. Creative Commons.) 
5.2.2.2. Cyclotron Production of 86Y 
The bare metal strontium is very chemically reactive due to rapid oxidation by air and 
reactivity with water, which produce strontium oxide and strontium hydroxide, respectively. Due 
to this reactivity, 86SrCO3 was used as the initial material. 86SrCO3 was heated at 1000-1100°C 
for 4-12 hours under Ar gas to produce 86SrO, which was immediately stored in an evacuated 
vessel to prevent the spontaneous conversion back to 86SrCO3 in air. The 86SrO was preferred to 
86SrCO3 because Yoo, et al. (2005) noted that 86SrO had a higher content of Sr per mass than 
86SrCO3 and observed experimentally that, relative to 86SrCO3, 86SrO could withstand greater 
beam current (6 vs. 2 µA) and could improve production yields of 86Y (4.5 vs. 2.3 mCi·uA-1·h-1). 
Shortly before the start of cyclotron bombardment, the 86SrO was compressed under 3,000 psi 
using a pneumatic press into a powder target holder made of platinum. The target holder 
consisted of a single piece of platinum, cut into a disk that fit into the solid target end station of 
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the cyclotron, with a dimple at the center cross hatched to improve the adhesion to the target 
material. The thickness of the compressed target is difficult to accurately measure, but assuming 
the powder is perfectly compressed, we estimated the target thickness to be ! = 4! !!!! = 1.16 
mm where m is the mass of the powder, d is the diameter of the cavity, and ρ is the density of the 
salt. The target was mounted in the CS-15 cyclotron (The Cyclotron Corporation, Berkeley) at 
the Mallinckrodt Institute of Radiology (MIR) and bombarded with protons to produce 86Y via 
the 86Sr(p,n)86Y reaction. 
5.2.3. Separation Chemistry 
5.2.3.1. Separation Chemistry for 89Zr 
Figure 5.6 summarizes the general steps in our production process. A stock of 
hydroxamate resin was made by functionalizing the weak cation-exchange resin with 
hydroxamate groups according to a procedure published in Holland, et al. (Holland, et al., 2009), 
based on chemistry developed by others (Herscheid, et al., 1983; Meijs, et al., 1994; Verel, et al., 
2003). Chemical separation of 89Zr from the natY foil was performed in an in-house built 
automated module installed inside a lead hot cell (Comecer, Castel Bolognese, Italy), typically 
on the day after bombardment. During setup for each separation of 89Zr, 100 mg of hydroxamate 
resin from this stock was loaded between two polyethylene (PE) frits (Grace, Deerfield, Illinois, 
United States), which were between two small pieces of glass wool, and loaded into a custom-
blown glass column reservoir that was then incorporated into the system with air-tight 
connections. The entire irradiated target assembly—target holder and target foil—was quickly 
dropped into a Teflon dissolution vessel mounted on the automated system. This transfer was 
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performed manually, the door to the hot cell was then closed, and the remaining steps in the 
purification process were performed remotely. 
 
Figure 5.6. A flowchart describing the process for production and isolation of 89Zr from an 
irradiated Y foil. 
Solid line: automated steps; dashed line: steps that were performed manually. (Image: Wooten, et 
al., 2013. Image courtesy of MDPI. Creative Commons.) 
Using a custom software program that was made in the LabVIEW platform (National 
Instruments, Austin, Texas, United States) running on a laptop outside the hot cell (Figure 5.10), 
10 mL 2 M HCl was added to the dissolution vessel to dissolve the natY target. After waiting ~1 h 
for complete dissolution, the dissolved target was transferred to the column through tubing using 
compressed air. Then, the Y was eluted from the column in 10 mL 2 M HCl and collected in a 
waste vial, leaving the 89Zr bound on the column. The column was rinsed with 10 mL water, 
which was collected in the same waste vial, and then the 89Zr was eluted in 1 mL 1 M oxalic acid 
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and collected in a product vial as 89Zr chelated by the oxalate ions (89Zr-oxalate). Although other 
studies have achieved greater recovery and activity per volume by collecting multiple fractions 
from the column (Holland, et al., 2009; Meijs, et al., 1994; Verel, et al., 2003), we currently have 
automated the collection for only one elution of the product for simplicity in the automated 
module. However, to compensate for collecting a single fraction, we increased slightly the 
volume of eluent to 1 mL. After collection of 89Zr in the product vial, the product was retrieved 
from the hot cell manually and then dispensed in 2 mL skirted microcentifuge tubes for 
distribution within our institution and/or shipping to extramural researchers. 
5.2.3.2. Separation Chemistry for 86Y 
A procedure for the chemical separation of 86Y from 86Sr was adapted from Avila-
Rodriguez, et al. (2008) and is summarized in Figure 5.7. The separation was performed in an in-
house built automated module installed inside a lead hot cell (Comecer, Castel Bolognese, Italy), 
typically a few hours after bombardment, to allow for the short lived 86mY to decay. During setup 
for each separation of 86Y, new solutions were loaded into the source vials and a new filter was 
placed over the glass frit of the separation column. The irradiated target was quickly dropped 
into the Teflon dissolution vessel mounted on the automated system. This was done manually, 
the door to the hot cell was then closed, and the remaining steps of purification performed 
remotely.  
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Figure 5.7. A flowchart that describes the process for the production and chemical 
separation of 86Y from an irradiated SrO target. 
Dashed boxes indicate steps that were performed manually, solid boxes are automated steps. 
A custom software program made in the LabVIEW platform was run on a laptop outside 
the hot cell to control the release of chemicals and transfer of material remotely. A volume of 3 
mL of 6 M HCl was added to the dissolution vessel to dissolve the SrO target. After waiting ~5 
min. for removal of the SrO powder from the target holder, 12 mL of 8 M NH4OH was added. 
The colloidal solution was transferred to the 0.45 µM filter through tubing using compressed air. 
The [86Sr]Sr(OH)2 passed through the filter. The first Sr fraction was collected. 2 x 12 mL of 
basic MilliQ water was passed to the dissolution vessel then the filter and extracted as a wash. A 
volume of 2 mL of 1 M HCl was slowly passed over the filter and the 86Y product was collected. 
The product was brought to dryness at 130 °C under Ar gas.  
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5.2.4. Automated Module 
5.2.4.1. Automated Module for 89Zr 
The path of fluids (liquids and air) through the system was controlled by solenoid-
actuated isolation valves, and, as a fail-safe, solenoid-actuated pinch valves prevented liquids 
from flowing through the flexible tubing at inappropriate times or in the opposite direction. 
Solenoid valves were manufactured by NResearch (West Caldwell, New Jersey, United States). 
Solvents only came in contact with polymers and glass in the system. The compressed air was 
adjusted by a pressure regulator (Swagelok). The flow of compressed air was precisely 
controlled by a hot wire digital mass flow controller (Pneutronics) that received commands from 
the computer. Before each separation, all liquid solvents were pre-loaded into the system by hand 
in glass vials capped with silicone rubber septa that allowed for insertion of two PEEK needles—
one connected to compressed air and one for transporting the liquid. The vials were then clipped 
onto the front of the module, and during the separation each liquid was extracted from its vial 
using positive pressure from the PEEK needle that was connected to compressed air. The general 
schematic of the entire system is shown in Figure 5.8.  
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Figure 5.8. Process flow diagram for the automated module used for chemical separation of 
89Zr from irradiated natY foils. 
CAP: compressed air pump; CV: check valve; HV: hand valve; MFC: mass flow controller; NC: 
normally closed; NO: normally open; R: radiation detector; RV: regulator valve; SI: solenoid 
isolation; SP: solenoid pinch; V: valve. Valves enclosed by a dashed box are part of a gradient 
manifold. Valves V14, V18, and V19 do not exist in the actual system, so they are not displayed 
here. (Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons. Original image 
was made using Edraw Max software (EdrawSoft, Sheung Wan, Hong Kong).) 
An automated module was designed and built to perform a 89Zr- separation protocol 
remotely inside a lead hot cell. The frame for this module (h × w × d = 21 × 18 × 11 in. = 0.53 × 
0.46 × 0.28 m) was constructed of extruded aluminum modular framing, to which walls were 
attached that were made of ultra high-molecular weight polyethylene. Various system 
components were mounted on these plastic walls, as pictured in Figure 5.9. The front panel of 
the module was hinged to allow easy access to the components and wiring inside the module. All 
liquids were pushed through the system by compressed air through flexible tubing. All liquid and 
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most gas connections were assembled using non-metallic connectors, which reduced exposure to 
metal contaminants. Many of the liquid connection pieces were designed for high-pressure liquid 
chromatography (HPLC) systems and were made of ethylene-tetrafluoroethylene (ETFE, 
Tefzel®); gas connections were made using stainless steel Swagelok® tube fittings (Swagelok, 
Solon, Ohio, United States). 
 
Figure 5.9. Photograph of the module for isolating 89Zr from natY metal target material. 
The entire target holder assembly was placed in the dissolution vessel after bombardment, the natY 
target material itself was dissolved and transferred to the column for immobilization of the 89Zr, 
leaving behind the Niobium target holder in the dissolution vessel. (Image: Wooten, et al., 2013. 
Image courtesy of MDPI. Creative Commons.)  
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A computer located outside of the hot cell was used to control the entire chemical 
separation process. A program was created on the LabVIEW platform that featured a graphical 
user interface (GUI) that provides instructions and controls for production personnel. Users could 
follow a step-by-step procedure with a pre-programmed control scheme and, if necessary, 
intervene by controlling individual valves in the event of a problem in the system. Using the 
GUI, the user can easily and precisely change the flow through the mass flow controller and 
thereby the speed at which liquids were pushed through the system, most importantly the speed 
of solvents through the column. We found that to improve recovery, the final eluent was allowed 
to sit on the column for ~20 min. and then slowly pushed through the column at ~0.2–1 mL/min. 
The GUI also included a live video feed from a mini color camera (ApexCCTV, Allen, Texas, 
United States) providing an up-close view of the liquid on the column, as well as real-time 
graphs that reported the radiation dose measured by four Si PIN-type photodiode detectors 
(Carroll & Ramsey, Berkeley, California, United States). These detectors were strategically 
placed close to the dissolution vessel, resin column, waste vial, and product vial (see Figure 5.8), 
allowing the user to monitor the movement of radioactivity through the system in real time. A 
screenshot of the GUI near the end of a separation process is shown in Figure 5.10.  
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Figure 5.10. Screenshot of the window containing the graphical user interface (GUI) that 
was used to control the automated module. 
(Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons. Program was created 
in the LabVIEW platform (National Instruments, Austin, Texas, United States). Programming 
performed by L.A. Lawrence.) 
5.2.4.2. Automated Module for 86Y 
An automated module was designed and built to perform the separation of 86Y and Sr 
inside of a lead hot cell. Madrid, et al. (2011) had previously developed a semi-automated 
module for the remote isolation of 86Y at WUSM/MIR, and we benefited from the experience 
gained in producing that module and utilizing it for isolation of 86Y; however, a newer 
replacement module was needed. The walls of the module were of ultra-high-molecular weight 
polyethylene, and most components were mounted onto these plastic walls. The front wall of the 
module was hinged to allow easy access to wiring and internal components. Figure 5.11 shows a 
process flow diagram for the system. Vacuum from a Venturi pump was used to pull all liquids 
through the system through flexible tubing and through narrow needles made in-house from 
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polyetheretherketone (PEEK™) tubing. The Venturi pump was powered by compressed air from 
the building and the speed of liquids through the system was controlled by pulsing valves open 
and closed during a step in the process—instead of leaving them open continuously during the 
step for maximum speed of liquids. Solenoid-actuated isolation valves were used to control the 
path of liquids and gases through the system, and, as a fail-safe, solenoid-actuated pinch valves 
were used, to prevent liquids from flowing through tubing in the wrong direction or at incorrect 
times. Solenoid valves were manufactured by NResearch. A hand valve adjusted the compressed 
air that entered the system from the building supply. To reduce risk of metal contaminants, 
solvents only came in contact with polymers and glass in the system, and no metal components. 
All liquid solvents were pre-loaded into the system before each separation by hand in glass V-
bottom vials, each capped with a lid that included a silicone rubber septa, which allowed for the 
insertion of PEEK needles for transporting air, vacuum, or liquids. The vials were clipped onto 
the front of the module, as seen in Figure 5.12. Each liquid was extracted from its vial by 
vacuum, necessitating vents on each input vial (Figure 5.11).  
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Figure 5.11. Process flow diagram for the automated module used for chemical separation of 
86Y from irradiated SrO powder targets. 
CAP: compressed air pump; CV: check valve; HV: hand valve; NC: normally closed; NO: 
normally open; PT: pressure transducer; R: radiation detector; SI: solenoid isolation; SP: solenoid 
pinch; V: valve; VP: venture pump; double line: PTFE tubing for compressed air or vent only; 
triple line: PTFE tubing for Ar gas only. Valves enclosed by a dashed box are part of a gradient 
manifold. Not pictured: manometer. (Image was made using Edraw Max software (EdrawSoft, 
Sheung Wan, Hong Kong).)  
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Figure 5.12. A photograph of the automated module for 86Y. 
 
 
 
To control the components of the module, a custom program was created in LabVIEW. 
This program included a GUI that provided instructions and controls for production personnel, as 
shown in screenshots in Figure 5.13. The computer followed a pre-programmed control scheme, 
that, if necessary, could be overridden to control individual valves in the event of a problem in 
the isolation process. The GUI also included a live video feed from mini color cameras 
(ApexCCTV), which provided up-close view of liquid at selected points in the system, such as, 
in Figure 5.13, the liquid passing onto the filter and the liquids flowing into output vials. Silicone 
PIN-type photodiode detectors (Carroll & Ramsey) can feed data to graphs in the GUI (Figure 
5.13) to monitor the movement of radiation through the system, which is important information 
that is complementary to the visual movement of liquids provided by the video cameras.  
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Figure 5.13. Screenshot of the window containing the graphical user interface (GUI) that 
controlled the automated module. 
(Program was created in the LabVIEW platform (National Instruments, Austin, Texas, United 
States). Programming performed by L.A. Lawrence.)  
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5.2.4.3. Design of Automated Module for 52Mn 
As described in Chapter 2, we chose to bombard non-enriched, electroplated chromium 
(natCr) because of reduced cost of material and the ability to produce batches of foil discs in an 
industrial hard chrome electroplating bath. These foils were held in a Niobium metal target 
holder with a screw-on lid that had an open window for the beam to pass through. natCr foils 
were bombarded with ~13.5 MeV protons from the CS-15 cyclotron at WUSM/MIR. In test 
separations performed by hand, and following the selected method from Graves, et al., the 
bombarded foil was digested in HCl, then ethanol was added before the solution was passed 
through a 100-300 mg column of AG 1-X8 resin, an anion-exchange resin. Under these 
conditions of that procedure, Cr(III) was eluted, while 52Mn(II) was immobilized on the column. 
Manganese-52(II) was eluted in 1 M HCl, dried down, re-dissolved in concentrated HCl, and 
then ethanol was added to return the activity to the previous conditions. The column was rinsed 
thoroughly with 2 M HCl, 6 M HCl, water, and then the ethanol/HCl mixture to restore it to its 
original condition. This separation procedure was repeated two more times, reusing the same 
resin each time. This procedure is summarized in Section 2.2.5.2, and a module was designed to 
automate this separation process. 
The result for this section was a process flow diagram for an automated module that will 
be constructed in the future. This diagram is shown in Figure 5.14, and, once it is constructed, 
this will be controlled by a LabVIEW program running on a laptop, similar to the programs for 
controlling the modules for 89Zr and 86Y (Sections 5.2.4.1 and 5.2.4.2). This program will control 
all of the electric solenoid-actuated valves and valve manifolds in the system, which will 
determine the movement of liquids to various destinations in the system. This entire process will 
be monitored in real time by observing the transport of liquids with small digital cameras and the 
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transport of radioactivity with small semiconductor radiation detectors. The necessary 
combinations of valve openings and closings will be pre-programmed into a step-by-step 
sequence in the LabVIEW program, while retaining the capability to actuate any individual 
component at any time simply by clicking its corresponding button. This capability is important 
for reacting to unexpected situations that can occur with routine productions. To reduce risks of 
liquid leaks associated with pushing liquids using air at positive pressure, this module is 
designed to transport liquids that are pulled through the system by vacuum, similar to the 86Y 
module (Section 5.2.4.2). The vacuum is generated by a Venturi pump that using a stream of 
compressed air originating from a source external to the module and hot cell. A digital MFC 
controlled by the LabVIEW program can control the flow rate of compressed air before the 
Venturi pump, thereby controlling the strength of the vacuum. 
5.2.5. Product Characterization 
The 89Zr product was characterized for activity amount, radionuclidic purity, and ESA. 
The amount of activity that was recovered was measured using a dose calibrator (Capintec, 
Ramsey, New Jersey, United States). The radionuclidic purity was characterized using a high-
purity germanium (HPGe) detector (Canberra, Meriden, Connecticut, United States). The 
product was diluted into a 2 mL skirted microcentrifuge tube, and a 10 min scan of the product 
was performed within one half-life of the original bombardment. To search for longer-lived 
contaminants, an aliquot of one production was allowed to decay for ~3 half-lives and then 
scanned for 12 hours. Gamma ray peaks were identified based on characteristic gamma-rays. Per 
Holland, et al. (2009), DFO titration was used to determine ESA, which is the radioactivity of the 
product isotope per total amount of metals in the product. To minimize non-specific binding of 
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other metals by the DFO, the DFO was challenged by 50 mM DTPA. The titration was carried 
out by thin layer chromatography (TLC) on pure cellulose blotting paper that was developed in 
50 mM DTPA and scanned using a radio-TLC scanner (Bioscan, Washington, D.C., United 
States). At this point, the productions of 86Y were mainly characterized by radioactivity as 
measured by an ionization dose calibrator. 
 
Figure 5.14. Process flow diagram for a module for the isolation of 52Mn from Cr metal. 
 
 
 
The final product was characterized for activity amount and radionuclidic purity. A dose 
calibrator (Capintec) was used to measure the amount of activity recovered. To characterize 
radionuclidic purity, the product was diluted in 2 mL skirted microcentrifuge tubes and scanned 
for 10 m, within one half-life of EOB, with a high-purity Ge detector (Canberra) connected to a 
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digital spectrum analyzer (Canberra). The samples were allowed to decay for ~3 half-lives and 
then scanned for 12 hours, to detect longer-lived contaminants. 
5.3. Results 
5.3.1. Results from Production of 89Zr 
The methods described in this work have been used successfully for several years for the 
cyclotron production and chemical separation of 89Zr. Typically, after the chemical separation 
was completed using the automated module, a dose calibrator was used to measure the activity of 
89Zr collected in the product and waste vials. To reduce radiation dose, the system was allowed 
to decay for one week before measuring the dissolution vessel, which still contained the 
irradiated Niobium target holder, and the intact column assembly, which still included the resin, 
frits, and glass wool. The radioactivity measured for all four major module components was 
decay-corrected to the end-of-bombardment (EOB) time for each production. The decay-
corrected activities were summed to give an estimated total radioactivity of 89Zr produced in 
each cyclotron bombardment. This estimate neglects any activity that was lost in tubing, valves, 
etc., but it allows us to compare the performance of the automated chemical separation for 
productions with different starting activities. The majority (74%±16%) of 89Zr was collected in 
the product vial and the largest loss of activity was to the column (18%±15%), which was greater 
than either the waste vial (4%±10%) or the dissolution vessel (3%±3%), as shown in Figure 5.15. 
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Figure 5.15. Distribution of 89Zr in various components after each production. 
For each production, the activity in each of the four primary system components was decay-
corrected to a common time point (end-of-bombardment in the cyclotron) and calculated as a 
percentage of the total activity. Displayed here are the average percentages for each component ± 
1 SD. N = 14. DV: radioactivity remaining in the dissolution vessel after isolation process. (Image: 
Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons.) 
The percentage of 89Zr activity collected in the product vial is the recovery rate of the 
chemical separation that was carried out using the automated module and is an important 
performance indicator for the separation process. In some cases this may be a result of us only 
collecting one elution instead of multiple fractions; otherwise, it may be because the stock of 
hydroxamate resin became less effective at binding Zr if it was stored for too long. We chose to 
make a stock of the resin for simplicity to avoid functionalizing a new batch of resin for each 
production.  
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Figure 5.16. Gamma spectra of diluted aliquots from the product vial from two different 
productions. DFO-89Zr titration curve that resulted in an effective specific activity of 63 
mCi⋅µmol−1 for a selected 89Zr production. 
(A) A 10 m scan taken on the same day as chemical separation, and (B) a 12 h scan taken 22 days 
after the chemical separation. Eγ: gamma-ray energy; a.u.: arbitrary units. Spectra were zoomed in 
on 0 ≤ Eγ ≤ 2,000 keV. Right panel: sigmoidal dose-response curve. DFO titration experiment was 
performed by E. Mebrahtu. (Images: Wooten, et al., 2013 (supplementary information). Images 
courtesy of MDPI. Creative Commons.) 
5.3.2. Results from Production of 86Y 
After chemical separation, the 86Y product vial was removed from the hot cell and a dose 
calibrator was used to measure the activity of 86Y collected. Before the next 86Y production, the 
dissolution vessel, target, filter paper, and Sr fraction were all surveyed in the dose calibrator to 
estimate percent recovery. The radioactivity measured for all five components were decay-
corrected to the EOB time for each production. The decay-corrected activities were then summed 
to give an estimated total radioactivity of 86Y produced. Before placing the target into the 
automated module, the activity of the entire target was measured using a dose calibrator, which 
allowed for the percent activity in each component to be calculated. The majority (59%±14% 
(not relative uncertainty)) of the 86Y was collected in the product vial, and the greatest loss of 
radioactivity was mainly lost in the elution of Sr (3%±4% (not relative uncertainty)). We found 
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that recovery of 86Y was extremely dependent on the type of filter paper used, with the 0.45 µm 
mesh providing the best recovery. 
 
Figure 5.17. Distribution of 86Y in various components after each production. 
 
 
 
For each production, the radioactivity in the product, waste, and Sr vials, as well as on the 
filter, were decay-corrected to a common timepoint and calculated as a percentage of the total 
activity. Displayed in Figure 5.17 are the average percentages for each component, with error 
bars representing the 2σ (95%) confidence interval. The number of productions (n) represented 
by this data was n=11. It should be noted that this production data from using the module for 86Y 
should be considered preliminary because it was collected during a phase of troubleshooting and 
optimization. Not included in this data were productions in which there was an obvious failure 
that resulted in a very large quantity of 86Y not being isolated.  
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5.4. Discussion 
5.4.1. Automated Module for 89Zr 
Automation is an important part of isotope production in particular and nuclear medicine 
in general because automated modules enable production centers to separate large activities of 
isotopes while still meeting institutional and federal regulations for radiation dose. Several 
groups have published on custom-made automated modules for various radiometals, including 
64Cu (Burke, et al., 2010; Kume, et al., 2012; Matarrese, et al., 2010; Welch, et al., 2006), 124I 
(Nagatsu, et al., 2011), 99mTc (Chattopadhyay, et al., 2012), 86Y (Park, et al., 2004), and 89Zr 
(Siikanen, et al., 2012; Wooten, et al., 2012). 
The Niobium target holders have been irradiated up to 15 µA without significant 
alterations of target or target holder. Since the same beam current, beam energy, and foil 
thickness were used for all productions in this work, the bombardment time (tb) was the only 
bombardment parameter that was adjusted to control the amount of activity produced in the 
cyclotron. The parameters for comparable publications varied widely. Excluding the Y2O3 pellet 
targets, only one publication (Dejesus and Nickles, 1990) used a foil that was close to ours in 
thickness. Also, the beam current, bombardment time, and µA⋅h all varied widely across 
publications. Not surprisingly, the Y2O3 targets used lower currents, presumably because of 
reduced heat transfer, while the sputtered targets received high beam current for long 
bombardment times. 
The predicted activity produced from a cyclotron was calculated by estimating beam 
energies at various points in the target using SRIM and calculating the reaction rate between 
these points using published empirical cross-section data for the natY(p,n)89Zr reaction (Birattari, 
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et al., 1973; Blosser and Handley, 1955; Church and Caretto, 1969; Khandaker, et al., 2012; 
Michel, et al., 1997; Saha, et al., 1966; Uddin, et al., 2005). These data were accessed and plotted 
through the NNDC online database (NNDC/BNL), as shown in Figure 5.3. We estimated that 
37% of the beam was lost in the rim of the lid of the target holder, instead of passing through the 
central window to irradiate the exposed natY foil. The reaction rate (R) was calculated, followed 
by the activity (A), using the standard equation for production of a radionuclide: A = R(1−e−λt) 
(Ehmann and Vance, 1991), where λ is the decay constant for 89Zr. 
To confirm the radionuclidic purity of the solution in the product vial, gamma 
spectroscopy was performed. Typically, a short (10 min.) scan of a diluted aliquot from the 
product vial was performed on the same day as each chemical separation (Figure 5.16). For one 
production, a long (12 h) scan was performed after waiting for several half-lives (~22 days) of 
89Zr to allow it to decay relative to longer-lived potential radiocontaminants, making them easier 
to detect by gamma spectroscopy. This spectrum indicated a radionuclidic purity of 89Zr equal to 
99.998% of total activity (99.95% of total atoms) and identified 88Zr as the only 
radiocontaminant. Even though our recovery percentage was less than other studies, our 
radionuclidic purity was on par with other publications, only one of which had a radionuclidic 
purity <99%. This high radionuclidic purity is likely because of the minimal overlap of the 
excitation function for the natY(p,n)89Zr reaction with the natY(p,2n)88Zr reaction, or any other 
potential reactions. For most productions of 89Zr in this work, ESA was determined by DFO 
titration, similar to Holland, et al. (2009). ESA accounts for the presence of any metal isotope 
(stable or radioactive) that can be chelated by the selected chelator, in this case, DFO. For each 
production, the results of the DFO titration were plotted and fit with a sigmoidal dose-response 
curve to produce an EC50 value, which was used to calculate ESA in mCi⋅µmol−1.  
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In this work, we present the cyclotron production of 89Zr using a biomedical cyclotron 
and the chemical separation of 89Zr from a Y foil target using an automated module. This module 
dissolved the Y foil in acid and then separated the 89Zr from Y using a hydroxamate resin 
column. Our methods reduced radiation dose to production personnel as the separation was 
carried out inside a lead hot cell, while the module was controlled by a laptop outside. The 
progress of the separation was monitored using radiation detectors in the module, and the final 
result for each production was a 89Zr(IV)-oxalate solution, and this solution was characterized for 
recovery of activity, radionuclidic purity, and ESA. Our 89Zr products had very high purity, 
similar to other published production methods. The procedures described in this work have been 
used for several years to routinely produce 89Zr for users at our institution and for shipping to 
other institutions. Lessons learned from production of 89Zr will be adapted for routine cyclotron 
production and chemical separation of other radiometals from solid targets. 
5.4.2. Automated Module for 86Y 
In this work, we present the cyclotron production of 86Y using a biomedical cyclotron and 
the chemical separation of 86Y from a SrO powder target using an automated module. This 
module dissolved the SrO powder in acid and then separated the 86Y from the Sr by passing 
through a filter in a basic solution. The 86Y was then passed through the filter paper using acid 
and collected in a separate output vial. Utilizing this automated module for routine production of 
86Y would reduce radiation dose to personnel, as the separation was performed inside a lead hot 
cell and controlled remotely by a computer that was located outside of the hot cell. The 
separation process was monitored with radiation detectors and cameras positioned on the module 
at strategic locations, and the final product for each production was a no-carrier-added solution 
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of 86Y in 1 M HCl. Drying down this product would reduce risk of spills and leaks during 
transport, and it could facilitate solvent exchange from 1 M HCl to a different desired solvent. 
We do not anticipate that drying down 86Y in 1 M HCl would compromise the solubility of the 
86Y product in water, so we expect that it can be re-dissolved easily. 
As mentioned earlier, the production results from the 86Y module that are presented in 
this chapter should be considered preliminary data. Not included in this data were productions in 
which there was an obvious failure that resulted in a very large quantity of 86Y not being isolated. 
Also, there were many productions in which the pressed powder target did not survive the 
cyclotron bombardment, resulting in a target with very little powder remaining in the dish of the 
target holder. (Currently, the powder targets for production of 86Y are covered.) The results that 
are presented in this dissertation for the semi-automated isolation of 86Y are from relatively early 
productions for this new module, which has been used more since those productions were 
performed. 
5.4.3. Automated Module for 52Mn 
52Mn is an important radioisotope of manganese for studying the chemical behavior of 
manganese in many applications. Manganese-52 also has attractive nuclear decay properties that 
make it attractive for radiolabelling of agents with long biological half-lives, such as 
macromolecules and nanoparticles, because of its long half-life, low positron energy, and 
sufficient branching ratio for positron emission. Many methods for isolating 52Mn from 
bombarded chromium target material have been proposed, but a very recent method utilizing a 
solution of ethanol and concentrated HCl to elute Cr(III) seems very efficient, robust, and 
suitable for automation. Thus, an automated module is a logical and important next step in the 
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routine production of 52Mn. Because of the half-life of 52Mn, it is practical to ship it domestically 
or even internationally without losing too much of it to decay. Therefore, it is likely that only a 
few automated modules will be constructed in the foreseeable future and that these units will be 
used to produce large enough batches that can be aliquotted and shipped to meet demand. 
As discussed in Chapter 2, scaled-up production of 52Mn can be achieved by bombarding 
Cr metal targets that are isotopically enriched 52Cr and/or greater in thickness, increasing proton 
energy not beyond ~24 MeV, or bombarding with deuterons in the 40à8 MeV range. 
Radiocontaminants co-produced from the latter two solutions would be easily removed by decay 
(51,52mMn and 52V) or by chemical isolation of 52Mn from the chromium target material (51Cr). 
Manganese-52 emits significant amounts of gamma radiation in addition to its 511 keV 
annihilation photons, so radiation safety is a significant issue with this PET radionuclide. Much 
study and care is applied to radiation dosimetry for patients receiving injected 
radiopharamaceuticals and to limiting exposure for the clinical personnel that administer these 
doses as a full-time job. However, it is also important to monitor and limit radiation dose to 
personnel responsible for the production of radionuclides and radiopharmaceuticals, especially 
since they are likely handling more radioactivity before some of it is lost to nuclear decay and 
yield losses from chemical processes. Automated modules are very useful in this respect, both 
for isolating radionuclides and synthesis of radiolabelled compounds, because they can be 
located inside a hot cell of any size and thickness necessary to protect personnel. The module 
that has been designed for the chemical isolation of 52Mn will play an important role in making 
this valuable PET radionuclide widely available by enabling routine, scaled-up productions of 
much larger activities than would otherwise be reasonable to handle by hand in an open 
laboratory benchtop setting, even inside of a lead castle. Based on general experience with 
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automated modules for chemical separations of PET radiometals, it is also possible that using 
such a module for isolating 52Mn in a hot cell could result in greater purity and consistency by 
reducing the influence of human factors and protecting the isolation procedure from 
environmental contaminants. 
5.5. Conclusions and Recommendations 
• Semi-automated modules for the scaled-up production of 89Zr and 86Y were 
constructed in collaboration with a team of people. These automated modules 
were able to carry out separations inside of a lead hot cell by moving solvents 
through tubing by vacuum or compressed air. The separation process was 
controlled from outside the hot cell by a laptop that was connected to the 
module and running a software program that was produced in-house. The 
ability to control separation processes remotely protects production personnel 
from significant radiation dose, and these modules have been used routinely to 
produce isotopes for use at institutions nationwide, including 89Zr for a 
clinical trial at our institution. 
• We have designed a similar module that will implement the anion-exchange 
separation method for 52Mn from a chromium metal target. 
• Recommended future directions: For the 52Mn automated module: assemble 
the module; automate with a custom software program; validate the module 
with increasing starting activities until it is ready for routine use; if collecting 
the final 52Mn product in the same glass vessel as the previous rounds 
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introduces contaminants in the final product, then a separate line and 
collection vessel for the final round of elution of 52Mn can be added to the 
design. 
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Chapter 6. Compiled Conclusions and 
Recommendations 
This dissertation has included concepts and results from applications for positron-
emitting radiometals, with an emphasis on 52Mn. These experiments have centered around the 
larger ideas that have defined the chapters of this dissertation: radionuclide production and 
isolation, biodistribution and PET imaging, applications in PET/MR, and automation for scaled-
up radionuclide production. The conclusions and recommended future directions for each of 
these ideas can be found at the end of each respective chapter, and they are summarized here: 
 
Chapter 1. Introduction 
• Manganese is important because of its natural role as an essential 
micronutrient in humans that is involved in several important processes for 
life. 
• Manganese has historically caused neurotoxicity when inhaled chronically 
from environmental contaminants, and occupational exposure to inhaled 
manganese continues to cause neurotoxicity, even in developed countries with 
occupational safety measures. 
• Manganese(II) is one of the most highly paramagnetic cations on the periodic 
table, which makes it a candidate for the metallic core in T1 contrast agents. 
Manganese(II) has very different chemistry, toxicity, and excretion route than 
the current standard cation Gd(III), so Mn(II) provides a meaningful 
alternative.  
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• A radiotracer for the study of manganese is important because of the 
sensitivity of many radioactive assays, the ease of quantification, and the 
availability of necessary equipment. In vivo imaging of manganese is also 
important for studying the above roles of manganese, and PET imaging has 
advantages over other nuclear emission imaging modalities (and the lack of a 
SPECT radioisotope of manganese). 
• Manganese-52 was selected because it is a positron-emitter with a sufficient 
total intensity of positrons, a relatively long half-life for nuclear decay that 
would enable studies spanning several days, and the ability to produce 52Mn 
from a non-enriched target bombarded with low-energy protons, which were 
available from a cyclotron at our institution. Manganese-52 is a good choice 
for studying manganese specifically, but and also has characteristics that make 
it competitive with other PET radiometals, such as a very low average 
positron energy, which can correspond to good spatial resolution in PET. 
 
Chapter 2. Nuclear Cross-Sections and Chemical Separation of 52Mn 
• Nuclear cross-sections have been measured for the natCr(p,x)52,52m,54Mn 
reactions for incident protons with energy ≤13 MeV, which is easily achieved 
by most cyclotrons at medical centers. The cross-section results agreed closely 
with theoretical simulations, and they can be used to predict yields of 
52,52m,54Mn when bombarding natural chromium with low-energy protons.  
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• Chemical isolation was performed using a published method that involved 
digesting the chromium target in HCl, replacing the HCl with dilute H2SO4 
and then immobilizing 52Mn(II) on a cation-exchange column. This method 
resulted with visible amounts of Cr(III) in the product. 
• Chemical isolation using a recently published method was more effective. 
This method involved digesting the chromium target in HCl, diluting this 
solution in ethanol, immobilizing 52Mn(II) on an anion-exchange column, and 
performing this process repeatedly. 
• Recommended future directions: Trace metal analysis after each round of the 
anion-exchange separation method to determine how many rounds are 
necessary; characterization of routine production including cyclotron yields, 
chemical recovery percentage, radionuclidic purity, and trace metals analysis. 
 
Chapter 3. Biodistribution and PET Imaging of 52Mn 
• Biodistribution studies of intravenously injected 52Mn(II) in mice showed 
uptake in many organs, most interestingly: salivary glands, brain, thyroid, 
thymus, pancreas, liver, kidney, and bone. 
• Similar studies in rats that extended to longer timepoints showed that activity 
in all of those organs decreases significantly over the course of seven days, 
except for brain, adrenals, and pancreas and confirmed that manganese is 
excreted almost exclusively through the feces and not the urine. 
• Biodistribution studies of inhaled manganese in mice showed uptake in lung, 
brain, thyroid, pancreas, liver, and kidney.  
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• PET imaging of [52Mn]MnCl2 in mice and rats confirmed the observations 
from biodistribution, including high signal from 52Mn in the pancreas at seven 
days post-injection, after the activity had significantly decreased in nearby 
tissues, such as the liver and kidneys. 
• Recommended future directions: PET/CT imaging using a CT contrast agent 
that will reveal the pancreas on CT, which will enable quantitative imaging of 
free manganese in the pancreas with possible applications in diagnostic 
imaging of diabetes. 
 
Chapter 4. Applications for 52Mn in PET/MR Imaging 
• A phantom containing various concentrations of non-radioactive 
Mn(II)Cl2·(H2O)4 dissolved in water ,was imaged by MRI using an inversion 
recovery pulse sequence. The signal from the images were analyzed, and these 
results were used to calculate the relaxivity of this compound in aqueous 
solution. 
• Another phantom was constructed that contained a matrix of different 
concentrations of non-radioactive Mn(II)Cl2·(H2O)4 dissolved in water to 
which different amounts of 52Mn had been added. This phantom was imaged 
by PET/MR and revealed changes in both MR and PET signals. 
• Recommended future directions: Investigate the utility of 52Mn by 
radiolabeling a compound that has been used to chelate Mn(II) for MRI 
imaging; perform PET/MR imaging of phantoms containing the compound 
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complexed with non-radioactive Mn(II) and radioactive 52Mn(II) in various 
concentrations and radioactivities. 
 
Chapter 5. Remotely-Controlled Modules for the Isolation of PET Radiometals 
• Semi-automated modules for the scaled-up production of 89Zr and 86Y were 
constructed in collaboration with a team of people. These automated modules 
were able to carry out separations inside of a lead hot cell by moving solvents 
through tubing by vacuum or compressed air. The separation process was 
controlled from outside the hot cell by a laptop that was connected to the 
module and running a software program that was produced in-house. The 
ability to control separation processes remotely protects production personnel 
from significant radiation dose, and these modules have been used routinely to 
produce isotopes for use at institutions nationwide, including 89Zr for a 
clinical trial at our institution. 
• We have designed a similar module that will implement the anion-exchange 
separation method for 52Mn from a chromium metal target. 
• Recommended future directions: For the 52Mn automated module: assemble 
the module; automate with a custom software program; validate the module 
with increasing starting activities until it is ready for routine use; if collecting 
the final 52Mn product in the same glass vessel as the previous rounds 
introduces contaminants in the final product, then a separate line and 
collection vessel for the final round of elution of 52Mn can be added to the 
design.  
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This dissertation has presented preliminary work in the production and biomedical 
applications of 52Mn, a radionuclide that holds potential for many more studies related to PET 
imaging and non-imaging of the behavior of manganese. 
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For PET radionuclides, the radioactivity of a sample can be conveniently measured by a 
dose calibrator. These devices depend on a “calibration setting number”, but many recommended 
settings from manuals were interpolated based on standard sources of other radionuclide(s). We 
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conducted HPGe gamma-ray spectroscopy, resulting in a reference for determining settings in 
two types of vessels containing one of several PET radionuclides. Our results reiterate the notion 
that in-house, experimental calibrations are recommended for different radionuclides and vessels. 
A.1. Introduction 
Many PET imaging agents that are currently in development, including peptides, 
antibodies, and nanoparticles, have biological half-lives of hours to days, so they require 
positron-emitting radiolabels with longer half-lives than traditional PET isotopes, such as 11C or 
18F. Other isotopes such as 64Cu, 86Y, 89Zr, and 124I, satisfy these criteria and are currently used as 
radiolabels for compounds in preclinical and clinical research (Ikotun and Lapi, 2011; Nayak and 
Brechbiel, 2009; Wadas et al., 2010). For studies using any of these isotopes, it is critical to 
obtain accurate measurements of radioactivity at numerous stages of the PET study, including: 
immediately following target irradiation, chemical separation, dispensing, radiolabelling, and 
pre-injection. These radioactivity measurements are commonly measured in laboratory and 
clinical settings using a dose calibrator, which provides fast results for the measurement of the 
radioactivity of a sample. This type of benchtop instrument has a small enough footprint and a 
small enough cost to be commonly installed in many different rooms that might be used during 
the workflow from cyclotron to injection. 
The user manuals provided by Capintec (2007, 2015) for the dose calibrators that were 
used in this investigation provided a good explanation of the physics of radiation measurement 
that are employed by these models of gas ionization dose calibrators. We only briefly summarize 
these explanations here. Dose calibrators measure the radioactivity of a sample based on the rate 
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at which it emits ionizing photon radiation—X-rays, gamma-rays, or other photons (e.g., from 
positron annihilation). With a few exceptions, particle radiation—alphas, betas, and positrons—
are not penetrating enough to cause ionization in the gas chamber. In many models of dose 
calibrators, the radioactive sample is lowered into the center of a cylindrical sealed chamber 
containing a gas. Photons in the 100-2,000 keV energy range do not directly produce the 
ionization signal for the dose calibrator, but rather they interact with the wall and/or gas of the 
chamber to release electrons, and these secondary electrons ionize the gas in the chamber enough 
to produce the electric signal that is measured by the device. Electric current is created in a 
circuit within the dose calibrator, and the magnitude of this current is directly proportional to the 
radioactivity of the isotope that emitted the radiation (for similar sample geometries). In the dose 
calibrators used in this investigation, the gas in the chamber was argon, which is also used in 
many other gas ionization dose calibrators. 
Since the radiation dose rates vary widely by isotope, the accuracy of these instruments 
relies on using the correct calibration setting for the isotope being measured. For ionization 
chambers connected to older, analog control units, a dial setting adjusts a potentiometer to 
change the gain in the detector for the isotope being measured (IAEA). In newer, digital dose 
calibrators, a “calibration setting number” (represented by the variable NA in certain user 
manuals) simply adjusts the digital output of the unit (Capintec, 2007, 2015; Chandra, 2011). In 
both generations of dose calibrators, numerous commonly used isotopes have pre-programmed 
settings that can be selected, but a custom calibration setting number must be entered (or dialed) 
for other isotopes. Many calibration setting numbers are recommended by Capintec in user 
manuals, but the vast majority of these values were calculated using an empirical linear fit 
equation that was based upon the detector response to only two isotopes in a single geometry 
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(Capintec, 2007, 2015). Specifically, these measurements were conducted for reference sources 
consisting of 5 mL of solution containing 57Co or 60Co in a glass ampoule with 0.6 mm wall 
thickness, obtained from the United States National Institute of Standards and Technology 
(NIST) (NIST, 2011; Capintec, 2007, 2015). 
Consequently, several publications have endeavored to experimentally determine new 
calibration setting numbers for various models of Capintec dose calibrators, sample geometries, 
and radionuclides. To measure reference activities, these investigations have used various 
radioanalytical techniques: HPGe detector (Beattie et al., 2014; Coursey et al., 1993; 
Zimmerman et al., 2001), NaI(Tl) detector (Zimmerman et al., 2002), 4πβ liquid scintillation 
(4πβ-LS) (Cessna et al., 2008; Mo et al., 2006; Zimmerman and Cessna, 2000; Zimmerman et 
al., 1999), or a different gas ionization chamber (Tyler and Woods, 2002, 2003). Some of the 
calibration setting numbers that were determined in these studies yielded radioactivity readouts 
that were dramatically different from the radioactivity readout from recommended settings. In at 
least one case, Capintec officially changed its recommended calibration for an isotope: Based on 
the results of Zimmerman, et al. (2001) and later Cessna, et al. (2008), the recommended setting 
number for 18F was changed from 439 to 472 for NIST ampoules and 484 for 3 mL plastic 
syringes (Capintec, 2009). Furthermore, the calibration setting numbers for the same isotopes in 
the same dose calibrator models were often greater for samples with larger volumes. Geometry 
effects are even more pronounced for isotopes that emit low-energy gamma-rays (Tyler and 
Woods, 2003); or positrons or beta particles (Capintec, 2007, 2015) because these radiations are 
more susceptible to systematic errors resulting from attenuation or scattering, respectively. 
We acknowledge that some facilities in radiochemistry and nuclear medicine may rely 
solely on Capintec dose calibrators to measure radioactivity—without access to a high-precision 
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reference measurement instrument, such as a HPGe detector. In Section A.2.3, we performed 
gamma-ray spectroscopy using a HPGe detector to quantify the amount of radioactivity in 
samples that served as references for the experimental determination of calibration setting 
numbers for two different sample geometries containing the PET isotopes 52Mn, 64Cu, 86Y, 89Zr, 
76Br and 124I. The two geometries that we tested were 2 mL microcentrifuge tubes, which are 
widely measured in dose calibrators for radiochemistry work, and 10 cc (10 mL) syringes, which 
are commonly measured in dose calibrators before injection of a radiopharmaceutical. 
A.2. Experimental 
A.2.1. Materials 
Ultrapure water (~18 MΩ) was obtained from a Millipore system (Billerica, 
Massachusetts, United States) and was used for diluting aliquots of radioactivity. 2 mL 
microcentrifuge tubes and 10 cc syringes were purchased from Fisher Scientific (Pittsburgh, 
Pennsylvania, United States). All 124I was purchased from 3D Imaging (Maumelle, Arkansas, 
United States). 
A.2.2. Radionuclide Production 
All other isotopes used in this work were produced on-site by (p,n) reactions in solid 
targets that were bombarded with protons from the CS-15 cyclotron (The Cyclotron Corporation, 
Berkeley, California, United States) at Washington University School of Medicine in St. Louis 
(WUSM). Various methods (Table A.1) were carried out by remotely-controlled automated 
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modules inside of lead hot cells to separate the following isotope products from the 
corresponding bulk solid target material: 64Cu (Kume et al., 2012; McCarthy et al., 1997), 76Br 
(McCarthy et al., 1999; Tolmachev et al., 1998), 86Y (Avila-Rodriguez et al., 2008; Yoo et al., 
2005), and 89Zr (Holland et al., 2009; Meijs et al., 1994; Wooten et al., 2012). Manganese-52 
was produced by bombarding a natural Cr foil target with protons (Wooten et al., 2015), 
followed by digesting the Cr foil in hydrochloric acid with no further purification. Iodine-124 
was produced by 3D Imaging (Berridge, 2013) in a manner similar to methods that were 
published by Knust, et al. (2000), Sheh, et al. (2000), and other published methods. For each 
isotope, aliquots were taken and diluted with ultrapure water as needed for gamma-ray 
spectroscopy (Section A.2.3) or dose calibrator measurements (Section A.2.4). 
Table A.1. Summary of isotope production methods that were followed or adapted for the 
isotopes used in this work. 
Product  Target  Isolation Method  Reference(s) 
Isotope  Isotope Material     
52Mn  52Cr 
(83.7%) 
natCr metal foil  (No isolation performed—only 
digestion of Cr target by HCl.) 
 - 
64Cu  64Ni 
(0.9%) 
Electroplated 
64Cu metal 
 Anion-exchange 
chromatography 
 AM: (Kume, et al., 2012) 
SC: (McCarthy et al., 1997) 
76Br  76Se 
(9.4%) 
Pressed 76Cu2Se 
pellet 
 Dry distillation followed by 
thermal chromatography 
 AM: Not yet published. 
SC: 
(McCarthy, et al., 1999) 
(Tolmachev, et al., 1998) 
86Y  86Sr 
(9.9%) 
Pressed 86SrO 
pellet 
 pH-based precipitation 
followed by filtration 
 AM: Not yet published. 
SC: 
(Avila-Rodriguez, et al., 2008) 
(Yoo, et al., 2005) 
89Zr  89Y 
(100%) 
natY metal foil  Hydroxamate resin 
chromatography 
 AM: (Wooten, et al., 2012) 
SC: 
(Holland, et al., 2009) 
(Meijs, et al., 1994) 
124I†  124Te 
(4.7%) 
TeO2/Al2O3  Dry distillation  SC: 
(Knust, et al., 2000) 
(Sheh, et al., 2000) 
All isotopes were produced via (p,n) reactions. †Purchased from 3D Imaging (Maumelle, Arkansas, United States). 
All other isotopes were produced in-house at WUSM/MIR. AM: automated module; SC: separation chemistry.  
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A.2.3. Gamma-Ray Spectroscopy 
The radioactivity per volume of the product solution was calculated based on gamma-ray 
spectroscopy results from one of two Canberra (Meriden, Connecticut, United States) brand 
HPGe detector systems: Detector 1 (model GC1818 with 18.9% efficiency) and Detector 2 
(model GC2018 with 24.5% efficiency) . Each detector was connected to a digital spectrum 
analyzer (DSA; model: DSA-1000) and operated by the Gamma Acquisition & Analysis module 
of the Genie 2000 spectroscopy software package (v. 3.3). The HPGe detector was calibrated for 
energy and efficiency based on the full-absorption photopeaks from a mixed-gamma reference 
source (Eckert & Ziegler Analytics, Atlanta, Georgia, United States). This calibration source 
consisted of a 2 mL skirted microcentrifuge tube that contained eight radioisotopes in a hardened 
epoxy, which was an identical geometry to the 2 mL microcentrifuge tubes used for counting 
emissions from our diluted isotope products. 
For each isotope considered in this study, an aqueous solution containing the isotope was 
serially diluted in 2 mL microcentrifuge tubes until the Ge detector yielded a dead time <5%. 
The dilution was produced in triplicate, and each of these three tubes was scanned long enough 
to acquire ≥103 counts for the gamma-ray with the highest branching ratio, which was typically 
10-30 min of detector live time. In the spectroscopy results, we identified at least one full-
absorption photopeak that corresponded to an identifying gamma-ray energy (Eγ) that was 
emitted by the isotope being measured. Gamma-ray energy(ies) with the highest branching 
ratio(s) without also being emitted by a metastable isomer (e.g., Eγ=1,434 keV from 52mMn) were 
used for analysis. The number of counts and detector efficiency for the selected peak were used 
to calculate the radioactivity per volume, assuming no decay during counting because the 
counting period was short (<5%) relative to the isotope’s half-life using the following equation: 
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 ! = !!!!!!!! , (A.1) 
where A is the radioactivity (Bq); Nc is the number of counts (net peak area) for the full-
absorption photopeak; εc is the counting efficiency for the detector at the corresponding gamma-
ray energy (dimensionless); Iγ is the branching ratio for the corresponding gamma-ray 
(dimensionless); tl is the detector live time during gamma-ray counting. The results calculated 
using Equation A.1 were decay-corrected to an arbitrary time in the past for all three tubes, 
averaged together, and then multiplied by the dilution factor to determine the radioactivity per 
volume of the original product solution at that common time. This value was then used to 
calculate the radioactivity per volume in the product solution at the time when the samples would 
be prepared for the dose calibrator measurement (Section A.2.4). 
A.2.4. Dose Calibrator Measurements 
Calibration setting numbers were determined from measurements using two models of 
dose calibrators from Capintec (Ramsey, New Jersey, United States): a model CRC-15R or a 
model CRC-25R. Characteristics of both of these models are given in Table A.2, and they use 
identical calibration setting numbers (Capintec, 2007, 2009, 2015). For each isotope, one 
radioactivity between 10-1,000 µCi was selected for measurement in a dose calibrator. Based on 
the radioactivity per volume calculated from the gamma-ray spectroscopy results, the 
radioactivity was decay-corrected to the approximate time of measurement in the dose calibrator. 
Then, the appropriate volume containing the radioactivity was transferred into either a 2 mL 
microcentrifuge tube or into a 10 cc syringe. The final volume in these vessels was 
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approximately 1 or 8 mL, respectively. The time from pipetting to the end of the final 
measurement in the dose calibrator was less than 15 min., so decay during that period was 
negligible for the isotopes studies. 
Table A.2. Shared characteristics of the CRC-15R and CRC-25R models of Capintec brand 
ionization dose calibrators. 
Well Diameter 6.1 cm 
Well Depth 25.4 cm 
Electrometer Accuracy Better than ±2% 
System Precision Better than ±0.1% FSD 
System Linearity Within ±2% 
Equation for recommended calibration numbers NA = 1076*(RA – 0.080) 
NA=Calibration number; RA=the response of the detector to Isotope A. (Sources: Capintec, 2007, 
2015). 
Each sample was placed in the dose calibrator, and the calibration setting number was 
adjusted until the screen displayed the expected radioactivity based on the gamma spectroscopy 
results (corrected for dilution and radioactive decay). During these measurements, the precision 
of the dose calibrator was set to read to the nearest 1 µCi. For some isotopes that emitted high or 
low dose rates of gamma radiation, it was necessary to find a calibration setting number that 
caused the control unit to display a multiple of the expected value so divisions or multiplication 
of the readout by an integer correction factor obtained a meaningful result. When using these dial 
settings to measure an unknown amount of radioactivity, the readout value would be divided or 
multiplied by the correction factor for that isotope, such as ÷2, ×2, ×10, and ×100, to yield the 
final radioactivity readout (ARO). For some of our experiments, the sample was removed from the 
dose calibrator and replaced in a different orientation to account for variations in the positioning 
of the vessel within the well of the dose calibrator. For these experiments where only one valid 
setting was recorded, we conservatively assumed an uncertainty of ±5 setting numbers to 
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manufacture a range of values. Additionally, for 52Mn, 64Cu, and 124I, the calibration setting 
number was varied over a large range to observe the effect on radioactivity readout on a wider 
scale. 
A.2.5. Data and Uncertainty Analysis 
The entire dose calibrator had an instrumental uncertainty of ±2% (Capintec, 2007, 
2015). Since the radioactivity is directly proportional to the radioactivity readout in the local 
range of calibration setting numbers, we calculated 2% of the maximum in each range, and 
added or subtracted it to the maximum or minimum of each range to get new values, !!!"# and !!!"#. If the displayed value needed to be multiplied or divided by a scaling factor, the number 
was adjusted by 2% and by the same scaling factor. The midpoint of this new range, !!!"#, was 
calculated as the mean of !!!"# and !!!"# for that trial, and the uncertainty of this midpoint was 
(!!!"# - !!!"#)/2. If the vessel was placed in the dose calibrator multiple times, the midpoints 
from each placement were averaged. The uncertainty in this mean resulted from propagating the 
individual uncertainty from each placement using the following equation: 
 !!!! = !! ! !!!!!!!!!  , (A.2) 
where !!! is the uncertainty in the average; n is the number of trials; and !!!! is the uncertainty 
in each value that was averaged together. Equation A.2 applies the total differential equation for 
the propagation of small uncertainties to the equation for the arithmetic mean, if all uncertainties 
are uncorrelated (Arras, 1998; Croarkin; Ku, 1966).  
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Dose calibrator measurements were performed on vessels in triplicate, each resulting in 
an average result with uncertainty. These results across the three vessels were averaged, and the 
uncertainty in each final result was obtained by propagating the uncertainties from the individual 
vessels through Equation A.2 (This time, with n=3.). The final average result was rounded to the 
nearest integer (because all dial settings are integers), and the uncertainty was accordingly 
rounded up to the nearest integer to be conservative. These results are the final values and 
uncertainties that are shown in Table A.3. 
A.3. Results 
Our results for calibration setting numbers for the Capintec dose calibrators are shown in 
Table A.3 for our six isotopes, both in 2 mL microcentrifuge tubes and in 10 cc syringes. Table 
A.3 also shows the gamma factor (Γ) for each of these isotopes, calculated by Smith and Stabin 
(2012) to express the dose rates for various isotopes based on a weighted average of gamma-ray 
energies and branching ratios—including annihilation photons. All results were greater than the 
recommended values found in the user manuals to varying degrees. This was interesting because 
the recommended values were interpolated from results based on 5 mL calibration sources, 
which would be near the midpoint of the two volumes.  
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Table A.3. Results for calibration setting numbers on Capintec CRC-15R and CRC-25R 
dose calibrators. 
Isotope Gamma Factora From Manualb New Calibration Setting Percent Difference in Radioactivity Readout 
 Γ (R·cm2/mCi·h)  2 mL Tube 10 cc Syringe (%) 
52Mn 18.4 676÷2 759±12 (÷2) 777±13 (÷2) +10.2% 
64Cu 1.05 15 or 16±2 108±2 (x2) -3.6%c 
  115 (×2)    
76Br 14 495÷2 604±9 (÷2) 800±9 (÷2) +52.6% 
86Y 18.9 711÷2 762±12 (÷2) 815±9 -44.1% 
89Zr 6.59 465 514±6 527±6 +11.2% 
124I 6.59 570 29±1 733±7 +24.6% 
For (x2) or (÷2), the radioactivity readout from the dose calibrator should be multiplied or divided 
by 2 to obtain the correct radioactivity measurement. aGamma factor describes the dose rate from 
gamma radiation emitted by an isotope. (Data from: (Smith and Stabin, 2012).) bAll recommended 
dial settings were the same in the manuals for both the CRC-15R and CRC-25R models, except 
for 76Br and 89Zr (not listed in the manual for the CRC-25R). (Recommended setting(s) from: 
Capintec, 2007, 2015). cCalculated relative to the radioactivity readout using setting: 15. 
For comparison, we measured each of the isotopes in a 10 cc syringe using our result for 
the calibration setting number and also the recommended value, and the percent difference 
relative to the measurement using the new value was calculated. These percentages of difference 
varied significantly (Table A.3), and other published works reported (Table A.4) that activities 
measured using recommended calibration setting numbers can differ slightly (~1-10%) or 
greatly: +50% for 90Y (Coursey et al., 1993); +45% and -42% for 125I in different geometries 
(Zimmerman et al., 2002); and +35% for 111In (Ceccatelli et al., 2007). In the majority of 
published studies listed in Table A.4, the radioactivity measured using recommended settings 
would overestimate the amount of radioactivity that was present in the sample.  
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Table A.4. Selected results from other studies that determined setting numbers for various 
medical radionuclides and models of Capintec dose calibrators. 
     Source  Result 
Isotope Reference Method Capintec Model1  
Vessel 
Geometry 
Vessel 
Volume 
Liquid 
Volume  
Setting 
Number2 
Readout 
Difference3 
      Vvessel (mL) 
Vsource 
(mL) 
 NA (-) (%) 
18F (Cessna, et al., 2008) 4πβ-LS 
CRC-
15R  
NIST 
ampoule 5 5  472 +6.4 
  " CRC-15R  Syringe 3 1  484 +8.9 
  " CRC-15PET  " " "  501 +12.7 
  " CRC-12  " " "  500 +13.3 
 (Mo, et al., 2006) 4πβ-LS 
CRC-
712M  
Wheaton 
vial - -  459 - 
 (Zimmerman, et al., 2001) HPGe CRC-12  
Monojet 
syringe 12 9  482 +8.3 
  " CRC-35R  
NIST 
ampoule - -  477 +6.2 
 
(Zimmerman 
and Cessna, 
2000) 
4πβ-LS CRC-12  Mallinckrodt dose vial 10 5  463 +4.5 
  " CRC-12  plastic syringe 12 9  482 +7.3 
89Zr (Beattie, et al., 2014) HPGe 
CRC-
15R  
borosilicate 
glass vial 20 10  517 +8.00-12.0 
90Y (Coursey, et al., 1993) HPGe CRC-12  
NIST 
ampoule - -  48 (×10) +50 
124I (Beattie, et al., 2014) HPGe 
CRC-
15R  
borosilicate 
glass vial 20 10  
494 
(with Cu 
filter) 
+14.9-28.0 
125I (Zimmerman, et al., 2002) NaI(Tl) CRC-12  
plastic 
syringe 5 -  497 +45 
  " CRC-12  conical glass dose vial 2 -  143 -42 
133Xe 
(Zimmerman 
and Cessna, 
2000) 
4πβ-LS CRC-12  Dupont  dose vial 3 -  181 -2.7 
  " CRC-12  NIST ampoule - -  184 -1.7 
188Re 
(Zimmerman 
and Cessna, 
2000) 
4πβ-LS CRC-12  SoloPak dose vial 5 -  
620 
(×10) +22.2 
 (Zimmerman, et al., 1999) 4πβ-LS CRC-12  
NIST 
ampoule - -  
630 
(×10) +30 
1All dose calibrator models were by Capintec. These results for calibration setting numbers may 
translate across certain models of Capintec dose calibrators, but not necessarily all models. 2Some 
calibration setting numbers require that the radioactivity readout be multiply or divided by a factor 
for an accurate measurement. 3This column is the percentage difference of the radioactivity 
readout using the calibration number from the user manual versus the radioactivity readout using 
the experimentally determined calibration number.  
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A.4. Discussion 
For selected isotopes and geometries, the radioactivity readout over a wide range of 
calibration setting numbers was also recorded. These data were plotted in Figure A.1 and 
demonstrate something similar to an inverse relationship of ARO to NA across small and large 
ranges for NA. These isotopes represented a variety of gamma-ray dose rates, such as 52Mn, 64Cu, 
and 124I, all in 2 mL microcentrifuge tubes. Readout radioactivity was normalized to the largest 
value that was measured using the calibration setting numbers in that experiment for that 
radionuclide. It is important to be aware of these relationships because the fitted equations can be 
used to calculate the correct radioactivity of a sample in case the incorrect setting is accidentally 
used in a measurement. Therefore, when using the dose calibrator, the calibration setting number 
used should be recorded in case rescaling is necessary in the future. 
 
Figure A.1. Plots of normalized readout radioactivity (ARO,norm) versus calibration setting 
numbers (NA) over large ranges of settings. 
Readout radioactivity was normalized to the largest value that was measured using the calibration 
setting numbers in that experiment for that radionuclide. Over large ranges for three isotopes with 
very different total gamma-ray dose rates: 52Mn, 64Cu, and 124I. All results in this figure were from 
samples in 2 mL microcentrifuge tubes.  
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Using gamma-ray spectroscopy results as a reference, calibration setting numbers for 
using Capintec dose calibrators to measure the radioactivity of six PET isotopes: 52Mn, 64Cu, 
76Br, 86Y, 89Zr, and 124I were determined experimentally for 2 mL microcentrifuge tubes and 10 
cc syringes. In many cases, results were significantly different from the calibration setting 
numbers recommended by the manufacturer. Since the CRC-15R and CRC-25R models of dose 
calibrators from Capintec were used, results can be used directly for that family of models, 
including: 15R, 15W, 25R, 25W, 127R, and Ultra-R (Capintec, 2009). However, since the 
manufacturer’s recommended settings are interpolated from other measurements that used a 
standard glass NIST source geometry, and because results show significant effects of sample 
geometry for several isotopes, we recommend utilizing a reference sample or high-precision 
reference measurement—such as HPGe gamma spectroscopy—to experimentally determine 
calibration setting numbers for various geometries and materials involving dose calibrator use. 
In most cases, calibration setting numbers differed from those recommended in the user 
manual, which meant that using the recommended calibration settings could result in 
radioactivity measurements higher or lower than expected. Additionally, settings determined for 
the 10 cc syringes were consistently greater than for the 2 mL geometry. Our results reiterate the 
widely known fact that experimentally determined dose calibrator settings for various 
radionuclides and sample geometries are necessary for accurate measurements of radioactivity. 
These settings have potentially significant implications for radiochemistry experiments, as well 
as dosimetry for pre-clinical and clinical applications of radionuclides, including the PET 
radionuclides that were examined in this work.  
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A.5. Conclusions and Recommendations 
Using gamma-ray spectroscopy results as a reference, we have experimentally 
determined calibration setting numbers for using certain Capintec dose calibrators to measure the 
radioactivity of six PET isotopes: 52Mn, 64Cu, 76Br, 86Y, 89Zr, and 124I. Measurements were 
conducted for 2 mL microcentrifuge tubes and 10 cc syringes to provide results for two vessels 
that are commonly placed in dose calibrators to measure radioactivity for either radiochemistry 
lab work or for in vivo injections, respectively. In many cases, our results were significantly 
different from the calibration setting numbers recommended by the manufacturer. As the CRC-
15R and CRC-25R models of dose calibrators from Capintec were used, our results can be used 
directly for that family of models, including: 15R, 15W, 25R, 25W, 127R, and Ultra-R 
(Capintec, 2009). However, since the calibrations settings recommended by the manufacturer are 
interpolated results based on measurements using a different source geometry than what is 
commonly used in practice for clinical and pre-clinical radiochemistry. Since our results show 
significant effects of sample geometry, we join with a body of literature to recommend 
performing in-house calibration for any radionuclide or vessel geometry by utilizing a high-
precision measurement, such as HPGe gamma spectroscopy, as a reference for cross-calibration. 
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